var title_f38_32_39424="Aflibercept: Patient drug information";
var content_f38_32_39424=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"8\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Aflibercept: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F14960433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F14960522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/44/25283?source=see_link\">",
"       Aflibercept (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/41/37524?source=see_link\">",
"       Aflibercept (ziv-aflibercept) (systemic): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17101 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-BF10BB01C4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_32_39424=[""].join("\n");
var outline_f38_32_39424=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?24/44/25283?source=related_link\">",
"      Aflibercept (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?36/41/37524?source=related_link\">",
"      Aflibercept (ziv-aflibercept) (systemic): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_32_39425="Patient information: von Willebrand disease (The Basics)";
var content_f38_32_39425=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?41/10/42145\">",
"         Patient information: Taking care of bruises (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?2/13/2262\">",
"         Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?5/55/6002\">",
"         Patient information: von Willebrand disease (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: von Willebrand disease (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/von-willebrand-disease-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H29329452\">",
"      <span class=\"h1\">",
"       What is von Willebrand disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Von Willebrand disease is a blood disease. It keeps blood from clotting normally. People with the disorder sometimes bruise easily or bleed too much when they get cut. Von Willebrand disease runs in families.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29329459\">",
"      <span class=\"h1\">",
"       What are the symptoms of von Willebrand disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of von Willebrand disease are often mild. For some people, the symptoms are so mild that they never have problems.",
"     </p>",
"     <p>",
"      If you have von Willebrand disease, you might:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Get nosebleeds a lot or have nosebleeds that last a long time",
"       </li>",
"       <li>",
"        Notice that your gums sometimes bleed for no reason",
"       </li>",
"       <li>",
"        Bruise easily and form lumps under your bruises",
"       </li>",
"       <li>",
"        Have very heavy or long-lasting periods (if you are a woman). For instance, your periods might last longer than 7 to 10 days and have large blood clots.",
"       </li>",
"       <li>",
"        Bleed more than normal when having medical procedures or surgery",
"       </li>",
"       <li>",
"        Bleed when you take",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        or other medicines that prevent blood clots",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29329466\">",
"      <span class=\"h1\">",
"       Is there a test for von Willebrand disease?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your doctor or nurse suspects you have von Willebrand disease, he or she can check for it with a blood test. He or she will also want to know as much as possible about the way you have bled in the past. Plus, your doctor or nurse will want to know if any of your family members have the disorder or have had problems with bleeding or bruising.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29329473\">",
"      <span class=\"h1\">",
"       Is there anything I can do on my own to reduce bleeding?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Follow these tips:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Do not take medicines that have",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?6/12/6342?source=see_link\">",
"         aspirin",
"        </a>",
"        , or medicines called &ldquo;NSAIDs.&rdquo; Examples of NSAIDs include",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/17/14614?source=see_link\">",
"         ibuprofen",
"        </a>",
"        (sold as Advil or Motrin) and",
"        <a class=\"drug drug_patient\" href=\"mobipreview.htm?43/35/44597?source=see_link\">",
"         naproxen",
"        </a>",
"        (sold as Aleve). These medicines can make bleeding worse.",
"       </li>",
"       <li>",
"        Be extra safe about preventing injuries if your doctor tells you to. For example, you might need to avoid contact sports, like hockey or football.",
"       </li>",
"       <li>",
"        Plan ahead for surgery or childbirth. If you are going to have surgery or any procedure that might make you bleed, talk to your doctor or nurse about your condition first. Do the same if you are going to have a baby. That way your doctor or nurse can be ready with the right medicines if you start to bleed too much. &nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29329480\">",
"      <span class=\"h1\">",
"       How is von Willebrand disease treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are many medicines used to treat von Willebrand disease. These medicines come in shots, pills, gels, and nasal sprays. You and your doctor or nurse might have to try a few different treatment approaches before you find the one that works best for you.",
"     </p>",
"     <p>",
"      If you are a woman, you might also need to take birth control or hormone pills, or use a device called an &ldquo;IUD&rdquo; that releases hormones. That&rsquo;s because the hormones in these treatments help reduce the bleeding that happens during a woman&rsquo;s period.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29329487\">",
"      <span class=\"h1\">",
"       What if I want to have a baby?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you want to have a baby, your doctor or nurse should watch you closely during your pregnancy. That way he or she can make sure that bleeding does not become an issue.",
"     </p>",
"     <p>",
"      Most women do not need treatment while they are pregnant, because von Willebrand disease gets better on its own during pregnancy. But after the baby is born, women can start to have serious bleeding. For 1 to 3 weeks after giving birth, women often need to take extra medicines to prevent bleeding. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H29329584\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/10/42145?source=see_link\">",
"       Patient information: Taking care of bruises (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/55/6002?source=see_link\">",
"       Patient information: von Willebrand disease (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=see_link\">",
"       Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?38/32/39425?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15887 Version 3.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-93.125.6.160-A4AE6C8C0C-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_32_39425=[""].join("\n");
var outline_f38_32_39425=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29329452\">",
"      What is von Willebrand disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29329459\">",
"      What are the symptoms of von Willebrand disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29329466\">",
"      Is there a test for von Willebrand disease?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29329473\">",
"      Is there anything I can do on my own to reduce bleeding?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29329480\">",
"      How is von Willebrand disease treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29329487\">",
"      What if I want to have a baby?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29329584\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/13/2262?source=related_link\">",
"      Patient information: Nonsteroidal antiinflammatory drugs (NSAIDs) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/10/42145?source=related_link\">",
"      Patient information: Taking care of bruises (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?5/55/6002?source=related_link\">",
"      Patient information: von Willebrand disease (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_32_39426="VF sectoral defects";
var content_f38_32_39426=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F58764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F58764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sectoral visual field defect",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 207px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Central sector-sparing homonymous hemianopia caused by anterior choroidal artery occlusion and incomplete lateral geniculate body lesion",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Zhang X, Kedar S, Lynn MJ, et al. Homonymous hemianopias: clinical-anatomic correlations in 904 cases. Neurology 2006; 66:906. Copyright &copy; 2006 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_32_39426=[""].join("\n");
var outline_f38_32_39426=null;
var title_f38_32_39427="Lymphoma liver CT";
var content_f38_32_39427=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F59628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F59628&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse large B cell lymphoma involving the liver",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 267px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography&nbsp;of the upper abdomen shows an enlarged liver containing many discrete nodular areas (arrows). The biopsy was consistent with diffuse large B-cell non-Hodgkin lymphoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Arnold S Freedman, MD, Jonathan W Friedberg, MD, and Pam DePiro, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_32_39427=[""].join("\n");
var outline_f38_32_39427=null;
var title_f38_32_39428="Ciclopirox: Patient drug information";
var content_f38_32_39428=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Ciclopirox: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/40/44676?source=see_link\">",
"     see \"Ciclopirox: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/62/42979?source=see_link\">",
"     see \"Ciclopirox: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F151212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ciclodan&reg;;",
"     </li>",
"     <li>",
"      Ciclodan&reg; Kit;",
"     </li>",
"     <li>",
"      Loprox&reg;;",
"     </li>",
"     <li>",
"      Pedipirox&trade; -4 Kit;",
"     </li>",
"     <li>",
"      Penlac&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F151213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Ciclopirox&reg;;",
"     </li>",
"     <li>",
"      Loprox&reg;;",
"     </li>",
"     <li>",
"      Penlac&reg;;",
"     </li>",
"     <li>",
"      Stieprox&reg;;",
"     </li>",
"     <li>",
"      Taro-Ciclopirox",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10014403\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat yeast infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10014402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701802",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to ciclopirox or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10014407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10014408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698333",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Short-term pain after use.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10014410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10014405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695632",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shake suspension well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705669",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Nail solution:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696161",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use 8 hours before bathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use on nails and nail beds every day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695571",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take off once weekly with rubbing alcohol.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705546",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin, shampoo:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on enough shampoo to make a lather.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695275",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Lather well and leave on for 3 minutes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695638",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Shampoo 2 times a week with 3 days between shampoos.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10014406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10014411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699506",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store nail solution in the original container after each use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699262",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from heat.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10014412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12146 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-168C04E0CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_32_39428=[""].join("\n");
var outline_f38_32_39428=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151212\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F151213\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014403\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014402\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014407\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014408\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014410\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014405\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014406\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014411\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10014412\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/40/44676?source=related_link\">",
"      Ciclopirox: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?41/62/42979?source=related_link\">",
"      Ciclopirox: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_32_39429="Evaluation of hearing loss in adults";
var content_f38_32_39429=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of hearing loss in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/32/39429/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/32/39429/contributors\">",
"     Peter C Weber, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/32/39429/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/32/39429/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/32/39429/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/32/39429/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/32/39429/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing loss is a common problem that everyone experiences from time to time. Most commonly it occurs when flying or traveling up a mountain, and a full sensation develops in the ears, leading to the feeling of wanting to pop the ears open in order to hear better. Diminished hearing also may occur during an ear infection. These causes of hearing loss are usually short-lived. The other extreme is the permanent sensorineural hearing loss that occurs with aging, which we will all experience to some degree.",
"   </p>",
"   <p>",
"    The evaluation of hearing loss in adults will be reviewed here. The etiology and treatment of hearing loss are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10490?source=see_link\">",
"     \"Etiology of hearing loss in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39300?source=see_link\">",
"     \"Hearing amplification in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF HEARING LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing loss may be classified into three types:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sensorineural, involving the inner ear, cochlea, or the auditory nerve.",
"     </li>",
"     <li>",
"      Conductive, involving any cause that in some way limits the amount of external sound from gaining access to the inner ear. Examples include cerumen impaction, middle ear fluid, or ossicular chain fixation (lack of movement of the small bones of the ear).",
"     </li>",
"     <li>",
"      Mixed loss, which is a combination of conductive and sensorineural hearing loss.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of abnormalities may lead to hearing loss of each type (",
"    <a class=\"graphic graphic_table graphicRef53903 \" href=\"mobipreview.htm?4/62/5101\">",
"     table 1",
"    </a>",
"    ). It is useful to begin the evaluation by classifying the loss as sensorineural or conductive, since this helps focus the remainder of the patient assessment. Conductive hearing loss is usually related to abnormalities of the outer or middle ear; sensorineural hearing loss is related to inner ear pathology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any patient complaining of hearing loss should have a full auditory history and examination performed. Important questions in the history include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      What was the onset and progression of the hearing loss?",
"     </li>",
"     <li>",
"      How well can the patient understand spoken words?",
"     </li>",
"     <li>",
"      Is the problem mainly with background noise (eg restaurants, parties) or is it just as bad in quiet settings?",
"     </li>",
"     <li>",
"      Is there pain or drainage out of the ear associated with the hearing loss?",
"     </li>",
"     <li>",
"      Is there a history of significant trauma, including noise and barotrauma?",
"     </li>",
"     <li>",
"      Is there a history of major infections?",
"     </li>",
"     <li>",
"      Is there a history of previous ear surgery?",
"     </li>",
"     <li>",
"      Is there associated tinnitus, vertigo, or disequilibrium?",
"     </li>",
"     <li>",
"      Is there a family history of hearing loss? There are a number of congenital and hereditary causes of hearing loss; presbycusis also can run in families.",
"     </li>",
"     <li>",
"      What medications are taken?",
"     </li>",
"     <li>",
"      Do headaches or visual disturbances occur before, during, or after episodes of hearing loss?",
"     </li>",
"     <li>",
"      What medications, including over-the-counter drugs, is the patient taking?",
"     </li>",
"     <li>",
"      History of other medical disorders such as diabetes, smoking, coronary artery disease, autoimmune diseases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The examination for some patients will involve only simple tests that can be performed in a primary care office. Many patients, however, will require formal audiologic testing or other specialized tests.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Office hearing evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a variety of methods used to test hearing in the office setting. These include a whispered voice test, tone-emitting otoscope, questionnaires, and tuning forks.",
"   </p>",
"   <p>",
"    A systematic review of the whispered voice test concluded that in four studies in adults the sensitivity for hearing impairment was 90 to 100 percent and the specificity was 70 to 87 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39429/abstract/1\">",
"     1",
"    </a>",
"    ]. To perform a whispered voice test, stand at arm's length behind the patient (to prevent lip reading) and mask hearing in one ear by occluding the ear canal and rubbing the tragus with a circular motion. Whisper a short sequence of letters and numbers and ask the patient to repeat them. Test the other ear in a similar manner.",
"   </p>",
"   <p>",
"    In addition to the whispered voice test, tone-emitting otoscopes",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    questionnaires are often used. In a randomized trial of screening strategies in 2305 veterans (mean age 61 years), fewer patients evaluated with a tone-emitting otoscope screened positive (19 percent versus 59 and 64 percent of patients evaluated with questionnaire and dual screening [questionnaire and otoscope], respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39429/abstract/2\">",
"     2",
"    </a>",
"    ]. Hearing aid use one year after screening was 6 percent in the tone-emitting otoscope group compared with 4 and 7 percent in the questionnaire and dual screening groups, respectively. Screening with the tone-emitting otoscope was the most efficient screening method, as the questionnaire led to unnecessary audiology evaluations with little added benefit in terms of hearing loss detection.",
"   </p>",
"   <p>",
"    Hearing status can be further assessed with tuning forks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39429/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients who cannot hear a 256 Hz tuning fork but can hear a 512 Hz tuning fork have a hearing loss of approximately 10 to 15 dB; patients who cannot hear a 512 Hz tuning fork have an approximate loss of at least 20 to 30 dB. An ear that hears normally should have air conduction (sound waves traveling to the tympanic membrane and converted into sound in the inner ear) that is louder than bone conduction (sound transmitted via the vibration of the skull into the cochlea). The Weber and Rinne tests examine the relative adequacy of air and bone conduction of sound.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Weber and Rinne tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Weber and Rinne tests can help direct the remainder of the evaluation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Weber test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Weber tuning fork test is performed by pressing the handle of the tuning fork to the bridge of the forehead, nose, or teeth and asking the patient if the sound is louder in one ear or the other. The sound is heard equally in both ears in patients with normal hearing or symmetric hearing loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Rinne test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Rinne test allows comparison of sound when the tuning fork is placed on the mastoid bone behind the ear (bone conduction), versus when the tuning fork is held near the ear (air conduction) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39429/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. A negative test occurs when sound is at least equally loud or louder when the fork is placed on bone as compared with when it is held next to the ear (bone&gt;air conduction). The Rinne test is said to be positive or normal when the vibrating fork placed near the ear is louder than when placed on the mastoid bone (air&gt;bone conduction).",
"   </p>",
"   <p>",
"    One method for performing the Rinne test is to press the handle of the tuning fork to the mastoid bone and ask the patient to tell the examiner when the sound is no longer audible. At that point, the vibrating end of the tuning fork is placed near the external auditory canal (EAC). If the patient can again hear the tuning fork, the Rinne test is positive (normal).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Weber and Rinne tests can then be used to help distinguish conductive from sensorineural hearing loss (",
"    <a class=\"graphic graphic_table graphicRef74212 \" href=\"mobipreview.htm?13/29/13787\">",
"     table 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef58032 \" href=\"mobipreview.htm?40/5/41043\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients complaining of a unilateral decrease in hearing, the Weber test suggests sensorineural hearing loss if the sound is louder on the \"good\" side; conductive hearing loss is suspected if the sound is louder on the \"bad\" side.",
"     </li>",
"     <li>",
"      A negative (abnormal) Rinne test, with bone&gt;air conduction, is consistent with conductive loss, particularly if the Weber test also lateralizes to that side.",
"     </li>",
"     <li>",
"      When the Weber test lateralizes to an ear in which the Rinne is positive (normal), the Rinne test in the opposite ear should be performed. A positive Rinne test in the contralateral ear suggests sensorineural hearing loss in this contralateral ear (ie, the Weber lateralized to the normal ear). An audiogram is indicated in this situation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Conductive hearing loss on one side is indicative of external or middle ear disease.",
"   </p>",
"   <p>",
"    Sensorineural hearing loss on one side suggests an inner ear disorder such as Meniere disease or a vestibular schwannoma (acoustic neuroma). If confirmed by audiometry, the patient with progressive asymmetric sensorineural hearing loss not clearly attributable to Meniere disease (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32729?source=see_link\">",
"     \"Meniere disease\"",
"    </a>",
"    ) should have an MRI or CT scan of the posterior fossa and internal auditory canal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Examination of the ear",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with conductive hearing loss should have an examination of the auricle and EAC performed to look for blockage of the EAC. The tympanic membrane (TM) should be viewed to ensure that there is no middle ear abnormality such as fluid or TM perforations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Pneumoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumoscopy is also performed to evaluate mobility of the TM. Positive pressure that forces air into the EAC thereby pushing down the TM, is done first. The pressure is then released, with the subsequent negative pressure pulling the TM outwards.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A nonmobile TM may occur because of fluid in the middle ear cavity, a mass in the middle ear cavity, or a stiff or sclerotic TM.",
"     </li>",
"     <li>",
"      A hypermobile TM may indicate ossicular chain disruption.",
"     </li>",
"     <li>",
"      The TM may only move with negative pressure; this can be caused by retraction of the TM or middle ear with a blocked eustachian tube, resulting in negative middle ear pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Formal audiologic assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formal audiologic assessment is performed by an audiologist in a soundproof environment. This evaluation provides very accurate and detailed information regarding a patient's hearing ability. The formal audiogram, with tympanogram and site of lesion testing, provides definitive information. Every audiologic workup should consist of a number of audiometric studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39429/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Pure tone, air, and bone conduction testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pure tone testing is commonly known as the audiogram. The patient is in a soundproof booth, and the audiologist assesses the sensitivity or ability to hear pure tone stimuli at the frequencies of 250, 500, 1000, 2000, 4000, and 8000 hz. The threshold for each stimulus is determined by finding the dB level at which the patient can detect the tone 50 percent of the time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39429/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hearing is tested with both air and bone conduction. Air conduction tests the ability to hear with ear phones via the normal mechanism of hearing: sound through the EAC, TM, and then middle ear system. Bone conduction is tested with a bone oscillator. The oscillator is placed on either mastoid and held in place, stimulating noise going into the skull and bypassing the middle ears by setting the fluid and cochlea in motion directly with bone vibration. Any difference between air and bone conduction thresholds is known as an",
"    <span class=\"nowrap\">",
"     air/bone",
"    </span>",
"    gap; a gap is consistent with conductive hearing loss (",
"    <a class=\"graphic graphic_figure graphicRef59939 \" href=\"mobipreview.htm?36/6/36964\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Speech audiometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Speech audiometry typically consists of two parts: the speech reception threshold (SRT) and the word discrimination score.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The SRT is the softest level at which a patient can correctly repeat 50 percent of presented spondee words. Spondee words are two-syllable words where each syllable is stressed, such as airplane, armchair, or pancake. SRT is recorded in decibels and serves as a cross-check for the pure tone air conduction thresholds. The SRT is typically equal to the pure tone air conduction average, &plusmn; 6 dB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39429/abstract/8\">",
"       8",
"      </a>",
"      ]. The pure tone average is the average decibel score at 500, 1000, and 2000 hz.",
"     </li>",
"     <li>",
"      The word discrimination score is the percentage of phonetically balanced words that a patient can correctly repeat at a given sensation level. Typically, testing is performed at 40 dB above the patient's SRT. This discrimination score serves two purposes: it can establish the prognosis for the use of a hearing aid, and it helps determine the site of the lesion. A poor discrimination score usually indicates significant neural degeneration; these individuals may not be good candidates for hearing aids, since the aid will amplify sound but may not allow the patient to understand what is being said.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Impedance audiometry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impedance audiometry is performed in two parts: tympanometry and stapedial reflex testing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39429/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The first component is tympanometry, which is the hard-copy version of pneumoscopy performed in the office. It is an objective measure of the changes in the acoustic impedance of the middle ear system in response to changes in air pressure. As the pressure increases during pneumoscopy, the eardrum is pushed medially; as negative pressure is placed, the eardrum protrudes laterally. The point of maximum compliance of the middle ear is identified; this indicates the current status of the air pressure in the middle ear.",
"   </p>",
"   <p>",
"    Five types of tympanograms can be seen (",
"    <a class=\"graphic graphic_figure graphicRef73425 \" href=\"mobipreview.htm?17/33/17949\">",
"     figure 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal middle ear pressure",
"     </li>",
"     <li>",
"      Little or no mobility, suggestive of fluid behind the TM",
"     </li>",
"     <li>",
"      Negative pressure in the middle ear suggestive of a retracted TM",
"     </li>",
"     <li>",
"      Type AS, a very stiff middle ear system that may be due to myringosclerosis or otosclerosis",
"     </li>",
"     <li>",
"      Type AD, the high compliant TM normally seen in ossicular chain discontinuity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Stapedial reflex testing may also be performed. Further discussion of this test is beyond the scope of this review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Other tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Various metabolic abnormalities have been known to either cause or be associated with sensorineural hearing loss. Thus, an evaluation of an unexplained sensorineural hearing loss should involve a complete laboratory evaluation to include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurement of blood sugar; small vessel disease as a result of diabetic vasculopathy can cause cochlear ischemia.",
"     </li>",
"     <li>",
"      Complete blood count with differential; anemia or a white blood cell dyscrasia may lead to sensorineural hearing loss by an unknown mechanism that may involve decreased oxygenation, microblockage of vessels, or infection.",
"     </li>",
"     <li>",
"      Thyroid stimulating hormone to rule out hyper or hypothyroidism.",
"     </li>",
"     <li>",
"      Serologic test for syphilis.",
"     </li>",
"     <li>",
"      Serologic tests for Sjogren's syndrome (ANA, RF, anti-Ro and anti-La) in patients who have dry eyes or dry mouth. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/42/27306?source=see_link&amp;anchor=H27#H27\">",
"       \"Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease\", section on 'Peripheral nervous system'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with unexplained conductive hearing loss should have a CT scan of the temporal bone.",
"     </li>",
"     <li>",
"      Patients with unilateral, fluctuating, or unexplained asymmetric sensorineural hearing loss should have an MRI with gadolinium.",
"     </li>",
"     <li>",
"      Patients with loss other than presbycusis (hearing loss of aging) should be evaluated by an ENT.",
"     </li>",
"     <li>",
"      Patients whose hearing loss is not improved by traditional hearing aids should be considered for evaluation by a center that performs various types of implants for hearing (eg, cochlear implants, Baha implants, or middle ear implants of various types). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/26/33186?source=see_link\">",
"       \"Patient information: Age-related hearing loss (presbycusis) (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/46/32482?source=see_link\">",
"       \"Patient information: Ear wax impaction (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hearing loss may have conductive, sensorineural, or mixed hearing loss (",
"    <a class=\"graphic graphic_table graphicRef53903 \" href=\"mobipreview.htm?4/62/5101\">",
"     table 1",
"    </a>",
"    ). Patients with hearing loss should undergo a directed history and examination. The examination should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An office test of hearing (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Office hearing evaluation'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Weber and Rinne tests to distinguish conductive from sensorineural hearing loss (see",
"      <a class=\"local\" href=\"#H6\">",
"       'Weber and Rinne tests'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with conductive hearing loss should undergo physical examination of the auricle and external auditory canal (EAC) looking for evidence of blockage to explain the hearing loss. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Examination of the ear'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients without an obvious etiology for hearing loss (such as external otitis or cerumen impaction) should undergo formal audiologic testing. The differential diagnosis of hearing loss is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10490?source=see_link\">",
"     \"Etiology of hearing loss in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients found to have progressive asymmetric sensorineural hearing loss should have an MRI with contrast or CT scan of the posterior fossa and internal auditory canal to exclude disorders such as vestibular schwannoma (acoustic neuroma). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40232?source=see_link\">",
"     \"Vestibular schwannoma (acoustic neuroma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with an unexplained sensorineural hearing loss should have the following laboratory tests: blood sugar, complete blood count with differential, thyroid stimulating hormone, and serologic test for syphilis.",
"   </p>",
"   <p>",
"    Patients with hearing loss where the etiology is unclear generally require referral to an otolaryngologist or ENT physician; patients with sudden hearing loss require urgent referral as treatment success is related to early initiation of treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38296?source=see_link\">",
"     \"Sudden sensorineural hearing loss\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39429/abstract/1\">",
"      Pirozzo S, Papinczak T, Glasziou P. Whispered voice test for screening for hearing impairment in adults and children: systematic review. BMJ 2003; 327:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39429/abstract/2\">",
"      Yueh B, Collins MP, Souza PE, et al. Long-term effectiveness of screening for hearing loss: the screening for auditory impairment--which hearing assessment test (SAI-WHAT) randomized trial. J Am Geriatr Soc 2010; 58:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39429/abstract/3\">",
"      Bagai A, Thavendiranathan P, Detsky AS. Does this patient have hearing impairment? JAMA 2006; 295:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39429/abstract/4\">",
"      Chole RA, Cook GB. The Rinne test for conductive deafness. A critical reappraisal. Arch Otolaryngol Head Neck Surg 1988; 114:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39429/abstract/5\">",
"      Burkey JM, Lippy WH, Schuring AG, Rizer FM. Clinical utility of the 512-Hz Rinne tuning fork test. Am J Otol 1998; 19:59.",
"     </a>",
"    </li>",
"    <li>",
"     Yueh, B, Souza, P, Collins, M, et al. Screening for auditory impairment: Which hearing aid tetst? A randomized clinical trail. Funded by the Health Services Research and Development Service. Department of Veterns Affairs Merit Review, Seattle, WA 2001.",
"    </li>",
"    <li>",
"     Rintelmann WF. Hearing Assessment, 2nd ed, Pro-Ed Inc, Austin 1990.",
"    </li>",
"    <li>",
"     Durrant JD, Lovrinic JH. Bases of Hearing Science, 2nd ed, Williams &amp; Wilkins, Baltimore 1984.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39429/abstract/9\">",
"      Baldwin RL, Carmichael L. Practical tympanometry and stapedial reflex testing in office practice. Ala Med 1983; 53:8.",
"     </a>",
"    </li>",
"    <li>",
"     Wiley TL, Fowler C. Acoustic Immittance Measures in Clinical Audiology: A Primer, 1st ed, Thompson, 1997.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6850 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-B2F8B938AB-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_32_39429=[""].join("\n");
var outline_f38_32_39429=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION OF HEARING LOSS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      HISTORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Office hearing evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Weber and Rinne tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Weber test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Rinne test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Interpretation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Examination of the ear",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Pneumoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Formal audiologic assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Pure tone, air, and bone conduction testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Speech audiometry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Impedance audiometry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Other tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/6850\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6850|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?40/5/41043\" title=\"figure 1\">",
"      Weber and Rinne tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/6/36964\" title=\"figure 2\">",
"      Audiogram conductive loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/33/17949\" title=\"figure 3\">",
"      Tympanograms in diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/6850|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?4/62/5101\" title=\"table 1\">",
"      Causes of hearing loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/29/13787\" title=\"table 2\">",
"      Interpreting Weber and Rinne tests",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/42/27306?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Extraglandular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/15/10490?source=related_link\">",
"      Etiology of hearing loss in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/24/39300?source=related_link\">",
"      Hearing amplification in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32729?source=related_link\">",
"      Meniere disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/26/33186?source=related_link\">",
"      Patient information: Age-related hearing loss (presbycusis) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?31/46/32482?source=related_link\">",
"      Patient information: Ear wax impaction (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/25/38296?source=related_link\">",
"      Sudden sensorineural hearing loss",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/18/40232?source=related_link\">",
"      Vestibular schwannoma (acoustic neuroma)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_32_39430="Global distribution malaria";
var content_f38_32_39430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F72797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F72797&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Global distribution of",
"    <em>",
"     P. falciparum",
"    </em>",
"    and",
"    <em>",
"     P. vivax",
"    </em>",
"    in 2005",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 492px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Distribution of",
"    <em>",
"     P. falciparum",
"    </em>",
"    . B) Distribution of",
"    <em>",
"     P. vivax",
"    </em>",
"    . Several sources of information on malaria risk (notably ITHGs on malaria chemoprophylaxis, altitude limits for dominant vectors, climate limits for malaria transmission and human population density thresholds) have been combined in a geographic information system to generate these maps. See the step-by-step guide in the main text for a full description of the methods used to derive these limits.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Guerra, CA, Snow, RW, Hay, SI. Mapping the global extent of malaria in 2005. Trends in Parasitology 2006; 22:353. Illustration used with permission of Elsevier Inc. All rights reserved. Copyright &copy;2005 Elsevier Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_32_39430=[""].join("\n");
var outline_f38_32_39430=null;
var title_f38_32_39431="Bile duct hyperplasia - high power";
var content_f38_32_39431=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50589&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bile duct hyperplasia (high power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A portal triad is packed with bile ducts, many cut in cross sections and all with lumens. This type of bile duct hyperplasia is seen most often in chronic bile duct obstruction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_32_39431=[""].join("\n");
var outline_f38_32_39431=null;
var title_f38_32_39432="Central vein stenosis associated with dialysis access";
var content_f38_32_39432=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Central vein stenosis associated with dialysis access",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/32/39432/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/32/39432/contributors\">",
"     Gerald A Beathard, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/32/39432/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/32/39432/contributors\">",
"     Steve J Schwab, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/32/39432/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/32/39432/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/32/39432/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 1, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of foreign indwelling objects into the central veins leads to the development of central venous stenosis. Primary attention has been directed toward indwelling catheters as the etiology for this problem in dialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, indwelling intracardiac wires and upper extremity peripherally inserted central venous catheters (PICCs) may also be culprits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/5-9\">",
"     5-9",
"    </a>",
"    ]. Other cases of central vein stenosis may occur with extrinsic compression of the left brachiocephalic vein from an ectatic aorta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/10\">",
"     10",
"    </a>",
"    ], but some occur without an identifiable antecedent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Problems caused by central vein stenosis are primarily related to the presence of an ipsilateral peripheral dialysis access that drains into the affected central veins. The patient frequently develops rapidly increasing massive edema of the access arm, with pain and discomfort that is commonly aggravated by the dialysis session. The prevention of central venous stenosis rests upon the avoidance of central venous dialysis catheters, particularly subclavian inserted catheters, which is the major cause of this complication.",
"   </p>",
"   <p>",
"    A detailed discussion of central vein stenosis associated with dialysis access is presented in this topic review. Thrombosis observed in patients with hemodialysis catheters is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/22/15722?source=see_link\">",
"     \"Thrombosis associated with chronic hemodialysis vascular access: Catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CAUSE AND INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the problem can develop without an identifiable antecedent, central vein stenosis is related primarily to the use of central catheters. Early intimal injury associated with focal endothelial denudation occurs with short-term central venous catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/13\">",
"     13",
"    </a>",
"    ]. Vein wall thickening, increased smooth muscle cells, and focal catheter attachments to the vein wall with thrombus and collagen occur with long-term catheter use.",
"   </p>",
"   <p>",
"    The etiology of these changes is not completely clear. It is thought to be primarily related to mechanical irritation and injury of the endothelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/14\">",
"     14",
"    </a>",
"    ]. If one observes a central venous catheter in place under fluoroscopy, it is seen to be in constant motion due to the movements of mediastinal structures created by the beating of the heart and the motions associated with respiration. There is a definite difference in incidence of stenosis between right- and left-sided catheters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/15-18\">",
"     15-18",
"    </a>",
"    ]. Anatomical differences between these two vessels described below support this mechanical trauma theory.",
"   </p>",
"   <p>",
"    Central vein stenosis is a relatively common complication in the dialysis patient. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study in which 133 hemodialysis patients underwent venography for access-related concerns over a 14-month period, 55 (41 percent) had evidence of significant central vein stenosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/19\">",
"       19",
"      </a>",
"      ]. These patients had a significantly longer duration on dialysis (43 versus 34 months) and a history of a previous dialysis catheter insertion",
"      <span class=\"nowrap\">",
"       (52/55",
"      </span>",
"      versus",
"      <span class=\"nowrap\">",
"       59/78",
"      </span>",
"      patients). Multivariate analysis demonstrated that number of catheters was a significant factor (OR 2.69), even after excluding subclavian insertions.",
"     </li>",
"     <li>",
"      In a study of 69 consecutive patients undergoing percutaneous placement of tunneled right internal jugular vein catheters, venography was performed prior to insertion of a guide-wire [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/11\">",
"       11",
"      </a>",
"      ]. Evidence of unexpected stenosis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angulation of the central veins was found in 29 cases (42 percent). Patients who had previously received tunneled internal jugular catheters had more than double the incidence of such abnormalities than those who had not.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of central vein stenosis associated with a hemodialysis catheter varies principally with the vessel previously utilized, the population studied, and the type of catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Subclavian vein",
"    </span>",
"    &nbsp;&mdash;&nbsp;With catheters (not just dialysis catheters) placed into the subclavian vein, the incidence of subsequent venous stenosis is approximately 30 to 50 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/14,20,21\">",
"     14,20,21",
"    </a>",
"    ]. The primary cause for this high incidence is the mechanical effects of the intravascular device. Direct injury to the vein is thought to occur since there is a curve created by the subclavian and innominate veins as they merge into the superior vena cava.",
"   </p>",
"   <p>",
"    An increased incidence of subclavian vein stenosis is also observed with an increased number of inserted catheters, length of time in place, number of dialysis sessions, and incidence of catheter-related infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/14,21,22\">",
"     14,21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study was conducted that used serial venographic studies to evaluate the long-term effects of subclavian vein dialysis catheters in 42 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/14\">",
"       14",
"      </a>",
"      ]. At the time of catheter removal, 45 percent of patients had stenoses and 7 percent had total thrombosis of the subclavian vein. Follow-up venographic studies revealed that 45 percent of these patients had at least some resolution of these abnormalities during the three-month period after catheter removal.",
"     </li>",
"     <li>",
"      In a retrospective study of 279 central venous infusion catheters in 238 patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/22\">",
"       22",
"      </a>",
"      ], catheter-related venous thrombosis occurred in 13 percent of patients with subclavian vein catheters, compared with 3 percent of patients with internal jugular vein catheters. The mean time to thrombosis was 36 days for subclavian catheters and 142 days for internal jugular vein catheters.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The incidence of stenosis with subclavian catheters is also greater with temporary catheters than with tunneled catheters. Temporary dialysis catheters are relatively stiffer, resulting in increased mechanical trauma to the vein. Under fluoroscopy, the catheter can be seen to be constantly moving with the movement of the heart and respiration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Left internal jugular vein",
"    </span>",
"    &nbsp;&mdash;&nbsp;A catheter inserted through the left internal jugular vein must be significantly longer due to the greater distance that must be traversed. This distance is also characterized by a complex anatomic pathway easily seen on fluoroscopy, which includes the angulations between the internal jugular vein, left brachiocephalic vein, and superior vena cava. An additional angulation is apparent in a three-dimensional model of the left-sided vasculature that occurs as the brachiocephalic vein crosses over the focal and relatively rigid fulcrum of the brachiocephalic artery and aorta [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/23\">",
"     23",
"    </a>",
"    ]. In addition, these structures cause extrinsic compression of the left brachiocephalic vein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/10\">",
"     10",
"    </a>",
"    ]. For these reasons, the left internal jugular vein is a relatively poor site for catheter placement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Right internal jugular vein",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the same type of catheter is inserted into the right internal jugular vein, the incidence of venous stenosis is much lower, in the range of 10 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/15-18,21\">",
"     15-18,21",
"    </a>",
"    ]. The right internal jugular vein does not create a curve as it merges into the innominate and superior vena cava.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Temporary dialysis catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;To minimize the risk of developing central vein stenosis, the use of a short-term temporary catheter is frequently advocated; however, even this approach can lead to problems. In a prospective study, for example, 57 patients with temporary dialysis catheters were studied with venography at the time of catheter removal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/24\">",
"     24",
"    </a>",
"    ]. Although the mean dwell time for the catheters was only 21 days, eight patients (14 percent) had central vein stenosis; in two it was greater than 50 percent. There were no differences with respect to rates of stenosis between those with right internal jugular vein and right subclavian vein catheters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Indwelling permanent pacemakers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with chronic kidney disease, or those with end-stage renal disease receiving hemodialysis, exhibit high rates of comorbid cardiac conditions, for which therapy using a Cardiac Implantable Electronic Device (CIED), either a pacemaker or a cardioverter-defibrillator, may be warranted. Although specific studies in patients with ESRD have not been reported, it has become apparent that when placed using a transvenous approach in the general population, these devices are associated with a relatively high frequency of central vein stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/7,8,25\">",
"     7,8,25",
"    </a>",
"    ]. In one study, for example, 202 patients were submitted to digital subtraction venography ipsilateral to their pacemaker implant six months after transvenous placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/8\">",
"     8",
"    </a>",
"    ]. The studies were abnormal in 129 patients (64 percent).",
"   </p>",
"   <p>",
"    The exact mechanism by which indwelling intracardiac wires inserted via central veins cause stenosis is not clear. However, as with catheters, mechanical irritation appears to be the most likely culprit. When observed under fluoroscopy, these wires can be observed in constant motion in concert with the movement of the heart (personal observation). The moving wire is in direct contact with the vessel wall, where there is a curve in the vessel where the left subclavian joins the left brachiocephalic, or where the brachiocephalic vein joins the superior vena cava.",
"   </p>",
"   <p>",
"    While most cases with a CIED-induced central venous stenosis are asymptomatic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/8\">",
"     8",
"    </a>",
"    ], high blood flow may overwhelm the capacity of the compromised central veins in the setting of an ipsilateral hemodialysis arteriovenous access. This may result in symptomatic and clinically significant venous hypertension manifest as mild to severe limb swelling, with or without associated access dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. During a 10-year period at one institution, 495 patients had transvenous pacemakers placed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/28\">",
"     28",
"    </a>",
"    ]. Twenty patients were identified with renal failure requiring hemodialysis and 14 had hemodialysis access in the extremity ipsilateral to the pacemaker. Ten of these cases (71 percent) developed symptoms including venous hypertension, arm swelling, pain, and neurologic symptoms. Eight of the symptomatic patients were found to have total subclavian vein occlusion. All 10 symptomatic patients required ligation of the hemodialysis access to control symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Peripherally inserted central catheters",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of peripherally inserted central catheter (PICC) lines is associated with a high incidence of venous stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/29\">",
"     29",
"    </a>",
"    ]. This is especially true for peripheral veins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/30\">",
"     30",
"    </a>",
"    ], but is also the case for central veins. This was shown in a study that reviewed venographic studies performed both before and after insertion of PICCs in 150 patients to determine the incidence of central venous stenosis or occlusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/9\">",
"     9",
"    </a>",
"    ]. It was found that 7.5 percent of patients with previously normal central venograms developed subsequent venographic abnormalities after PICC placement; 4.8 percent developed central venous stenosis and 2.7 percent had central venous occlusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A central vein stenosis or even a central venous occlusion is usually asymptomatic unless there is an ipsilateral functioning access [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/8\">",
"     8",
"    </a>",
"    ]. The usual presenting symptom is ipsilateral arm edema. However, not all patients with central vein stenosis have obvious symptoms. In two reports, for example, only 50 and 67 percent of those with a central lesion had arm edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/6,31\">",
"     6,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The markedly increased pressure created by blood flow within the graft or fistula results in arm edema that can be massive and incapacitating in some patients. In these instances, the patient generally has significant pain and discomfort in his or her arm.",
"   </p>",
"   <p>",
"    Additional symptoms or signs may include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pleural effusion [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/32\">",
"       32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Tortuous, dilated venous collaterals over the patient's upper chest, neck, shoulder, and upper arm",
"     </li>",
"     <li>",
"      An increased risk of infection",
"     </li>",
"     <li>",
"      Difficult cannulation of the graft for dialysis",
"     </li>",
"     <li>",
"      An increased incidence of thrombosis of an ipsilateral access",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient with massive arm edema in their access arm is virtually diagnostic of central venous stenosis. Patients with more peripheral lesions, even those that are severe, do not generally develop these symptoms. Occasionally, in a patient with both a central and peripheral lesion, the peripheral stenosis appears to prevent the markedly increased central venous pressure that would otherwise result from the central location. In this setting, symptoms may appear if only the peripheral lesion is treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dialysis patient with any of the symptoms",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    signs previously mentioned should be suspected of central vein stenosis. The presence of massive arm edema in the access arm is virtually pathognomonic of central vein stenosis. However, angiography is required for diagnosis of the lesion, which can be observed in the subclavian and innominate veins and even the superior vena cava.",
"   </p>",
"   <p>",
"    Fifty percent is generally quoted as the criterion for defining stenosis. However, in some instances, the appearance of the lesion in the standard fluoroscopic view can be misleading. The central veins in these patients can dilate and become ectatic to a marked degree. These changes can obscure the exact features of the stenotic lesion. Thus, the severity of the changes that result from the central venous hypertension and the profusion of associated collaterals, in combination with the anatomical appearance of the lesion, serve as a complex to indicate the presence of a significant lesion and enable one to judge its severity.",
"   </p>",
"   <p>",
"    The clinical behavior of lesions in the subclavian and innominate veins is similar. Superior vena cava syndrome can occur with superior vena cava lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/33\">",
"     33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19338?source=see_link\">",
"     \"Malignancy-related superior vena cava syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Indirect evidence of the presence of central vein stenosis can also be obtained using Doppler ultrasound. In a study designed to evaluate the value of duplex ultrasound in identifying the presence of central vein stenosis, 67 patients underwent both duplex sonographic evaluation of the axillary and internal jugular veins and contrast venography prior to placement of a central venous catheter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/34\">",
"     34",
"    </a>",
"    ]. Duplex evaluation included visual evidence of veno-occlusive disease as well as the presence or absence of normal transmitted polyphasic atrial waves and respiratory variation of flow. Directed sonographic imaging of the axillary and internal jugular vein allowed detection of access route veno-occlusive disease with a sensitivity of only 33 percent. Alternatively, when Doppler flow analysis found atrial waveforms that were not polyphasic, central conduit occlusive disease was detected with a sensitivity of 80 percent. A normal polyphasic atrial waveform virtually excluded the possibility of a more central venous occlusion or stenosis greater than 80 percent.",
"   </p>",
"   <p>",
"    Ultrasonography can also be very helpful in detecting the presence of stenosis in the central circulation prior to central vein catheterization. The presence of polyphasic atrial waveforms on Doppler ultrasound virtually excludes the presence of severe central venous occlusive disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, by looking at the pattern of cardiac pulsatility and respiratory phasicity on ultrasound examination of the right and left internal jugular veins and the right and left subclavian veins, it is possible to draw conclusions as to the status of the subclavian, innominate, and superior vena cava veins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/35\">",
"     35",
"    </a>",
"    ]. In addition, when placing a tunneled hemodialysis catheter using real-time ultrasound guidance for the cannulation, significant enlargement of the internal jugular vein observed with ultrasound with a Valsalva maneuver is generally indicative of a patent vein (personal observation).",
"   </p>",
"   <p>",
"    Magnetic resonance angiography and even three-dimensional magnetic resonance studies were previously used to evaluate the central veins of dialysis patients suspected of having problems [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/36\">",
"     36",
"    </a>",
"    ]. However, the administration of gadolinium during magnetic resonance imaging has been strongly linked to an often severe disease called nephrogenic systemic fibrosis in patients with moderate to severe renal disease, particularly those requiring dialysis. As a result, it is recommended that gadolinium-based imaging be avoided in dialysis patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=see_link\">",
"     \"Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three approaches to management: observation, endovascular treatment (angioplasty with or without stenting), and surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Not all anatomically stenotic central veins require treatment, even if the lesion observed is high grade (&gt;50 percent). In some instances, simple observation represents not only a satisfactory approach, but the preferred approach. The determining factor should be the patient's clinical picture.",
"   </p>",
"   <p>",
"    Thus, asymptomatic lesions, even if greater than 50 percent stenosis, do not require treatment, and are better managed by simple observation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/37\">",
"     37",
"    </a>",
"    ]. This was shown in a retrospective study of 35 patients in which the natural history of high grade (&gt;50 percent) asymptomatic central venous stenosis in hemodialysis patients and the outcome of treatment with percutaneous transluminal angioplasty were documented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/37\">",
"     37",
"    </a>",
"    ]. Differences in rate of lesion progression between treated and non-treated patients were tabulated. Twenty-eight percent of lesions were not treated, and the remainder was treated with angioplasty. No untreated lesion progressed to symptoms, stent placement, or additional stenosis. Eight percent of treated cases were followed by stenosis or symptom escalation; one patient developed arm swelling, four required stents, and four developed additional stenosis.",
"   </p>",
"   <p>",
"    In some instances, total occlusion of the central vein occurs, but a profusion of collaterals develops such that the patient is essentially asymptomatic. These decompressed cases should not be treated, only observed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Percutaneous angioplasty with or without stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the complexity of surgical therapy, percutaneous intervention with transluminal angioplasty is the treatment of choice for central venous stenosis. This is in agreement with the recommendations from the 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines for vascular access [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initial success rates with angioplasty have been good and the complication rate has been very low. However, the duration of primary patency has not been comparable to that seen with peripheral lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/6,39-42\">",
"     6,39-42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a report involving 862 cases of venous stenosis with 50 cases of central venous stenosis, for example, the initial success rate for treatment of the central lesions was 89 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/39\">",
"       39",
"      </a>",
"      ]. Nevertheless, the 30-day and 180-day unassisted patency rates were 74 and 25 percent, respectively, compared with a 94 percent initial success rate for peripheral venous lesions and a 90 and 77 percent rate at 30 and 180 days, respectively. The reason that these central lesions recur so rapidly is that many of them tend to be elastic.",
"     </li>",
"     <li>",
"      Better results were reported in a study of 35 patients with angiographic evidence of central venous stenosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/42\">",
"       42",
"      </a>",
"      ]. The initial technical success rate was 89 percent. Primary patency for angioplasty was 85, 55, 43, and 0 percent at 30 days, six months, one year, and two years, respectively. Assisted primary patency rates were 88, 80, and 64 percent at 30 days, one year, and two years, respectively.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In most patients, long-term patency can be maintained with repeated angioplasty. However, for symptomatic lesions that respond poorly to balloon angioplasty, stent deployment has been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/43-48\">",
"     43-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2006",
"    <span class=\"nowrap\">",
"     K/DOQI",
"    </span>",
"    guidelines recommend that stent placement be considered if the following occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute elastic recoil of the vein (greater than 50 percent stenosis) after angioplasty",
"     </li>",
"     <li>",
"      Recurrent stenosis within a three-month period post-angioplasty",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are little data to demonstrate the benefit of stents for central vein stenosis in hemodialysis patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/41\">",
"     41",
"    </a>",
"    ]. Some studies have purported to show a benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/46,47\">",
"     46,47",
"    </a>",
"    ] and others have shown no difference when compared with angioplasty alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common reason for recurrence of the problem after stent placement has been the development of neointimal hyperplasia in or adjacent to the stent. In these cases, it is possible to perform an angioplasty dilatation within the stent. Because of this problem, the use of a stent cannot be considered the final solution. It only delays the problem, which, in many cases, eventually leads to a loss of the access.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Implantable cardiac devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central venous stenosis associated with a cardiovascular implantable electronic device (CIED), such as a pacemaker or internal cardiac defibrillator, represents a special situation. Treatment of the lesion is complicated by presence of the transvenous wires connected to the device. A variety of interventions have been employed in the management of lead-induced central venous stenosis, ranging from ligation of the access to angioplasty with and without stent placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/28,49-51\">",
"     28,49-51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While ligation of the access may be necessary in some cases to control symptoms, it obviously has the major disadvantage of the loss of the means for dialysis and should be avoided if at all possible. Angioplasty has been shown to have a measure of success in preserving the access.",
"   </p>",
"   <p>",
"    The primary patency rates with this approach to therapy have not been as good as cases without the presence of transvenous CIED leads, but secondary patencies have been acceptable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/51\">",
"     51",
"    </a>",
"    ]. The concern that the angioplasty procedure might damage the CIED leads has not materialized. In a multicenter study, the patency rates for angioplasty used to manage lead-induced central venous stenosis were reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/51\">",
"     51",
"    </a>",
"    ]. Twenty-eight consecutive hemodialysis patients underwent angioplasty, with a technical success rate of 95 percent. The primary patency rates were 18 and 9 percent at 6 and 12 months, respectively. The secondary patency rates were 95, 86, and 73 percent at 6, 12, and 24 months, respectively. On average, 2.1 procedures per year were required to maintain secondary patency. There were no procedure-related complications.",
"   </p>",
"   <p>",
"    While the use of stents has been promoted by many investigators in the general management of central venous stenosis, the use of these devices in the presence of pre-existing CIED leads raises a serious concern [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. These devices are susceptible to infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/52\">",
"     52",
"    </a>",
"    ] and with renal dysfunction there is an increased risk of CIED infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CIED infection may be silent without local signs or symptoms suggesting generator-pocket infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/54\">",
"     54",
"    </a>",
"    ]. General issues surrounding the clinical presentation and management of these infections are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44345?source=see_link\">",
"     \"Infections involving cardiac implantable electronic devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Complete removal of all hardware is the recommended treatment for patients with established CIED infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. The presence of a stent can complicate the removal procedure for CIED leads. In the presence of an endovascular stent, percutaneous lead extraction may not be feasible, leaving open heart surgery as the only option. This problem has resulted in a recommendation by the Heart Rhythm Society expert consensus on transvenous lead extraction and the American Heart Association that central venous lesions associated with CIED leads not be stented [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/58\">",
"     58",
"    </a>",
"    ]. If a lesion is present that requires stenting, consideration should be given to removing the leads prior to the procedure and replacing them afterwards. A better choice would be to avoid stenting if at all possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Surgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical therapy may be warranted in instances in which endovascular therapy is unsuccessful or met with only short-term success. The standard approach has been to treat such lesions surgically with either a bypass graft from the axillary to the jugular vein [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/59,60\">",
"     59,60",
"    </a>",
"    ] or an internal jugular to axillary vein transposition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Both of these techniques require that the obstructive lesion be located lateral to the internal jugular vein.",
"   </p>",
"   <p>",
"    When the location of the problem is more central, the surgical approach becomes more difficult. In these cases, a technique that bypasses the obstructed vein to the atrium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/63\">",
"     63",
"    </a>",
"    ] or a bypass to the ipsilateral femoral vein by tunneling a graft subcutaneously along the thoracoabdominal wall has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39432/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Access occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some instances, the best choice for managing a patient with severe symptoms is occlusion of the access. Although this will result in a rapid resolution of the symptoms of venous hypertension, the access is lost. There are several ways that this can be accomplished.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Surgical ligation &mdash; Surgical ligation requires the patient to go to surgery and have an incision made, followed by the tying of a ligature around the graft to occlude it.",
"     </li>",
"     <li>",
"      Manual occlusion &mdash; It is possible to thrombose a graft by manually occluding it for 25 to 30 minutes. Although this is not always effective, it is a simple process and, when effective, it saves the patient from a surgical procedure. This should be done on a non-dialysis day to avoid",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      effects.",
"     </li>",
"     <li>",
"      Balloon occlusion &mdash; The graft can also be occluded by introducing a sheath, inserting a 4 French Fogarty catheter, and inflating it. The catheter should be filled with 0.75 mL of sterile saline and equipped with a valve to prevent premature deflation. The graft will clot within 25 to 30 minutes. We generally leave the balloon inflated for an hour as a safety measure. This is also best done on a non-dialysis day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients and clinicians should be educated about the requirement for peripheral vein preservation in chronic renal disease. There should be a moratorium on the use of PICC lines and subclavian catheter insertions in all patients with established chronic renal failure or who are at high risk for developing end-stage renal disease. Suggested criteria include: (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Cause and incidence'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serum creatinine &gt;3.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (&gt;265.2",
"      <span class=\"nowrap\">",
"       &micro;mol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Estimated creatinine clearance &lt;50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"     </li>",
"     <li>",
"      Diabetic patients with proteinuria (&gt;150",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient evaluation prior to the placement of a permanent dialysis access should include a careful determination of prior episodes of central vein cannulation. If there is a positive history or if there is suspicion that the patient had a central venous catheter in the past, upper extremity duplex ultrasound and possibly venography should be performed. If these do not show any evidence of a lesion, then the extremity can be safely used for access placement even if there has been a prior central venous catheter. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis and evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Every attempt should be made to place a catheter in the right internal jugular vein, with the left internal jugular vein used as an alternative. The subclavian vein should",
"      <strong>",
"       not",
"      </strong>",
"      be used unless there is no plan for the patient to ever have an upper extremity hemodialysis access placed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Right internal jugular vein'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Left internal jugular vein'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dialysis patients, or those who are likely to advance to end-stage renal disease should be managed in a way that protects the central veins when a cardiovascular implantable electronic device (CIED) is needed. With the high incidence of central vein lesions associated with pacemakers and implantable cardioverter-defibrillators, concern over the transvenous placement of these devices seems warranted, and physicians should carefully weigh the benefits and risks of the CIED prior to placement in this patient population. The potential for loss of the central veins dictates the need to avoid CIED placement on the same side as a dialysis vascular access. In addition, if a CIED is already in place, the contralateral arm should be used for dialysis access. Epicardial cardiac rhythm devices are an alternative to a transvenous approach that may be appropriate when a CIED is initially placed or exchanged. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Indwelling permanent pacemakers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Implantable cardiac devices'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When a hemodialysis patient presents with evidence of a central venous lesion, a venogram should be performed as early as possible. Delay can result in complete occlusion of the vein. Individualization in the management of this problem is important. Efforts should always be made to preserve the access, whenever possible. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis and evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to note that not all patients with subclavian stenosis and obstruction are symptomatic. In patients who develop the problem slowly and remains asymptomatic, collateral vessels may adequately decompress the system. In this circumstance, it is best not to intervene provided the patient remains asymptomatic. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment becomes necessary if the patient is symptomatic or has hemodynamic problems from the lesion. In these cases, balloon venoplasty is the initial treatment. If the lesion appears recoiled after venoplasty to a degree that affects blood flow or it recurs rapidly (within three months or less), placement of a stent can be considered. There is no evidence to suggest that stenting under other circumstances is of any value. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with symptomatic lesions that are totally occlusive, unresponsive to venoplasty with stenting, or recur rapidly in spite of angioplasty and stenting should be referred for surgical therapy. For stenotic lesions within the subclavian vein, peripheral to the junction of the internal jugular vein, a bypass to that vessel will resolve the central venous hypertension. If the stenotic lesion is central to the internal jugular vein, ie, within the brachiocephalic or superior vena cava, access occlusion may be necessary. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgical therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/1\">",
"      Davis D, Petersen J, Feldman R, et al. Subclavian venous stenosis. A complication of subclavian dialysis. JAMA 1984; 252:3404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/2\">",
"      Fant GF, Dennis VW, Quarles LD. Late vascular complications of the subclavian dialysis catheter. Am J Kidney Dis 1986; 7:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/3\">",
"      Glaze RC, MacDougall ML, Wiegmann TB. Thrombotic arm edema as a complication of subclavian vein catheterization and arteriovenous fistula formation for hemodialysis. Am J Kidney Dis 1986; 7:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/4\">",
"      Yevzlin AS. Hemodialysis catheter-associated central venous stenosis. Semin Dial 2008; 21:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/5\">",
"      Stone WJ, Wall MN, Powers TA. Massive upper extremity edema with arteriovenous fistula for hemodialysis. A complication of previous pacemaker insertion. Nephron 1982; 31:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/6\">",
"      Beathard GA. Percutaneous transvenous angioplasty in the treatment of vascular access stenosis. Kidney Int 1992; 42:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/7\">",
"      Sticherling C, Chough SP, Baker RL, et al. Prevalence of central venous occlusion in patients with chronic defibrillator leads. Am Heart J 2001; 141:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/8\">",
"      Da Costa SS, Scalabrini Neto A, Costa R, et al. Incidence and risk factors of upper extremity deep vein lesions after permanent transvenous pacemaker implant: a 6-month follow-up prospective study. Pacing Clin Electrophysiol 2002; 25:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/9\">",
"      Gonsalves CF, Eschelman DJ, Sullivan KL, et al. Incidence of central vein stenosis and occlusion following upper extremity PICC and port placement. Cardiovasc Intervent Radiol 2003; 26:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/10\">",
"      Itkin M, Kraus MJ, Trerotola SO. Extrinsic compression of the left innominate vein in hemodialysis patients. J Vasc Interv Radiol 2004; 15:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/11\">",
"      Taal MW, Chesterton LJ, McIntyre CW. Venography at insertion of tunnelled internal jugular vein dialysis catheters reveals significant occult stenosis. Nephrol Dial Transplant 2004; 19:1542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/12\">",
"      Oguzkurt L, Tercan F, Yildirim S, Torun D. Central venous stenosis in haemodialysis patients without a previous history of catheter placement. Eur J Radiol 2005; 55:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/13\">",
"      Forauer AR, Theoharis C. Histologic changes in the human vein wall adjacent to indwelling central venous catheters. J Vasc Interv Radiol 2003; 14:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/14\">",
"      Hern&aacute;ndez D, D&iacute;az F, Rufino M, et al. Subclavian vascular access stenosis in dialysis patients: natural history and risk factors. J Am Soc Nephrol 1998; 9:1507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/15\">",
"      Lin BS, Kong CW, Tarng DC, et al. Anatomical variation of the internal jugular vein and its impact on temporary haemodialysis vascular access: an ultrasonographic survey in uraemic patients. Nephrol Dial Transplant 1998; 13:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/16\">",
"      Schwab SJ, Beathard G. The hemodialysis catheter conundrum: hate living with them, but can't live without them. Kidney Int 1999; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/17\">",
"      Wivell W, Bettmann MA, Baxter B, et al. Outcomes and performance of the Tesio twin catheter system placed for hemodialysis access. Radiology 2001; 221:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/18\">",
"      Salgado OJ, Urdaneta B, Colmenares B, et al. Right versus left internal jugular vein catheterization for hemodialysis: complications and impact on ipsilateral access creation. Artif Organs 2004; 28:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/19\">",
"      MacRae JM, Ahmed A, Johnson N, et al. Central vein stenosis: a common problem in patients on hemodialysis. ASAIO J 2005; 51:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/20\">",
"      Cimochowski GE, Worley E, Rutherford WE, et al. Superiority of the internal jugular over the subclavian access for temporary dialysis. Nephron 1990; 54:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/21\">",
"      Schillinger F, Schillinger D, Montagnac R, Milcent T. Post catheterisation vein stenosis in haemodialysis: comparative angiographic study of 50 subclavian and 50 internal jugular accesses. Nephrol Dial Transplant 1991; 6:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/22\">",
"      Trerotola SO, Kuhn-Fulton J, Johnson MS, et al. Tunneled infusion catheters: increased incidence of symptomatic venous thrombosis after subclavian versus internal jugular venous access. Radiology 2000; 217:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/23\">",
"      Salik E, Daftary A, Tal MG. Three-dimensional anatomy of the left central veins: implications for dialysis catheter placement. J Vasc Interv Radiol 2007; 18:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/24\">",
"      Oguzkurt L, Tercan F, Torun D, et al. Impact of short-term hemodialysis catheters on the central veins: a catheter venographic study. Eur J Radiol 2004; 52:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/25\">",
"      Lickfett L, Bitzen A, Arepally A, et al. Incidence of venous obstruction following insertion of an implantable cardioverter defibrillator. A study of systematic contrast venography on patients presenting for their first elective ICD generator replacement. Europace 2004; 6:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/26\">",
"      Deighan CJ, McLaughlin KJ, Simpson K, Jones JM. Unsuspected subclavian vein stenosis resulting from a permanent pacing wire. Nephrol Dial Transplant 1996; 11:2333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/27\">",
"      Korzets A, Chagnac A, Ori Y, et al. Subclavian vein stenosis, permanent cardiac pacemakers and the haemodialysed patient. Nephron 1991; 58:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/28\">",
"      Teruya TH, Abou-Zamzam AM Jr, Limm W, et al. Symptomatic subclavian vein stenosis and occlusion in hemodialysis patients with transvenous pacemakers. Ann Vasc Surg 2003; 17:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/29\">",
"      Saad TF, Vesely TM. Venous access for patients with chronic kidney disease. J Vasc Interv Radiol 2004; 15:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/30\">",
"      Allen AW, Megargell JL, Brown DB, et al. Venous thrombosis associated with the placement of peripherally inserted central catheters. J Vasc Interv Radiol 2000; 11:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/31\">",
"      Schwab SJ, Quarles LD, Middleton JP, et al. Hemodialysis-associated subclavian vein stenosis. Kidney Int 1988; 33:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/32\">",
"      Wright RS, Quinones-Baldrich WJ, Anders AJ, Danovitch GM. Pleural effusion associated with ipsilateral breast and arm edema as a complication of subclavian vein catheterization and arteriovenous fistula formation for hemodialysis. Chest 1994; 106:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/33\">",
"      Aujla N, McCauley J, Sorkin M. Superior vena cava syndrome due to subclavian hemodialysis catheters. Mil Med 1990; 155:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/34\">",
"      Rose SC, Kinney TB, Bundens WP, et al. Importance of Doppler analysis of transmitted atrial waveforms prior to placement of central venous access catheters. J Vasc Interv Radiol 1998; 9:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/35\">",
"      Patel MC, Berman LH, Moss HA, McPherson SJ. Subclavian and internal jugular veins at Doppler US: abnormal cardiac pulsatility and respiratory phasicity as a predictor of complete central occlusion. Radiology 1999; 211:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/36\">",
"      Paksoy Y, Gormus N, Tercan MA. Three-dimensional contrast-enhanced magnetic resonance angiography (3-D CE-MRA) in the evaluation of hemodialysis access complications, and the condition of central veins in patients who are candidates for hemodialysis access. J Nephrol 2004; 17:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/37\">",
"      Levit RD, Cohen RM, Kwak A, et al. Asymptomatic central venous stenosis in hemodialysis patients. Radiology 2006; 238:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/38\">",
"      K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations 2006 Updates Hemodialysis adequacy Peritoneal Dialysis Adequacy Vascular Access. Am J Kidney Dis 2006; 48(Suppl 1):S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/39\">",
"      Beathard GA. The treatment of vascular access graft dysfunction: a nephrologist's view and experience. Adv Ren Replace Ther 1994; 1:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/40\">",
"      Kovalik EC, Newman GE, Suhocki P, et al. Correction of central venous stenoses: use of angioplasty and vascular Wallstents. Kidney Int 1994; 45:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/41\">",
"      Clark TW. Nitinol stents in hemodialysis access. J Vasc Interv Radiol 2004; 15:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/42\">",
"      Surowiec SM, Fegley AJ, Tanski WJ, et al. Endovascular management of central venous stenoses in the hemodialysis patient: results of percutaneous therapy. Vasc Endovascular Surg 2004; 38:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/43\">",
"      Sprouse LR 2nd, Lesar CJ, Meier GH 3rd, et al. Percutaneous treatment of symptomatic central venous stenosis [corrected]. J Vasc Surg 2004; 39:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/44\">",
"      Vorwerk D, Guenther RW, Mann H, et al. Venous stenosis and occlusion in hemodialysis shunts: follow-up results of stent placement in 65 patients. Radiology 1995; 195:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/45\">",
"      Gray RJ, Horton KM, Dolmatch BL, et al. Use of Wallstents for hemodialysis access-related venous stenoses and occlusions untreatable with balloon angioplasty. Radiology 1995; 195:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/46\">",
"      Vesely TM, Hovsepian DM, Pilgram TK, et al. Upper extremity central venous obstruction in hemodialysis patients: treatment with Wallstents. Radiology 1997; 204:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/47\">",
"      Vogel PM, Parise C. SMART stent for salvage of hemodialysis access grafts. J Vasc Interv Radiol 2004; 15:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/48\">",
"      Bakken AM, Protack CD, Saad WE, et al. Long-term outcomes of primary angioplasty and primary stenting of central venous stenosis in hemodialysis patients. J Vasc Surg 2007; 45:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/49\">",
"      Konner K, Vorwerk D. Permanent pacemaker wires causing subclavian vein stenosis in presence of AV fistula--is it ever wrong to try angioplasty and stenting? Nephrol Dial Transplant 1997; 12:1735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/50\">",
"      Teo N, Sabharwal T, Rowland E, et al. Treatment of superior vena cava obstruction secondary to pacemaker wires with balloon venoplasty and insertion of metallic stents. Eur Heart J 2002; 23:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/51\">",
"      Asif A, Salman L, Carrillo RG, et al. Patency rates for angioplasty in the treatment of pacemaker-induced central venous stenosis in hemodialysis patients: results of a multi-center study. Semin Dial 2009; 22:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/52\">",
"      Baddour LM, Epstein AE, Erickson CC, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010; 121:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/53\">",
"      Lekkerkerker JC, van Nieuwkoop C, Trines SA, et al. Risk factors and time delay associated with cardiac device infections: Leiden device registry. Heart 2009; 95:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/54\">",
"      Chamis AL, Peterson GE, Cabell CH, et al. Staphylococcus aureus bacteremia in patients with permanent pacemakers or implantable cardioverter-defibrillators. Circulation 2001; 104:1029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/55\">",
"      Love CJ, Wilkoff BL, Byrd CL, et al. Recommendations for extraction of chronically implanted transvenous pacing and defibrillator leads: indications, facilities, training. North American Society of Pacing and Electrophysiology Lead Extraction Conference Faculty. Pacing Clin Electrophysiol 2000; 23:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/56\">",
"      Chua JD, Wilkoff BL, Lee I, et al. Diagnosis and management of infections involving implantable electrophysiologic cardiac devices. Ann Intern Med 2000; 133:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/57\">",
"      Sohail MR, Uslan DZ, Khan AH, et al. Management and outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. J Am Coll Cardiol 2007; 49:1851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/58\">",
"      Wilkoff BL, Love CJ, Byrd CL, et al. Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA). Heart Rhythm 2009; 6:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/59\">",
"      Currier CB Jr, Widder S, Ali A, et al. Surgical management of subclavian and axillary vein thrombosis in patients with a functioning arteriovenous fistula. Surgery 1986; 100:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/60\">",
"      Fulks KD, Hyde GL. Jugular-axillary vein bypass for salvage of arteriovenous access. J Vasc Surg 1989; 9:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/61\">",
"      Puskas JD, Gertler JP. Internal jugular to axillary vein bypass for subclavian vein thrombosis in the setting of brachial arteriovenous fistula. J Vasc Surg 1994; 19:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/62\">",
"      Gertler JP. Decompression of the occluded subclavian vein in the patient with ipsilateral threatened access by transposition of the internal jugular vein. ASAIO J 1995; 41:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/63\">",
"      El-Sabrout RA, Duncan JM. Right atrial bypass grafting for central venous obstruction associated with dialysis access: another treatment option. J Vasc Surg 1999; 29:472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39432/abstract/64\">",
"      Ayarragaray JE. Surgical treatment of hemodialysis-related central venous stenosis or occlusion: another option to maintain vascular access. J Vasc Surg 2003; 37:1043.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1913 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-AB43D6AFE1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_32_39432=[""].join("\n");
var outline_f38_32_39432=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CAUSE AND INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Subclavian vein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Left internal jugular vein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Right internal jugular vein",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Temporary dialysis catheters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Indwelling permanent pacemakers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Peripherally inserted central catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS AND EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Observation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Percutaneous angioplasty with or without stenting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Implantable cardiac devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Surgical therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Access occlusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/19/44345?source=related_link\">",
"      Infections involving cardiac implantable electronic devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/56/19338?source=related_link\">",
"      Malignancy-related superior vena cava syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/22/31082?source=related_link\">",
"      Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/22/15722?source=related_link\">",
"      Thrombosis associated with chronic hemodialysis vascular access: Catheters",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_32_39433="Juvenile systemic sclerosis (scleroderma)";
var content_f38_32_39433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Juvenile systemic sclerosis (scleroderma)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/32/39433/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/32/39433/contributors\">",
"     Francesco Zulian, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/32/39433/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/32/39433/contributors\">",
"     Thomas JA Lehman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/32/39433/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/32/39433/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/32/39433/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Scleroderma is a spectrum of disorders that can occur at any stage of life, although the clinical patterns of childhood sclerosis differ from that of adulthood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The predominant form of childhood sclerosis is localized scleroderma. Juvenile systemic sclerosis (JSSc) is uncommon, but has the most significant morbidity of the sclerotic disorders.",
"   </p>",
"   <p>",
"    JSSc is a chronic, multisystem, connective tissue disorder characterized by symmetrical fibrous thickening and hardening of the skin combined with fibrous changes in internal organs, such as the esophagus, intestinal tract, heart, lungs, and kidneys. The extent of skin involvement and the accompanying pattern of internal organ involvement form the basis for the classification of systemic sclerosis in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/2\">",
"     2",
"    </a>",
"    ]. Provisional classification criteria for juvenile systemic sclerosis (JSSc) using consensus-based methodologies have been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the clinical presentation, diagnosis, and management of juvenile systemic sclerosis (JSSc). Localized scleroderma and the pathogenesis of systemic sclerosis are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40985?source=see_link\">",
"     \"Localized scleroderma in childhood\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/63/19450?source=see_link\">",
"     \"Pathogenesis of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal types of systemic sclerosis include the following subsets in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/3\">",
"     3",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44087?source=see_link\">",
"     \"Classification of scleroderma disorders\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Diffuse cutaneous systemic sclerosis (dcSSc)",
"     </li>",
"     <li>",
"      Limited cutaneous systemic sclerosis (lcSSc)",
"     </li>",
"     <li>",
"      Overlap syndrome",
"     </li>",
"     <li>",
"      Prescleroderma",
"     </li>",
"     <li>",
"      Scleroderma-sine scleroderma in which patients have only internal organ involvement and no skin involvement",
"     </li>",
"     <li>",
"      Environmentally-induced scleroderma",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children, most patients have the dcSSc type and the lcSSc form is uncommon. Only one case of childhood scleroderma-sine scleroderma has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/4\">",
"     4",
"    </a>",
"    ], and there are no reports of environmentally-induced scleroderma in childhood. Prescleroderma is an increasingly recognized condition in children, which progresses to dcSSc.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated incidence of JSSc in the United Kingdom and Ireland was 0.27 cases per million children per year in a 2005 to 2007 survey [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/5\">",
"     5",
"    </a>",
"    ]. The incidence of JSSc in other populations is not known. In general population studies, children constitute only 3 percent of all cases of SSc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/6\">",
"     6",
"    </a>",
"    ]. It has been estimated that less than 10 percent of all patients develop systemic sclerosis before the age of 20 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    JSSc occurs three times more often in girls than in boys among those older than eight years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. However, the risk in both sexes is similar in younger children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOGENESIS AND GENETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cause of systemic sclerosis is unknown and the pathogenesis appears to be complex. The process involves three components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immune activation",
"     </li>",
"     <li>",
"      Endothelial (vascular) damage",
"     </li>",
"     <li>",
"      Excessive synthesis of extracellular matrix with increased deposition of structurally normal collagen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic factors appear to increase the susceptibility to development of systemic sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A full discussion of the pathogenesis and genetic and environmental risk factors for systemic sclerosis is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/63/19450?source=see_link\">",
"     \"Pathogenesis of systemic sclerosis (scleroderma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/65?source=see_link\">",
"     \"Risk factors for and possible causes of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The onset of JSSc is usually insidious and the interval between onset and diagnosis in childhood is often prolonged. Following onset the course may be prolonged with periods of active and inactive disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of children with JSSc present with skin changes (tightening, thinning, and atrophy) of the hands and face,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Raynaud phenomenon (",
"    <a class=\"graphic graphic_table graphicRef66446 \" href=\"mobipreview.htm?16/50/17195\">",
"     table 1",
"    </a>",
"    ). Other presenting complaints include arthralgia, muscle weakness and pain, subcutaneous calcification (calcinosis), dysphagia, and dyspnea.",
"   </p>",
"   <p>",
"    This was illustrated in a multi-center retrospective study of 153 children with juvenile systemic sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/10\">",
"     10",
"    </a>",
"    ]. The median age of onset was 8.1 years and the mean duration of symptoms prior to diagnosis was 1.9 years. Almost 80 percent of the patients were girls. Eleven percent had a family history of autoimmune disease. Symptoms or findings at diagnosis were as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Raynaud phenomenon &mdash; 70 percent",
"     </li>",
"     <li>",
"      Proximal skin induration &mdash; 63 percent",
"     </li>",
"     <li>",
"      Musculoskeletal symptoms (eg, arthralgia, muscle weakness, and arthritis) &mdash; 33 percent",
"     </li>",
"     <li>",
"      Weight loss &mdash; 18 percent",
"     </li>",
"     <li>",
"      Dyspnea &mdash; 10 percent",
"     </li>",
"     <li>",
"      Dysphagia &mdash; 10 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Early JSSc may mimic juvenile polyarthritis as affected patients often present with swollen hands or feet (",
"    <a class=\"graphic graphic_picture graphicRef74951 \" href=\"mobipreview.htm?6/50/6946\">",
"     picture 1",
"    </a>",
"    ). These symptoms may persist for weeks, before skin changes as a result of sclerosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    Raynaud phenomenon emerge.",
"   </p>",
"   <p>",
"    Skin changes characteristically evolve in the following sequence:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Edema",
"     </li>",
"     <li>",
"      Induration and edema, resulting in skin tightening and contractures",
"     </li>",
"     <li>",
"      Atrophy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The duration of the first two phases vary, with edema usually occurring over months and induration lasting from three to five years. The residual atrophic phase persists as an integral part of the disease process.",
"   </p>",
"   <p>",
"    During the atrophic phase, the skin becomes sclerotic (waxy in texture, tight, and hard) and bonds to subcutaneous structures. This is particularly noticeable over the digits and face, where the characteristic facial appearance may be the first clue to the diagnosis.",
"   </p>",
"   <p>",
"    Raynaud phenomenon is often the presenting symptom. It may precede other manifestations by years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/12\">",
"     12",
"    </a>",
"    ]. Raynaud phenomenon is more common in the fingers but can be observed in the toes, ears, lips, tongue, and the tip of the nose. The presence of digital ulcers in a child with Raynaud phenomenon strongly suggests the diagnosis of JSSc. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6921?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the Raynaud phenomenon\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Musculoskeletal involvement is common and characteristically occurs at or near the onset of the disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arthralgia is usually mild and transient. It is the presenting symptom in about 15 percent of children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Joint contractures are most common at the proximal intraphalangeal joints and elbows.",
"     </li>",
"     <li>",
"      Arthritis and myositis may occur in up to 30 percent of children, and are characteristic of the overlapping manifestations that may precede a diagnosis of JSSc [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/13\">",
"       13",
"      </a>",
"      ]. Myositis leads to muscle weakness and myalgia, and is associated with elevated levels of creatinine kinase (CPK). Myocarditis may occur and children with significantly elevated CPK should be appropriately evaluated.",
"     </li>",
"     <li>",
"      Periarticular and subcutaneous calcinosis may occur in one-fifth of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/10\">",
"       10",
"      </a>",
"      ], whereas bone resorption is uncommon in children and adolescents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Telangiectasia is less commonly present in children than adults with JSSc (",
"    <a class=\"graphic graphic_picture graphicRef72449 \" href=\"mobipreview.htm?20/49/21264\">",
"     picture 2",
"    </a>",
"    ). Nailfold capillary abnormalities are common. The periungual nailfold is the most accessible site for detection. Examination with an ophthalmoscope may demonstrate capillary dropout, tortuous dilated loops, and occasionally distorted capillary architecture (",
"    <a class=\"graphic graphic_picture graphicRef72422 \" href=\"mobipreview.htm?0/38/608\">",
"     picture 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef79285 \" href=\"mobipreview.htm?19/15/19701\">",
"     picture 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Children rarely present with complaints of visceral organ involvement. Direct questioning is often required to elicit a history of dysphagia, diarrhea, myalgia, or dyspnea, suggesting internal organ involvement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     General laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;About one-fourth of patients have anemia of chronic disease, or less commonly, macrocytic anemia due to malabsorption of vitamin B12 or folate. Leukocytosis is not prominent. Patients with myositis will have elevated creatinine kinase. Eosinophilia is present in 15 percent of patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Other organ involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with JSSc, visceral organ involvement may be widespread and can be associated with significant morbidity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Gastrointestinal disease &mdash; During the disease course, gastrointestinal involvement is reported to occur in 30 to 74 percent of children with JSSc [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/10,13\">",
"       10,13",
"      </a>",
"      ]. Most affected patients have esophageal dysfunction, resulting in gastroesophageal reflux and dysphagia. Large bowel involvement may present as alternating complaints of constipation and diarrhea, bloating, abdominal discomfort, or malabsorptive stools.",
"      <br/>",
"      <br/>",
"      Radiologic and functional studies of the GI tract often demonstrate abnormalities even in the absence of symptoms. Manometry and intraesophageal 24-hour pH monitoring are sensitive indicators of diminished lower esophageal sphincter tone and gastroesophageal reflux [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/35/41529?source=see_link\">",
"       \"Gastrointestinal manifestations of systemic sclerosis (scleroderma)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pulmonary disease &mdash; Pulmonary involvement, although frequently asymptomatic until there is dyspnea, may present as a dry, hacking cough [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/17\">",
"       17",
"      </a>",
"      ]. Unlike adults, interstitial pulmonary fibrosis, a devastating complication, is rarely reported in children with JSSc [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/10,13\">",
"       10,13",
"      </a>",
"      ]. Pulmonary vascular disease occurs either independently or as a result of pulmonary fibrosis in less than 4 percent of patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/13\">",
"       13",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Screening tests for pulmonary disease in children with JSSc include chest radiograph, high resolution computed tomography (HRCT), and pulmonary function studies:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pulmonary function studies &mdash; Pulmonary diffusion (DLCO) and spirometry are sensitive measures of involvement of the respiratory tract and are used as a screening test for pulmonary disease in children with JSSc. These studies may be abnormal despite normal chest radiographs.",
"     </li>",
"     <li>",
"      Chest radiograph &mdash; The chest radiograph, due to its low sensitivity in revealing early signs of lung involvement, should not be used as a screening test for pulmonary disease in children with JSSc. The classic radiographic feature only appears when an advanced degree of interstitial lung disease is present and consists of symmetric, reticulonodular shadowing, most pronounced at the lung bases.",
"     </li>",
"     <li>",
"      High resolution computed tomography &mdash; HRCT may reveal pulmonary disease even in the presence of a normal chest radiograph. In children with JSSc, HRCT findings may include groundglass opacification, subpleural micronodules, linear opacities, and honey combing appearance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/18,19\">",
"       18,19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Echocardiography is important for detecting pulmonary hypertension.",
"      <br/>",
"      <br/>",
"      Early diagnosis and therapy are important, as lung disease is one of the major causes of death in children with JSSc [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/20,21\">",
"       20,21",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29224?source=see_link\">",
"       \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cardiac involvement &mdash; Although uncommon, cardiac involvement is a significant cause of morbidity among children with JSSc [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/10,13\">",
"       10,13",
"      </a>",
"      ]. Cardiac fibrosis may lead to conduction defects, arrhythmias, and impaired ventricular function. Pericardial effusions are common but are not usually of hemodynamic significance. In addition, pulmonary hypertension caused by pulmonary vascular disease can lead to myocardial damage and right heart failure.",
"      <br/>",
"      <br/>",
"      Severe cardiomyopathy, although rare, requires prompt and aggressive immunosuppressive therapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/20\">",
"       20",
"      </a>",
"      ]. Cardiorespiratory complications are the leading cause of death in children with JSSc [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/10,21\">",
"       10,21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Renal involvement &mdash; The reported prevalence of renal crisis in children with JSSc ranges from 0.7 to 4 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/10,13\">",
"       10,13",
"      </a>",
"      ]. In a case series of 153 children with systemic sclerosis, about 10 percent had renal involvement (such as proteinuria, hematuria, or progressive renal failure) but there was only one child with acute renal crisis, accelerated hypertension, and renal failure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/10\">",
"       10",
"      </a>",
"      ]. Although renal involvement in children may not be as severe as what is seen in adult patients, the abrupt onset of accelerated hypertension with acute renal failure (scleroderma renal crisis) is a severe and life-threatening complication. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35801?source=see_link\">",
"       \"Scleroderma renal crisis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Disease progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;JSSc is usually most active during the first three to five years following onset of disease. Typical findings include fatigue, weight loss, rapidly advancing skin sclerosis, arthritis, myositis, and tendonitis. Visceral involvement also commonly occurs during this period.",
"   </p>",
"   <p>",
"    After the first five years of disease, constitutional symptoms often abate, skin abnormalities may stabilize or occasionally improve, but visceral involvement may progress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of JSSc in childhood is often delayed because of its rarity and the subtle initial manifestations. The diagnosis is established clinically by the presence of typical skin thickening and hardening (sclerosis) that is not confined to one area (ie, not localized scleroderma) and visceral involvement. The diagnosis is further supported by the presence of associated autoantibodies.",
"   </p>",
"   <p>",
"    A multicenter multinational group representing the Paediatric Rheumatology European Society (PRES), the American College of Rheumatology (ACR), and European League Against Rheumatism (EULAR) defined nomenclature and criteria to diagnosis and classify JSSc based upon clinical features and laboratory parameters [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a patient less than 16 years of age, JSSc is diagnosed if the major criterion and at least 2 of 20 minor criteria are present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/2\">",
"     2",
"    </a>",
"    ]. The criteria are as follows (",
"    <a class=\"graphic graphic_table graphicRef57048 \" href=\"mobipreview.htm?22/26/22956\">",
"     table 2",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major criterion (required) &mdash; Proximal",
"      <span class=\"nowrap\">",
"       sclerosis/induration",
"      </span>",
"      of the skin",
"     </li>",
"     <li>",
"      Minor criteria &mdash; Two of the following are required:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Skin &mdash; Sclerodactyly",
"     </li>",
"     <li>",
"      Vascular &mdash; Raynaud phenomenon, nailfold capillary abnormalities, or digital tip ulcers",
"     </li>",
"     <li>",
"      Gastrointestinal &mdash; Dysphagia or gastroesophageal reflux",
"     </li>",
"     <li>",
"      Renal &mdash; Renal crisis or new onset arterial hypertension",
"     </li>",
"     <li>",
"      Cardiac &mdash; Arrhythmias or heart failure",
"     </li>",
"     <li>",
"      Respiratory &mdash; Evidence of pulmonary fibrosis, abnormality of diffusion capacity of the lungs for carbon monoxide (DLCO), or pulmonary hypertension",
"     </li>",
"     <li>",
"      Musculoskeletal &mdash; Tendon friction ribs, arthritis, or myositis",
"     </li>",
"     <li>",
"      Neurological &mdash; Neuropathy or carpal tunnel syndrome",
"     </li>",
"     <li>",
"      Serological testing &mdash; Presence of antinuclear antibodies or SSc selective autoantibodies (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Laboratory tests and pathology'",
"      </a>",
"      below)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Laboratory tests and pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although no laboratory test confirms the diagnosis of JSSc, the presence of autoantibodies is supportive. High titers of antinuclear antibodies (ANA) are reported in 80 to 97 percent of children with JSSc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. Anti-topoisomerase I (ScI-70) antibodies are less frequent in children (20 to 30 percent) compared with adults (30 to 40 percent), as are anticentromere antibodies, which are found in 7 to 8 percent of children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/10,13\">",
"     10,13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, routine blood tests (eg, complete blood cell count, serum chemistries, and urinalysis) are not helpful diagnostically.",
"   </p>",
"   <p>",
"    A skin biopsy may sometimes be helpful to differentiate JSSc from other syndromes. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because JSSc involves the skin, muscle, and internal organs, the differential diagnosis involves other multi-system organ diseases with skin involvement including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Juvenile dermatomyositis",
"     </li>",
"     <li>",
"      Mixed connective tissue disease",
"     </li>",
"     <li>",
"      Systemic lupus erythematosus",
"     </li>",
"     <li>",
"      Juvenile idiopathic arthritis (juvenile rheumatoid arthritis)",
"     </li>",
"     <li>",
"      Overlap syndrome",
"     </li>",
"     <li>",
"      Scleredema",
"     </li>",
"     <li>",
"      Eosinophilic fasciitis",
"     </li>",
"     <li>",
"      Chronic graft versus host disease",
"     </li>",
"     <li>",
"      Nephrogenic systemic fibrosis",
"     </li>",
"     <li>",
"      Phenylketonuria with sclerodermatous skin lesions",
"     </li>",
"     <li>",
"      Syndromes of premature aging (eg, Progeria and Werner syndrome)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other rheumatologic disorders with both skin and internal organ involvement, such as mixed connective tissue disease and the overlap syndromes, are the most difficult conditions to differentiate from JSSc. Juvenile idiopathic arthritis with \"dry arthritis\" and mild inflammatory laboratory changes may be especially difficult to distinguish from JSSc. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/24/43401?source=see_link\">",
"     \"Clinical manifestations of mixed connective tissue disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3447?source=see_link\">",
"     \"Definition and diagnosis of mixed connective tissue disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nephrogenic systemic fibrosis (NSF) is a fibrosing disorder seen only in patients with kidney failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/22\">",
"     22",
"    </a>",
"    ]. It is characterized by thickening and hardening of the skin overlying the extremities and trunk and by marked expansion and fibrosis of the dermis in association with CD34-positive fibrocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/22\">",
"     22",
"    </a>",
"    ]. The lesions are often preceded by edema and may initially be misdiagnosed as cellulitis. Skin involvement occurs in all patients and systemic involvement in some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/22\">",
"     22",
"    </a>",
"    ]. The prevalence of systemic involvement is unknown, but a number of different organ system manifestations have been described.",
"   </p>",
"   <p>",
"    The diagnosis of NSF is based upon histopathologic examination of a biopsy of an involved site. On microscopic examination, there is a subtle proliferation of dermal fibroblasts in early lesions and florid proliferation of fibroblasts and dendritic cells in more advanced disease. Inflammatory infiltrates are usually absent. Collagen bundles with surrounding clefts are prominent and dermal mucin and elastic fibers are variably increased. The cause is unknown, but increasing evidence has implicated gadolinium containing contrast agents in the pathogenesis of NSF. The latent period between gadolinium exposure and disease onset is usually two to four weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/23-27\">",
"     23-27",
"    </a>",
"    ], although the reported range is as wide as 2 days to 18 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In young children, phenylketonuria and progeria may mimic JSSc:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In phenylketonuria, skin lesions usually appear during the first year of life, and are symmetric and poorly demarcated. They occur most frequently on the lower extremities and trunk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In progeria, the skin changes also typically develop during the first year of life. Lesions are characterized by thickened, bound-down skin on the abdomen, flanks, proximal thighs, and upper buttocks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Werner syndrome most often presents in adolescents. It is characterized by generalized atrophy of the muscle and subcutaneous tissue, graying of the hair, baldness, and scleroderma-like skin changes and ulcers on the extremities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LIMITED CUTANEOUS SYSTEMIC SCLEROSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited cutaneous systemic sclerosis (lcSSc) is less common in children than in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/13,33,34\">",
"     13,33,34",
"    </a>",
"    ]. This variant is seen in about 10 to 36 percent of children with systemic sclerosis. In the",
"    <span class=\"nowrap\">",
"     PRES/ACR/EULAR",
"    </span>",
"    Provisional Classification Criteria for Juvenile Systemic Sclerosis, lcSSc is not distinguished as a separate entity from JSSc [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Clinical manifestations of lcSSc",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sclerosis classically involves the fingers, sometimes extending to the hands and lower part of the arm. It also may involve the perioral area of the face and less often the feet. Involvement of the hands can be disabling, and it is exacerbated by vascular insufficiency, digital pitting scars (",
"    <a class=\"graphic graphic_picture graphicRef60308 \" href=\"mobipreview.htm?40/55/41854\">",
"     picture 5",
"    </a>",
"    ), terminal bone tuft resorption (",
"    <a class=\"graphic graphic_picture graphicRef68280 \" href=\"mobipreview.htm?41/31/42480\">",
"     picture 6",
"    </a>",
"    ), and digital ulcers.",
"   </p>",
"   <p>",
"    Other clinical findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Raynaud phenomenon, which is frequently complicated with digital ulceration and critical ischemia leading to gangrene [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Calcinosis (",
"      <a class=\"graphic graphic_picture graphicRef67757 \" href=\"mobipreview.htm?23/5/23647\">",
"       picture 7",
"      </a>",
"      ), which is often more severe than in dcSSc.",
"     </li>",
"     <li>",
"      Telangiectasia (",
"      <a class=\"graphic graphic_picture graphicRef72449 \" href=\"mobipreview.htm?20/49/21264\">",
"       picture 2",
"      </a>",
"      ), which is more widespread than in dcSSc.",
"     </li>",
"     <li>",
"      Gastrointestinal involvement, with esophageal dysfunction seen at presentation. The small and large intestine may become involved later.",
"     </li>",
"     <li>",
"      Pulmonary hypertension, which is progressive. Although it occurs infrequently in children, it the most common cause of death for those with lcSSc.",
"     </li>",
"     <li>",
"      Neurologic manifestations, including headache, seizures, encephalitis and EEG alterations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Uveitis, arthritis, and vasculitis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PRE-SCLERODERMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pre-scleroderma is seen in children with Raynaud phenomenon who have abnormal nailfold capillaroscopic findings and positive antinuclear antibodies (",
"    <a class=\"graphic graphic_table graphicRef80559 \" href=\"mobipreview.htm?3/41/3741\">",
"     table 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef72422 \" href=\"mobipreview.htm?0/38/608\">",
"     picture 3",
"    </a>",
"    ). Almost all these patients (90 percent) will progress to systemic sclerosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. All children with Raynaud phenomenon should therefore be screened with disease-specific autoantibodies (such as ANA, anti-Scl-70, anticentromere, and anti-RNA polymerase antibodies) and with nailfold capillaroscopy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SYSTEMIC SCLEROSIS-SINE SCLERODERMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic sclerosis-sine scleroderma is extremely rare in childhood. The single published case described a six-year-old child who presented with nocturnal seizures, Raynaud phenomenon, and cardiopulmonary scleroderma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/4\">",
"     4",
"    </a>",
"    ]. The only cutaneous evidence of scleroderma was a slight thickening of the skin above the ankle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8773854\">",
"    <span class=\"h1\">",
"     SIMILARITIES AND DIFFERENCES BETWEEN CHILDREN AND ADULTS WITH SSC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children have significantly less frequent involvement of all organs at diagnosis, except for the prevalence of arthritis, compared with adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/10,13,37\">",
"     10,13,37",
"    </a>",
"    ]. Differences with adults become less evident during follow-up, with the exception of interstitial lung involvement, gastroesophageal dysmotility, renal involvement, and arterial hypertension, which are much more common in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/10,13,37,38\">",
"     10,13,37,38",
"    </a>",
"    ]. The prevalence of arthritis and muscle inflammation are slightly more common in children than adults, while Raynaud phenomenon and skin sclerosis are less frequent in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/10,37\">",
"     10,37",
"    </a>",
"    ]. Rates of pulmonary fibrosis and cardiac scleroderma are similar [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/38\">",
"     38",
"    </a>",
"    ]. The limited cutaneous form is rare in children, but more frequent in adults. However, a substantial number of patients with childhood-onset SSc were diagnosed either during adolescence or as young adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/13\">",
"     13",
"    </a>",
"    ]. Thus, it is possible that the limited cutaneous subset may be under diagnosed in younger children because the full clinical picture may only evolve later.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8773861\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF DISEASE ACTIVITY AND SEVERITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory assessment of disease activity or severity is difficult. Regular follow-up and clinical review are the cornerstones of monitoring activity and progression. Many serologic markers of activity, such as ICAM-1, collagen propeptides, products of type I collagen breakdown, immunologic markers (sIL-2 receptor, neopterin) or vascular activation markers (E-selectin, thrombomodulin, von Willebrand factor) have been proposed throughout the years, but none has shown significant correlation with the clinical status of the patient.",
"   </p>",
"   <p>",
"    Objective assessment is necessary for organ-based complications, such as pulmonary fibrosis, pulmonary hypertension, or renal involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/39\">",
"     39",
"    </a>",
"    ]. In addition, sequential skin scores can be recorded. To provide a more global index of severity, a scoring system has been proposed in adult patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/40\">",
"     40",
"    </a>",
"    ]. A multidimensional severity score, Juvenile Systemic Sclerosis Severity Score (J4S), has been developed to assess JSSc disease severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/41\">",
"     41",
"    </a>",
"    ]. This instrument includes nine organ system categories, scored from 0 to 4, weighting various organ system involvement on the basis of their clinical importance. J4S may have several applications for the pediatric age group, since it can be used to guide decision-making in daily clinical practice, compare study populations, and identify potentially reversible aspects of the disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;A carefully designed treatment program is based upon the disease progression, activity, and severity. This multi-team approach includes:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Skin care",
"     </li>",
"     <li>",
"      Exercise program to maintain functional ability",
"     </li>",
"     <li>",
"      Vascular protection",
"     </li>",
"     <li>",
"      Psychologic and social support",
"     </li>",
"     <li>",
"      Pharmacologic therapy including discussions on available options",
"     </li>",
"     <li>",
"      Surgical procedures if needed",
"     </li>",
"     <li>",
"      Education of the patient and family to help understand the complexity of management decisions, guide decision making, and to facilitate compliance with an often difficult and time consuming treatment plan",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Nonpharmacologic measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonpharmacologic measures include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The child should be encouraged to be as physically active as possible. Physiotherapy will help maintain functional ability, muscle strength, and joint movement while preventing flexion contractures. It should be performed consistently, as erratic and irregular regimens will be less effective.",
"     </li>",
"     <li>",
"      The use of corrective splints may be necessary to treat or prevent contractures. Splints may be required for an extended period of time.",
"     </li>",
"     <li>",
"      General skin care includes avoiding irritating or drying substances and the daily application of lanolin or water-soluble cream as an emollient.",
"     </li>",
"     <li>",
"      Patients and parents should be told to avoid cold, trauma, heat, and sun exposure. Cold and trauma can exacerbate symptoms. These children are also susceptible to hyperpigmentation from sunlight and have difficulty in dissipating heat through sclerotic skin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pharmacologic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pharmacologic management of patients with JSSc is challenging. Therapy can be directed as:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disease modifying therapy, which is directed at controlling the underlying disease process and includes immunomodulatory and antifibrotic agents.",
"     </li>",
"     <li>",
"      Organ targeted therapy, which is directed toward complications of specifically involved organs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of JSSc is mainly symptomatic and focuses on clinical manifestations and organ involvement (",
"    <a class=\"graphic graphic_algorithm graphicRef61685 \" href=\"mobipreview.htm?37/11/38078\">",
"     algorithm 1",
"    </a>",
"    ). No drug has been shown to be of unequivocal benefit in either children or adults with systemic sclerosis. In addition, many of these drugs have significant side effects. As a result, careful consideration must be made as to whether or not to initiate treatment, including balancing the known toxicities of the medications against the unknown possible therapeutic gain. Whenever possible these children should be referred to a specialized pediatric rheumatology center for consideration of appropriate therapy.",
"   </p>",
"   <p>",
"    The EULAR Scleroderma Trials and Research (EUSTAR) group has established evidence based recommendations for use in clinical practice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/42\">",
"     42",
"    </a>",
"    ]. The main aim of these recommendations is to provide guidance to adult and pediatric rheumatologists to correctly approach and choose the treatment for SSc patients. Possible combinations of these approaches to treatment are suggested by the algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef61685 \" href=\"mobipreview.htm?37/11/38078\">",
"     algorithm 1",
"    </a>",
"    ). There are no validated recommendations for JSSc. Thus, the therapeutic approach is based upon studies in adults and the author&rsquo;s experience.",
"   </p>",
"   <p>",
"    A more complete discussion of agents used as disease modifying therapy is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/18/23849?source=see_link\">",
"     \"Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a brief discussion of the complications of involved organs and their specific therapy. Pediatric-specific literature is reviewed here. A more complete discussion on organ based treatment for systemic sclerosis is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13642?source=see_link\">",
"     \"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8774232\">",
"    <span class=\"h3\">",
"     Raynaud phenomenon",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vascular complications of systemic sclerosis, usually manifested as Raynaud phenomenon (RP), are difficult to treat. Specific treatment of RP may be necessary in addition to avoidance of precipitating circumstances, such as cold or emotional stress. The most widely used vasodilator therapy is calcium channel blockers (CCBs), and of these",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    is the drug most commonly used.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/53/37716?source=see_link\">",
"     Iloprost",
"    </a>",
"    has been reported to be safe and effective in treatment of ischemic digits in children with dSSc and other connective tissue diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/43\">",
"     43",
"    </a>",
"    ]. In view of costs and feasibility, CCBs should be considered the first-line therapy in the treatment of RP. Intravenous prostanoids should be used when CCBs fail and there is severe ischemia. The author suggests administering nifedipine at a dose of 0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight hours. This dose can be progressively increased to 0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    depending on efficacy and side effects, up to maximum 10",
"    <span class=\"nowrap\">",
"     mg/dose.",
"    </span>",
"    As an alternative,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/61/42969?source=see_link\">",
"     nicardipine",
"    </a>",
"    20 mg at nighttime can be given (maximum dose 20 mg twice daily). Use of these drugs for Raynaud phenomenon is off-label. Treatment of RP is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/30/28138?source=see_link\">",
"     \"Treatment of the Raynaud phenomenon resistant to initial therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8774306\">",
"    <span class=\"h3\">",
"     Digital ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Digital ulcers (DU) are another severe and disabling complication of dcSSc. In view of overall risk-to-benefit considerations, the author suggests CCBs and prostanoids as first-line therapy in SSc-related DU.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/16/40200?source=see_link\">",
"     Bosentan",
"    </a>",
"    is a potential adjunctive treatment if the clinical response is unsatisfactory, aiming at the prevention of new DU rather than for healing DU. However, there are two major concerns related to the use of bosentan: potential liver injury and teratogenicity. Treatment of DU is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13642?source=see_link&amp;anchor=H13#H13\">",
"     \"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults\", section on 'Raynaud phenomenon'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/30/28138?source=see_link\">",
"     \"Treatment of the Raynaud phenomenon resistant to initial therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8774380\">",
"    <span class=\"h3\">",
"     Interstitial lung disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary alveolitis is predominant early, and later progresses to fibrosis. The author suggests initiating therapy for pulmonary alveolitis with low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (0.2 to 0.4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day)",
"    <strong>",
"     and",
"    </strong>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (CPM), either as a daily oral regimen (1 to 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) or as a monthly single intravenous pulse (500 to 750",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per month). The diagnosis and treatment of interstitial lung disease in patients with systemic sclerosis is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/19/7482?source=see_link\">",
"     \"Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35382?source=see_link\">",
"     \"Evaluation for and diagnosis of lung disease in systemic sclerosis (scleroderma)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26329?source=see_link\">",
"     \"Clinical manifestations of systemic sclerosis (scleroderma) lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8774428\">",
"    <span class=\"h3\">",
"     Pulmonary arterial hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the most lethal complications is pulmonary arterial hypertension (PAH), which can occur in the context of established interstitial fibrosis in lcSSc. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6935?source=see_link\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26342?source=see_link\">",
"     \"Pulmonary vascular disease in systemic sclerosis (scleroderma): Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8774484\">",
"    <span class=\"h3\">",
"     Skin involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapies for skin involvement vary depending upon the extent of skin sclerosis. The author suggests a weekly regimen of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , 15",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    as a single oral or subcutaneous dose per week for at least one year, in combination with low dose oral glucocorticoids if the skin involvement is isolated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13642?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults\", section on 'Skin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/18/23849?source=see_link\">",
"     \"Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8774512\">",
"    <span class=\"h3\">",
"     Renal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for renal crisis was uniformly dismal until the introduction of angiotensin-converting enzyme inhibitors (ACEi) (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/59/9145?source=see_link\">",
"     captopril",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    ) brought about a remarkable improvement in the outlook for prevention of vascular damage, effective long-term control of blood pressure, and stabilization of renal function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13642?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults\", section on 'Treatment of hypertension and renal disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemodialysis with or without bilateral nephrectomy and transplantation was an option in cases of irreversible renal failure or uncontrollable hypertension. However the advent of angiotensin converting enzyme inhibitors makes this of primarily historic interest only.(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35801?source=see_link\">",
"     \"Scleroderma renal crisis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8774575\">",
"    <span class=\"h3\">",
"     Musculoskeletal involvement",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of musculoskeletal involvement (myositis, arthritis, and tenosynovitis) includes the use glucocorticoids. The author suggests a dose of 0.3 to 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day. Patients on glucocorticoids should be carefully monitored for blood pressure and renal function, because of a potential increased risk of scleroderma renal crisis. Attention should be paid especially to patients with early dcSSc and high or rapidly progressing skin score. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13642?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults\", section on 'Musculoskeletal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8774595\">",
"    <span class=\"h3\">",
"     Gastrointestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies in children with JSSc address the most effective management for gastrointestinal disease, which includes gastroesophageal reflux, erosive esophagitis, and malabsorption due to bacterial overgrowth. Treatment of these disorders is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13642?source=see_link&amp;anchor=H19#H19\">",
"     \"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults\", section on 'Gastrointestinal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/35/41529?source=see_link\">",
"     \"Gastrointestinal manifestations of systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8774614\">",
"    <span class=\"h3\">",
"     Experimental therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) for early diffuse scleroderma and lung disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/19/7482?source=see_link\">",
"     \"Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the most aggressive approaches to therapy is immunoablation followed by reconstitution with autologous hemopoietic stem cell transplantation (HSCT). The rationale for this therapy is the ablation of self-reactive lymphocytic clones, which are responsible for the disease process. Mortality rate is relatively high, although it is still an option to consider for pediatric patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/44,45\">",
"     44,45",
"    </a>",
"    ] who are early in the disease course (three years or less from the first non-Raynaud sign or symptom) before unmodifiable damage has resulted (eg, fibrosis). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/18/23849?source=see_link&amp;anchor=H8#H8\">",
"     \"Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)\", section on 'Autologous stem cell transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other investigational approaches are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/18/23849?source=see_link&amp;anchor=H15#H15\">",
"     \"Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)\", section on 'Future approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Disease monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Validated clinical outcome measures for children with SSc are lacking. The author uses parameters that have been established in adults. These organ-specific parameters include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Skin thickness score &mdash; Skin induration is measured using the Modified Rodnan Skin Score (MRSS). Normative values using the MRSS for children without scleroderma have been established [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/46\">",
"       46",
"      </a>",
"      ]. In children, MRSS correlates with the body mass index (BMI) and the Tanner stage and it should be corrected for these two parameters in children. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/11/37045?source=see_link&amp;anchor=H3#H3\">",
"       \"Pretreatment evaluation of adults with systemic sclerosis (scleroderma)\", section on 'Cutaneous'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Forced vital capacity (FVC) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/39\">",
"       39",
"      </a>",
"      ] (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35382?source=see_link\">",
"       \"Evaluation for and diagnosis of lung disease in systemic sclerosis (scleroderma)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/11/37045?source=see_link&amp;anchor=H9#H9\">",
"       \"Pretreatment evaluation of adults with systemic sclerosis (scleroderma)\", section on 'Pulmonary'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Diffusing capacity for carbon monoxide (DLCO)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other proposed outcome measures for adult SSc include high-resolution computed tomography of the lung (HRCT), a six-minute walking test (6MWT), creatinine clearance, and reported outcome by patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/11/37045?source=see_link\">",
"     \"Pretreatment evaluation of adults with systemic sclerosis (scleroderma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two tools that measure patient function and quality of life have been validated for children with juvenile idiopathic arthritis (JIA) and juvenile dermatomyositis (JDM), the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ-PF50). Although these two instruments appear to be excellent tools to measure clinical outcome in children with SSc, especially in clinical trials, validation of these measures is required.",
"   </p>",
"   <p>",
"    In adults, the response to treatment for Raynaud phenomenon (RP) can be assessed by",
"    <span class=\"nowrap\">",
"     patient/parents",
"    </span>",
"    RP activity assessment, clinician RP activity assessment, RP frequency (number of attacks per week), and RP duration (mean duration of RP attacks per week) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/43\">",
"     43",
"    </a>",
"    ]. Digital ulcers as complication of RP or vasculitis can be evaluated by both digital ulcer count and pain. A prospective validation of these parameters in children is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1048307\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, the prognosis of SSc in children appears better than in adults. Survival rates for childhood onset SSc at 5, 10, 15, and 20 years after diagnosis are 89, 80 to 87, 74 to 87, and 69 to 82 percent respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/13,21,48\">",
"     13,21,48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The commonest causes of death in children are related to the involvement of cardiac, renal, and pulmonary systems. Cardiomyopathy is a leading cause of early death, especially in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/20,48\">",
"     20,48",
"    </a>",
"    ]. This complication is rare and usually associated with diffuse cutaneous disease and features of polymyositis. An aggressive immunosuppressive treatment is effective on muscle, skin, and lung involvement, but may not prevent progression of myocardial dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diffuse cutaneous SSc subset is considered a risk factor for higher mortality in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], but does not appear so relevant in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/48\">",
"     48",
"    </a>",
"    ]. Similarly, in adult series the presence of antitopoisomerase I and anti RNA polymerase III antibodies and male gender are associated with poorer survival, while in children no clear relationship was found between serological features, age at onset, gender, and mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39433/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with juvenile systemic sclerosis (JSSc) have a significant risk of severe morbidity and often have a poor prognosis.",
"     </li>",
"     <li>",
"      Juvenile systemic sclerosis (JSSc) is characterized by symmetrical fibrous thickening and hardening of the skin combined with fibrous changes in internal organs, such as the esophagus, intestinal tract, heart, lungs, and kidneys. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment is divided into three components: nonpharmacologic measures, disease modifying therapy, and therapy for specific complications. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonpharmacologic measures include skin care, exercise program, and the use of corrective splints. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Nonpharmacologic measures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pharmacologic management of children with juvenile systemic sclerosis is challenging, since there are no controlled trials. Treatment is based primarily upon studies from adult patients, and is primarily organ targeted therapy directed at controlling the complications of specifically involved organs. Thus, pharmacologic therapy is tailored to the individual needs of the patient based upon their specific clinical manifestations of the disease and organ involvement. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Pharmacologic therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/1\">",
"      Denton CP, Derrett-Smith EC. Juvenile-onset systemic sclerosis: children are not small adults. Rheumatology (Oxford) 2009; 48:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/2\">",
"      Zulian F, Woo P, Athreya BH, et al. The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. Arthritis Rheum 2007; 57:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/3\">",
"      LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/4\">",
"      Navon P, Halevi A, Brand A, et al. Progressive systemic sclerosis sine scleroderma in a child presenting as nocturnal seizures and Raynaud's phenomenon. Acta Paediatr 1993; 82:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/5\">",
"      Herrick AL, Ennis H, Bhushan M, et al. Incidence of childhood linear scleroderma and systemic sclerosis in the UK and Ireland. Arthritis Care Res (Hoboken) 2010; 62:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/6\">",
"      Cassidy JT, Sullivan DB, Dabich L, Petty RE. Scleroderma in children. Arthritis Rheum 1977; 20:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/7\">",
"      Kornreich HK, King KK, Bernstein BH, et al. Scleroderma in childhood. Arthritis Rheum 1977; 20:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/8\">",
"      Medsger TA Jr. Epidemiology of systemic sclerosis. Clin Dermatol 1994; 12:207.",
"     </a>",
"    </li>",
"    <li>",
"     Zulian F, Cassidy JT. The systemic sclerodermas and related disorders. In: Textbook of pediatric rheumatology, 6th ed, Cassidy JT, Petty RE, Laxer RM, Lindsley CB (Eds), Elsevier Saunders, Philadelphia 2010. p.414.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/10\">",
"      Martini G, Foeldvari I, Russo R, et al. Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. Arthritis Rheum 2006; 54:3971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/11\">",
"      Agarwal SK. The genetics of systemic sclerosis. Discov Med 2010; 10:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/12\">",
"      Nigrovic PA, Fuhlbrigge RC, Sundel RP. Raynaud's phenomenon in children: a retrospective review of 123 patients. Pediatrics 2003; 111:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/13\">",
"      Scalapino K, Arkachaisri T, Lucas M, et al. Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease. J Rheumatol 2006; 33:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/14\">",
"      Ingegnoli F, Zeni S, Gerloni V, Fantini F. Capillaroscopic observations in childhood rheumatic diseases and healthy controls. Clin Exp Rheumatol 2005; 23:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/15\">",
"      Dolezalova P, Young SP, Bacon PA, Southwood TR. Nailfold capillary microscopy in healthy children and in childhood rheumatic diseases: a prospective single blind observational study. Ann Rheum Dis 2003; 62:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/16\">",
"      Weber P, Ganser G, Frosch M, et al. Twenty-four hour intraesophageal pH monitoring in children and adolescents with scleroderma and mixed connective tissue disease. J Rheumatol 2000; 27:2692.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/17\">",
"      Eid NS, Buchino JJ, Schikler KN. Pulmonary manifestations of rheumatic diseases. Pediatr Pulmonol Suppl 1999; 18:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/18\">",
"      Koh DM, Hansell DM. Computed tomography of diffuse interstitial lung disease in children. Clin Radiol 2000; 55:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/19\">",
"      Seely JM, Jones LT, Wallace C, et al. Systemic sclerosis: using high-resolution CT to detect lung disease in children. AJR Am J Roentgenol 1998; 170:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/20\">",
"      Quartier P, Bonnet D, Fournet JC, et al. Severe cardiac involvement in children with systemic sclerosis and myositis. J Rheumatol 2002; 29:1767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/21\">",
"      Foeldvari I, Zhavania M, Birdi N, et al. Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey. Rheumatology (Oxford) 2000; 39:556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/22\">",
"      Galan A, Cowper SE, Bucala R. Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 2006; 18:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/23\">",
"      Del Galdo F, Wermuth PJ, Addya S, et al. NF&kappa;B activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Ann Rheum Dis 2010; 69:2024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/24\">",
"      Kay J, Czirj&aacute;k L. Gadolinium and systemic fibrosis: guilt by association. Ann Rheum Dis 2010; 69:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/25\">",
"      Rees O, Agarwal SK. Nephrogenic systemic fibrosis: UK survey of the use of gadolinium-based contrast media. Clin Radiol 2010; 65:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/26\">",
"      Rota E, Nallino MG, Bainotti S, Formica M. Nephrogenic systemic fibrosis: an unusual scleroderma-like fibrosing disorder. Rheumatol Int 2010; 30:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/27\">",
"      Tsushima Y, Kanal E, Thomsen HS. Nephrogenic systemic fibrosis: risk factors suggested from Japanese published cases. Br J Radiol 2010; 83:590.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/cder/drug/advisory/gadolinium_agents_20061222.htm (Accessed on January 01, 2008).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/29\">",
"      Cokun T, Ozalp I, Kale G, G&ouml;&uuml; S. Scleroderma-like skin lesions in two patients with phenylketonuria. Eur J Pediatr 1990; 150:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/30\">",
"      Nova MP, Kaufman M, Halperin A. Scleroderma-like skin indurations in a child with phenylketonuria: a clinicopathologic correlation and review of the literature. J Am Acad Dermatol 1992; 26:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/31\">",
"      Jansen T, Romiti R. Progeria infantum (Hutchinson-Gilford syndrome) associated with scleroderma-like lesions and acro-osteolysis: a case report and brief review of the literature. Pediatr Dermatol 2000; 17:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/32\">",
"      Epstein CJ, Martin GM, Schultz AL, Motulsky AG. Werner's syndrome a review of its symptomatology, natural history, pathologic features, genetics and relationship to the natural aging process. Medicine (Baltimore) 1966; 45:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/33\">",
"      WINTERBAUER RH. MULTIPLE TELANGIECTASIA, RAYNAUD'S PHENOMENON, SCLERODACTYLY, AND SUBCUTANIOUS CALCINOSIS: A SYNDROME MIMICKING HEREDITARY HEMORRHAGIC TELANGIECTASIA. Bull Johns Hopkins Hosp 1964; 114:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/34\">",
"      Beltramelli M, Vercellesi P, Frasin A, et al. Localized severe scleroderma: a retrospective study of 26 pediatric patients. Pediatr Dermatol 2010; 27:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/35\">",
"      Kallenberg CG, Wouda AA, Hoet MH, van Venrooij WJ. Development of connective tissue disease in patients presenting with Raynaud's phenomenon: a six year follow up with emphasis on the predictive value of antinuclear antibodies as detected by immunoblotting. Ann Rheum Dis 1988; 47:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/36\">",
"      Zufferey P, Depairon M, Chamot AM, Monti M. Prognostic significance of nailfold capillary microscopy in patients with Raynaud's phenomenon and scleroderma-pattern abnormalities. A six-year follow-up study. Clin Rheumatol 1992; 11:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/37\">",
"      Della Rossa A, Valentini G, Bombardieri S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 2001; 60:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/38\">",
"      Foeldvari I, Nihtyanova SI, Wierk A, Denton CP. Characteristics of patients with juvenile onset systemic sclerosis in an adult single-center cohort. J Rheumatol 2010; 37:2422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/39\">",
"      Panigada S, Ravelli A, Silvestri M, et al. HRCT and pulmonary function tests in monitoring of lung involvement in juvenile systemic sclerosis. Pediatr Pulmonol 2009; 44:1226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/40\">",
"      Hudson M, Steele R, Canadian Scleroderma Research Group (CSRG), Baron M. Update on indices of disease activity in systemic sclerosis. Semin Arthritis Rheum 2007; 37:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/41\">",
"      La Torre F, Martini G, Russo R, et al. A preliminary disease severity score for juvenile systemic sclerosis. Arthritis Rheum 2012; 64:4143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/42\">",
"      Kowal-Bielecka O, Landew&eacute; R, Avouac J, et al. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR). Ann Rheum Dis 2009; 68:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/43\">",
"      Zulian F, Corona F, Gerloni V, et al. Safety and efficacy of iloprost for the treatment of ischaemic digits in paediatric connective tissue diseases. Rheumatology (Oxford) 2004; 43:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/44\">",
"      Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010; 95:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/45\">",
"      Annaloro C, Onida F, Lambertenghi Deliliers G. Autologous hematopoietic stem cell transplantation in autoimmune diseases. Expert Rev Hematol 2009; 2:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/46\">",
"      Foeldvari I, Wierk A. Healthy children have a significantly increased skin score assessed with the modified Rodnan skin score. Rheumatology (Oxford) 2006; 45:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/47\">",
"      Furst D, Khanna D, Matucci-Cerinic M, et al. Systemic sclerosis - continuing progress in developing clinical measures of response. J Rheumatol 2007; 34:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/48\">",
"      Martini G, Vittadello F, Kasap&ccedil;opur O, et al. Factors affecting survival in juvenile systemic sclerosis. Rheumatology (Oxford) 2009; 48:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/49\">",
"      Scussel-Lonzetti L, Joyal F, Raynauld JP, et al. Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival. Medicine (Baltimore) 2002; 81:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39433/abstract/50\">",
"      Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81:139.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6422 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-BD74261493-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_32_39433=[""].join("\n");
var outline_f38_32_39433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOGENESIS AND GENETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      General laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Other organ involvement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Disease progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Laboratory tests and pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LIMITED CUTANEOUS SYSTEMIC SCLEROSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Clinical manifestations of lcSSc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PRE-SCLERODERMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SYSTEMIC SCLEROSIS-SINE SCLERODERMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8773854\">",
"      SIMILARITIES AND DIFFERENCES BETWEEN CHILDREN AND ADULTS WITH SSC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8773861\">",
"      ASSESSMENT OF DISEASE ACTIVITY AND SEVERITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Nonpharmacologic measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8774232\">",
"      - Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8774306\">",
"      - Digital ulcers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8774380\">",
"      - Interstitial lung disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8774428\">",
"      - Pulmonary arterial hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8774484\">",
"      - Skin involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8774512\">",
"      - Renal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8774575\">",
"      - Musculoskeletal involvement",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8774595\">",
"      - Gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8774614\">",
"      - Experimental therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Disease monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1048307\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/6422\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6422|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"mobipreview.htm?37/11/38078\" title=\"algorithm 1\">",
"      Treatment of the manifestations of systemic sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6422|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/50/6946\" title=\"picture 1\">",
"      Swollen hands early scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/49/21264\" title=\"picture 2\">",
"      Telangiectasia in scleroderma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/38/608\" title=\"picture 3\">",
"      Nailfold capillaroscopy in SSc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?19/15/19701\" title=\"picture 4\">",
"      Nailfold capillaroscopy - Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?40/55/41854\" title=\"picture 5\">",
"      Digital pitting scars in SSc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/31/42480\" title=\"picture 6\">",
"      Terminal bone tuft resorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/5/23647\" title=\"picture 7\">",
"      Calcinosis systemic sclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/6422|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/50/17195\" title=\"table 1\">",
"      Presentation JSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/26/22956\" title=\"table 2\">",
"      Prelim class criteria JSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/41/3741\" title=\"table 3\">",
"      Systemic sclerosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/3/44087?source=related_link\">",
"      Classification of scleroderma disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/48/6921?source=related_link\">",
"      Clinical manifestations and diagnosis of the Raynaud phenomenon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/24/43401?source=related_link\">",
"      Clinical manifestations of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26329?source=related_link\">",
"      Clinical manifestations of systemic sclerosis (scleroderma) lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/23/3447?source=related_link\">",
"      Definition and diagnosis of mixed connective tissue disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/35/35382?source=related_link\">",
"      Evaluation for and diagnosis of lung disease in systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/35/41529?source=related_link\">",
"      Gastrointestinal manifestations of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/18/23849?source=related_link\">",
"      Immunomodulatory and antifibrotic approaches to the treatment of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/1/40985?source=related_link\">",
"      Localized scleroderma in childhood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13642?source=related_link\">",
"      Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/63/19450?source=related_link\">",
"      Pathogenesis of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/11/37045?source=related_link\">",
"      Pretreatment evaluation of adults with systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/19/7482?source=related_link\">",
"      Prognosis and treatment of interstitial lung disease in systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/49/6935?source=related_link\">",
"      Pulmonary vascular disease in systemic sclerosis (scleroderma): Definition, classification, risk factors, screening, and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/46/26342?source=related_link\">",
"      Pulmonary vascular disease in systemic sclerosis (scleroderma): Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/4/65?source=related_link\">",
"      Risk factors for and possible causes of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35801?source=related_link\">",
"      Scleroderma renal crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/30/28138?source=related_link\">",
"      Treatment of the Raynaud phenomenon resistant to initial therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_32_39434="Clinical variability in sickle cell anemia";
var content_f38_32_39434=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical variability in sickle cell anemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/32/39434/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/32/39434/contributors\">",
"     Martin H Steinberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/32/39434/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/32/39434/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/32/39434/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/32/39434/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/32/39434/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Homozygosity for a unique hemoglobin gene mutation (HBB glu6val, GAG &mdash;&gt; GTG, sickle hemoglobin, HbS), located on chromosome 11, causes sickle cell anemia (SCA). Upon deoxygenation, HbS molecules polymerize into intracellular fibers, forming a high molecular weight gel and causing the sickle cell deformity. This process initiates an elaborate and incompletely understood pathophysiological cascade that includes injury to the sickle red cell; intravascular and extravascular hemolysis; adhesive interactions among sickle cells, endothelial cells, other blood cells, and plasma factors; reperfusion injury; and inflammation. As a result of this cascade, vital tissues are injured, impairing their function, causing localized pain (ie, the sickle cell vasoocclusive crisis) and, in many cases, premature death for the affected individual.",
"   </p>",
"   <p>",
"    The clinical features of SCA are exceptionally heterogeneous. As in most \"single-gene\" disorders, clinical heterogeneity is influenced by other genes that shape its intermediate phenotypes. The products of modifier genes, sometimes called epistatic genes, are also likely to interact, thus determining the specific phenotype within each affected family and patient (eg, stroke risk, other vasoocclusive events, HbF level, response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/38/3689?source=see_link\">",
"     \"Genetic association studies: Principles and applications\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical variability of SCA will be discussed here [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Other features of the HbS molecule and the clinical features of SCA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30104?source=see_link\">",
"     \"Sickle hemoglobin polymer: Structure and functional properties\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link\">",
"     \"Overview of the clinical manifestations of sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical heterogeneity is also present among the different genotypes of sickle cell disease (eg, SCA, HbSC disease, HbS-beta thalassemia) and is often accounted for by the presence and nature of the hemoglobin molecule that accompanies HbS (eg, HbD, HbC, HbE). The variability of sickle cell disorders due to the simultaneous inheritance of the gene for HbS from one parent and a different beta chain variant or beta thalassemia from the other (ie, a compound heterozygous genotype) is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=see_link\">",
"     \"Variant sickle cell syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before discussing the individual factors affecting the SCA phenotype, it is useful to briefly review those processes which are involved from initiation of HbS polymerization through sickle vasoocclusion and hemolysis.",
"   </p>",
"   <p>",
"    Red blood cells in SCA typically contain approximately 33 grams of hemoglobin per 100 mL of packed red cells; generally, over 90 percent of the hemoglobin is HbS, with the remainder being variable amounts of fetal hemoglobin (HbF) and HbA2. In the absence of transfusion, HbA is not present, since in SCA both beta globin genes code for HbS. Even in its fully oxygenated state, the viscosity of sickle cell blood, due to increased internal viscosity, as well as a reduction in red cell membrane deformability, is 1.5-fold that of normal red cells at an equivalent packed cell volume, and is increased to 10-fold that of normal red cells on deoxygenation.",
"   </p>",
"   <p>",
"    Several factors under varying degrees of genetic control may contribute to the SCA phenotype, including:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Increased production of HbF",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      HbA2, both of which inhibit HbS polymer formation",
"     </li>",
"     <li>",
"      Decreased cell density, as can occur when alpha thalassemia is also present, leading to reduced HbS polymer, reduced internal viscosity of the red cell and improved red cell survival (ie, decreased hemolysis).",
"     </li>",
"     <li>",
"      Reduced overall oxygen affinity of the sickle cell. Levels of 2,3-BPG are increased, although the major effect on oxygen affinity is due to intracellular polymerization of the HbS molecule. This can lead to hemoglobin desaturation at various sites, including pulmonary capillaries, arterial blood, and systemic capillary beds",
"     </li>",
"     <li>",
"      Extreme sensitivity of the sol-to-gel transition of HbS to changes in cellular hydration. Dehydration, which increases the mean corpuscular hemoglobin concentration (MCHC), significantly decreases the time needed to form the sickle polymer, which may be critical when the cell is traversing systemic capillary beds and releasing oxygen to the tissues",
"     </li>",
"     <li>",
"      Damage to the red cell membrane, including both physical and oxidative challenges [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/8,9\">",
"       8,9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Interaction between red cell membrane antigens and circulating plasma proteins, leukocytes, the vascular endothelium, and cytokine release patterns",
"     </li>",
"     <li>",
"      Variability of intravascular hemolysis that leads to nitric oxide (NO) scavenging and reduced NO availability. An example of the importance of NO availability in SCA can be found elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=see_link&amp;anchor=H20#H20\">",
"       \"Pulmonary complications of sickle cell disease\", section on 'Mechanism'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     FETAL HEMOGLOBIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal hemoglobin (HbF), the best understood and most powerful genetic modifier of SCA, inhibits the polymerization of HbS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/10\">",
"     10",
"    </a>",
"    ]. How the levels of HbF are modulated remains an important area of continued study. Ample clinical evidence has shown that as HbF levels increase, most disease complications and mortality decrease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/11-13\">",
"     11-13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=see_link&amp;anchor=H3#H3\">",
"     \"Specific therapies for sickle cell disease\", section on 'Reactivating fetal hemoglobin synthesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two examples will serve to show the magnitude of this effect in patients with sickle cell disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increase in HbF from 5 to 15 percent decreases the incidence of acute chest syndrome by half in all age groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/14,15\">",
"       14,15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Subjects with compound heterozygosity for HbS and hereditary persistence of HbF, a condition in which each red cell has high concentrations of HbS, no HbA, and 20 to 30 percent HbF evenly distributed among red cells, are not anemic and do not suffer from vasoocclusive manifestations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=see_link&amp;anchor=H9#H9\">",
"       \"Variant sickle cell syndromes\", section on 'Sickle-hereditary persistence of fetal Hb'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several amino acid differences in the gamma-globin chain of HbF and the delta-globin chain of HbA2, compared with the beta-globin chain of HbA, prevent the incorporation of HbF and HbA2 into the HbS polymer and account for the special \"therapeutic\" effects of high HbF and HbA2 concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. As HbA2 levels rarely exceed 5 percent in sickle cell disease, the antipolymerization effects of this molecule are minor compared with HbF, whose levels can exceed 20 percent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30104?source=see_link&amp;anchor=H12#H12\">",
"     \"Sickle hemoglobin polymer: Structure and functional properties\", section on 'Non-S hemoglobins'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=see_link&amp;anchor=H3#H3\">",
"     \"Specific therapies for sickle cell disease\", section on 'Reactivating fetal hemoglobin synthesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemoglobin F is restricted to a subset of red cells (F-cells), whose numbers are genetically determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/19\">",
"     19",
"    </a>",
"    ]. The HbF level in any individual is determined by the absolute number of F-cells, the amount of HbF per F-cell, and the differential survival of F-cells versus non-F-cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/20\">",
"     20",
"    </a>",
"    ]. The number of genes involved and the mode of inheritance of this variability are unknown, although this is an area of active study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20650?source=see_link\">",
"     \"Regulation of erythropoiesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23001?source=see_link&amp;anchor=H15#H15\">",
"     \"Structure and function of normal human hemoglobins\", section on 'Fetal hemoglobin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Control of HbF expression",
"    </span>",
"    &nbsp;&mdash;&nbsp;HbF levels are normally set by genetic control mechanisms involving silencing of the gamma-globin genes, transcriptional control of gamma-globin gene expression, and erythroid progenitor cell proliferation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/13,26\">",
"     13,26",
"    </a>",
"    ]. Genetic variation in the cis- and trans-acting factors that regulate HbF expression may account for some disease heterogeneity in SCA.",
"   </p>",
"   <p>",
"    Globin gene switching in the beta-like globin gene cluster is controlled at cellular and molecular levels and, despite considerable study, remains incompletely understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. Switching involves the complex interactions of erythroid specific and ubiquitous transacting transcription factors with the beta-globin gene locus control region (LCR) (",
"    <a class=\"graphic graphic_figure graphicRef65642 \" href=\"mobipreview.htm?6/32/6656\">",
"     figure 1",
"    </a>",
"    ) and other cis-acting sequences that act positively or negatively in transcriptional regulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/30-34\">",
"     30-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As erythroid progenitors differentiate during embryonic, fetal, and adult development, stage-specific transcription programs are activated and deactivated, allowing transcription of embryonic genes in early gestation, fetal genes during most of gestation and early extrauterine life, and adult globin genes afterwards. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23001?source=see_link\">",
"     \"Structure and function of normal human hemoglobins\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Response to hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is likely that the same genetic factors controlling \"resting\" HbF levels also influence response to treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    (HU). Examples include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, individuals with the best HbF response to HU were less likely to have their HbS gene on a Bantu (BAN) haplotype chromosome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/35\">",
"       35",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Cis-acting elements'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In a study of 30 sibling pairs with SCA or HbS-beta thalassemia, there was a high positive correlation between sibs for HbF levels before and during treatment with HU, as well as concordant changes in overall HbF response, increases in red cell mean corpuscular volume, and treatment-associated decreases in white blood cell count [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=see_link&amp;anchor=H5#H5\">",
"       \"Specific therapies for sickle cell disease\", section on 'Hydroxyurea'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a study of 386 individuals with SCA, single nucleotide polymorphisms within the SAR1A (secretion-associated and RAS-related protein) regulatory elements were shown to contribute to differences in the regulation of HbF levels as well as the response to treatment with HU [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a small study, 10 patients with SCA and concomitant alpha thalassemia trait",
"      <span class=\"nowrap\">",
"       (aa/a-)",
"      </span>",
"      had a lesser response to HU than 20 patients with SCA who had a normal alpha gene complement",
"      <span class=\"nowrap\">",
"       (aa/aa)",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When 320 single nucleotide polymorphisms (SNPs) in 29 candidate genes were studied in 137 sickle cell anemia patients treated with HU, both multiple linear regression and a nonlinear regression method suggested associations between SNPs within the 6q22.3-23.2 and 8q11-q12 linkage peaks and the change in HbF level after 2 years of treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Effect of age",
"    </span>",
"    &nbsp;&mdash;&nbsp;HbF is the major hemoglobin at the time of birth in subjects with SCA, its protective effects being responsible for the lack of symptoms due to SCA up to about three months of age. By six months of age, HbF constitutes less than 1 percent of total hemoglobin in normal subjects. However, in SCA HbF levels decline more slowly than in normal subjects and remain increased, but vary by two orders of magnitude, from levels as low as 0.5 percent to as high as 30 percent or more [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/18,38,39\">",
"     18,38,39",
"    </a>",
"    ]. In SCA, HbF levels stabilize at approximately four years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cis-acting elements",
"    </span>",
"    &nbsp;&mdash;&nbsp;HbS mutations occurred and were established in different populations at least five times in ancient history, each time on different genetic backgrounds (ie, the Senegal (SEN), Benin (BEN), Bantu (BAN), Cameroon (CAM), and Arab-Indian beta globin gene-like cluster haplotypes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/40\">",
"     40",
"    </a>",
"    ]. In this setting, the term \"haplotype\" refers to a combination of single nucleotide polymorphisms (SNPs) on a single chromosome, usually within the context of a particular gene, or in the case of globin genes, a linked cluster of genes.",
"   </p>",
"   <p>",
"    Three of these haplotypes, Benin, Bantu, and Senegal, are found in most African patients with SCA, while the Arab-Indian haplotype is common in India and the Eastern Province of Saudi Arabia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. In Africa, most patients with SCA are homozygous for one of the three beta-globin gene cluster haplotypes noted above, while in the United States, most patients are compound heterozygotes for two different haplotypes.",
"   </p>",
"   <p>",
"    Genetic differences among beta(S)-gene bearing chromosomes suggest the possibility of variations in cis-acting elements that modulate globin gene expression. In the best defined example of these polymorphisms, a C&mdash;&gt;T polymorphism present 5' to the G(gamma)-globin gene in the Senegal and Arab-Indian haplotypes is usually associated with higher HbF levels than present in the Benin and Bantu haplotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. This HBG2 C&mdash;&gt;T SNP (rs7482144) is the so-called Xmn1 restriction site. In a study of patients with SCA from New York City, the presence of at least one chromosome with the Senegal haplotype was associated with higher hemoglobin levels, and lesser degrees of hemolysis than any other non-Senegal haplotype [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/45\">",
"     45",
"    </a>",
"    ]. The functional basis for this association is unknown.",
"   </p>",
"   <p>",
"    Despite this, considerable differences in HbF levels are present among individuals within any given haplotype, suggesting that diverse genetic elements, and not elements associated with this single SNP alone, simultaneously affect HbF expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/46\">",
"     46",
"    </a>",
"    ]. As an example, transcription factor binding motifs in proximal and distal promoter elements of the HbF genes may contain point mutations that cause an increased level of HbF in adults. Proteins that bind the CAAT and TATA boxes of the gamma-globin gene promoter may also act as gene suppressors and promoters, influencing HbF production [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A GATA-GAGA SNP that might be a silencing element is present -567 base pairs 5' of the G gamma-globin gene promoter, and was associated with increased HbF. This GATA motif was capable of binding GATA-1 transcription factor; analyses suggested a negative regulatory activity present between nucleotides -675 and -526. The SNP increased promoter activity by two- to three-fold in erythroid cell lines. It disrupts GATA-1 binding and the associated repressor complex, abolishing its silencing effect and resulting in the up- regulation of gamma-globin gene expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/47,48\">",
"     47,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Beta-globin gene cluster locus control region",
"    </span>",
"    &nbsp;&mdash;&nbsp;A group of conserved DNAase hypersensitive sites and their surrounding DNA 5' to the epsilon globin gene comprises the beta-globin gene cluster locus control region (LCR) (",
"    <a class=\"graphic graphic_figure graphicRef65642 \" href=\"mobipreview.htm?6/32/6656\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/49-51\">",
"     49-51",
"    </a>",
"    ]. In a still undefined fashion, the LCR plays a critical role in the tissue and developmental specific expression of the beta-globin-like genes. Hypersensitive sites each contain different combinations of conserved binding domains for erythroid specific and ubiquitous DNA-binding proteins that influence gene transcription [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/52-57\">",
"     52-57",
"    </a>",
"    ]. Some sequences in the hypersensitive sites are polymorphic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. The LCR may also function as an erythroid cell-specific enhancer, a chromatin opening domain, and an insulator [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/49,61-66\">",
"     49,61-66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most studies of the influence of the LCR on HbF production have focused on 5' HS-2, which appears to be the only 5' hypersensitive site that is polymorphic among HbS-associated haplotypes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/67\">",
"     67",
"    </a>",
"    ]. To date, despite some interesting observations, SNPs in the LCR associated with HbF in sickle cell anemia have yet to be pinpointed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/68-71\">",
"     68-71",
"    </a>",
"    ]. Other regulatory elements have been proposed to lie -530 base pairs 5' to the beta-globin gene and 5' to the A gamma-globin gene.",
"   </p>",
"   <p>",
"    Phylogenetic conservation of non-coding DNA regions 5' to the LCR suggests that these regions also serve important regulatory functions. In addition, both human and mouse beta-globin gene clusters show sequences outside the hypersensitive sites of the LCR that are highly conserved. Olfactory receptor genes and their flanking sequences 5' to the LCR on chromosome 11 may also control expression of beta-like (and gamma-) globin genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/66,72-74\">",
"     66,72-74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Any effect of the beta-globin gene cluster haplotype on the phenotype of SCA appears to be dependent on the HbF level associated with the haplotype that is associated with the presence of the 5' HBG2 C&mdash;&gt;T SNP. Other studies have suggested that regions 5' to the gamma-globin genes have regulatory importance. Multiple point mutations in the promoters of the gamma-globin genes have been found to modulate gamma-globin gene expression and cause the nondeletion HPFH phenotype. These SNPs might account for higher than usual HbF levels in rare patients with SCA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Trans-acting factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The -158 SNP 5' to HBG2 and other postulated haplotype-associated effects on HbF account for less than 25 percent of the variability of HbF in sickle cell anemia, suggesting that trans-acting regulatory elements exert control over HbF levels.",
"   </p>",
"   <p>",
"    Two quantitative trait loci (QTLs) are strongly associated with HbF in sickle cell anemia. These are the 6q22.3-23.2 HBS1L-MYB intergenic region, first described in an extended Asian-Indian family, and a QTL at 2p16, identified in a genome-wide association study of healthy adults that mapped to BCL11A, a zinc-finger protein, which accounted for 15 percent of F cell variance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/32,75-79\">",
"     32,75-79",
"    </a>",
"    ]. BCL11A acts as a developmental stage-specific repressor of gamma-globin gene expression; high levels of BCL11A protein are restricted to adult erythroid progenitors that make little HbF [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/32,80\">",
"     32,80",
"    </a>",
"    ]. SNPs in the BCL11A, HBS1L-MYB and the Xmn1 SNP account for more than 20 to 50 percent of the variation of HbF in SCA and are related to the rate of painful episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/81-83\">",
"     81-83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The HBS1L-MYB intergenic polymorphism is also associated with HbF among sickle cell anemia patients of African descent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/79,81,84,85\">",
"     79,81,84,85",
"    </a>",
"    ], although much less significantly when compared with Europeans or Chinese, due to their much lower minor allele frequencies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/86\">",
"     86",
"    </a>",
"    ]. It could be that there are other HMIP variants associated with HbF levels among people of African descent that are not tracked well by SNP rs9399137.",
"   </p>",
"   <p>",
"    The most significant functional motif accounting for HMIP modulation of HbF is a 3 bp deletion polymorphism, which is in complete linkage dysequilibrium with the SNP rs9399137 shown by several genome-wide association studies to be most significantly associated with HbF in Europeans, Asians, and African Americans [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/86\">",
"     86",
"    </a>",
"    ]. It is located near erythroid specific DNase I hypersensitive site 2 within the HMIP block 2, 42.6 kb upstream of HBS1L and 83.8 kb upstream of MYB. In close proximity to the 3 bp deletion polymorphism, there is binding of four erythropoiesis-related transcription factors, TAL1, E47, GATA2, and RUNX1. Furthermore, the short DNA fragment encompassing the 3 bp deletion polymorphism appears to have enhancer-like activity based on in vitro transient transfection experiments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/86\">",
"     86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Panels of haplotype tagging SNPs in the beta-globin gene-like cluster and in QTLs on chromosomes 8q and Xp were genotyped in two independent SCA patient groups to study their association with baseline HbF levels. In one group of 327 individuals, three SNPs in TOX (thymus high mobility protein; 8q12.1) were associated with HbF. Three additional SNPs in TOX showed significant association in a second group of 987 individuals. Joint analysis of all SNPs and covariates confirmed the association with TOX. TOX belongs to a conserved high-mobility group box protein family that binds the minor groove of DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional 850 SNPs in 320 candidate genes and QTLs were studied in a group of 1518 adults and children with SCA and validated in an independent group of 211 adults. In individuals aged 24 years or older, five SNPs in TOX, two SNPs in the beta-globin gene-like cluster, two SNPs in the Xp QTL, and one SNP in chromosome 15q22 were associated with HbF. When patients younger than 24 years were examined, additional genes, including four with roles in nitric oxide metabolism, were associated with HbF levels. These observations raise the possibility that different genes might modulate the rate of decline of HbF and the final HbF levels in SCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small guanosine triphosphate (GTP)-binding protein, secretion-associated and RAS-related (SAR1A) protein, is inducible by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    and might play a pivotal role in induction of gamma-globin gene expression via its role in erythroid maturation. Polymorphisms in the SAR1A promoter were associated with differences in HbF levels or the HbF response to hydroxyurea in patients with SCA. Three previously described SNPs in the upstream 5' untranslated region (-809 C-T, -502 G-T and -385 C-A) were significantly associated with the HbF response in SCA patients treated with hydroxyurea and four SNPs (rs2310991, -809 C-T, -385 C-A and rs4282891) were significantly associated with the change in absolute HbF level after two years of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genes for the epsilon-globin chain of the embryo and the gamma- globin chain of the fetus are silenced during normal postnatal development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/88\">",
"     88",
"    </a>",
"    ]. The mechanisms of silencing are still unknown, but may involve methylation of the promoters of these genes. Methylation is mediated by DNA methyl transferases, some of which are capable of de novo CpG methylation.",
"   </p>",
"   <p>",
"    Histone deacetylation and methylation may precede DNA methylation and control this process, suggesting that the configuration of chromatin may have an active role in gene expression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/89-91\">",
"     89-91",
"    </a>",
"    ]. As examples, gene silencing is associated with methylation of lysine 9 in histone H3, lysine 4 methylation is associated with gene expression, and histone acetylation is required for an active chromatin configuration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/92\">",
"     92",
"    </a>",
"    ]. The possibility exists that differences in genes controlling these processes are responsible for some of the variability in HbF concentrations among individuals with SCA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Sex-linked factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A possible F-cell production (FCP) locus has been localized to the short arm of the X chromosome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/93\">",
"     93",
"    </a>",
"    ]. This locus may account, in part, for the higher levels of HbF in females compared with males, an observation that has been made in both the normal population and those with SCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/46\">",
"     46",
"    </a>",
"    ]. While the X-linked FCP locus was thought to be a major determinant of HbF levels in SCA and account for about 40 percent of the overall variation in HbF levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/94\">",
"     94",
"    </a>",
"    ], in genome-wide association studies this QTL has not been found to be associated with HbF in patients with SCA or beta thalassemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/79,81\">",
"     79,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ALPHA THALASSEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chromosome 16 contains two alpha globin genes encoding identical proteins (",
"    <a class=\"graphic graphic_figure graphicRef65642 \" href=\"mobipreview.htm?6/32/6656\">",
"     figure 1",
"    </a>",
"    ); accordingly, each normal individual possesses four active alpha globin genes. Alpha thalassemia, present in more than 30 percent of the black population, is usually due to the deletion of one or two of these alpha globin genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=see_link&amp;anchor=H29#H29\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\", section on 'The alpha thalassemia syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While the loss of a single or even two alpha globin genes is clinically trivial in otherwise normal individuals, alpha thalassemia affects the phenotype of SCA by reducing the overall concentration of hemoglobin within the individual red cell (ie, the mean corpuscular hemoglobin concentration, MCHC), along with a reduction in mean corpuscular volume (MCV), and a lessened degree of hemolysis and anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/96\">",
"     96",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=see_link&amp;anchor=H8#H8\">",
"     \"Variant sickle cell syndromes\", section on 'Sickle-alpha thalassemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The reduced red cell concentration of HbS in subjects with the combination of SCA and alpha thalassemia diminishes the polymerization potential of HbS, leads to the presence of a lesser number of dense and poorly deformable cells, and has the effect of raising the patient's overall hematocrit. However, the higher hematocrit is still associated with HbS-containing red cells, resulting in an overall increase in blood viscosity. Perhaps because of this, patients with SCA-alpha thalassemia have more episodes of certain complications like pain, acute chest events, and osteonecrosis than do patients with SCA alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/11,97-99\">",
"     11,97-99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An initial report associating coincident alpha thalassemia and SCA with increased HbF levels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/100\">",
"     100",
"    </a>",
"    ] has not been confirmed in studies of larger numbers of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/46,100-105\">",
"     46,100-105",
"    </a>",
"    ]. An early report suggested that alpha thalassemia was associated with longevity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/106\">",
"     106",
"    </a>",
"    ], but was controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/12\">",
"     12",
"    </a>",
"    ]. Some studies have shown that the presence of alpha thalassemia, and a reduction in intravascular hemolysis is associated with reduced mortality. In other reports, the simultaneous presence of alpha thalassemia and SCA has been associated with the following effects:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reduction in the extent of peripheral retinal vessel closure, without an effect on the frequency of proliferative sickle retinopathy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/107\">",
"       107",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduction in the incidence of stroke in children [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/108\">",
"       108",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Protection against high cerebral blood velocities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/109,110\">",
"       109,110",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduction in the incidence of leg ulcers [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/111\">",
"       111",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      In some children with high HbF levels, alpha thalassemia appeared to preserve splenic function [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/112\">",
"       112",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Lower prevalence of glomerulopathy (macroalbuminuria) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/113\">",
"       113",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced prevalence of priapism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/114\">",
"       114",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Reduced response to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some tribal populations with the Arab-Indian haplotype of SCA and very high HbF levels have a gene frequency of alpha thalassemia approaching 100 percent, associated with a milder disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. This salutary effect appears to be the result of a complex interplay among the Arab-Indian haplotype, high levels of HbF, and alpha thalassemia. When the combined effects of alpha thalassemia and beta-globin gene haplotype were studied, the risk of organ failure was most common in carriers of a Bantu haplotype and least common in Senegal haplotype carriers. Regardless of haplotype, the presence of alpha thalassemia decreased the risk of organ failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/117,118\">",
"     117,118",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, not all population studies have shown a clinical benefit from the presence of alpha thalassemia. In a study from Jamaica, the absence of alpha thalassemia gene deletions coupled with a high HbF presaged benign disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/119\">",
"     119",
"    </a>",
"    ]. When Jamaican clinical phenotypes of SCA were clustered into two or three groups, neither alpha thalassemia nor the beta-globin gene cluster haplotype appeared to influence the clinical events defining the groups [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/120\">",
"     120",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perhaps some of the discrepant results of earlier studies are a result of considering only the",
"    <span class=\"nowrap\">",
"     vasoocclusive/viscosity",
"    </span>",
"    complications of disease. Other studies suggest that hemolytic anemia is closely associated with its own constellation of subphenotypes.",
"   </p>",
"   <p>",
"    Studies of the effects of hemolysis on nitric oxide (NO) bioavailability suggest that alpha thalassemia protects against disease complications related to the intensity of hemolysis (eg, priapism, leg ulcers, stroke, and perhaps pulmonary hypertension) while increasing the risk of complications more directly related to blood viscosity (eg, painful episodes, acute chest syndrome, osteonecrosis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/114\">",
"     114",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Intravascular hemolysis in SCA is likely to contribute to complications associated with NO deficiency. The distribution of serum lactate dehydrogenase (LDH) values was used as a surrogate measure of intravascular hemolysis in two patient groups with sickle cell anemia. Chronic hyper-hemolysis was defined by the top LDH quartile and was compared with the lowest LDH quartile. Patients with hyper-hemolysis had higher systolic blood pressure, higher prevalence of leg ulcers, priapism, and pulmonary hypertension, while osteonecrosis and vasoocclusive pain were less prevalent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/121\">",
"     121",
"    </a>",
"    ]. Hyper-hemolysis was influenced by fetal hemoglobin and alpha thalassemia, and was a risk factor for earlier death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     POTENTIAL DISEASE MODULATORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following sections describe alterations within the sickle cell as well as interactions between the sickle cell and its environment. Although genetic variations of the individual elements of these interacting systems are known, we are only beginning to understand how these might affect the clinical variability of sickle cell anemia (SCA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13644148\">",
"    <span class=\"h2\">",
"     Overall disease severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1265 patients with either &ldquo;severe&rdquo; or &ldquo;mild&rdquo; disease based on a network model of disease severity, a genome-wide association study (GWAS) discovered 40 single nucleotide polymorphisms (SNPs) that were strongly associated with sickle cell severity (odds for association &gt;1000) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/122\">",
"     122",
"    </a>",
"    ]. Of the 32 SNPs that could be analyzed in an independent set of 163 patients, 5 were replicated, 8 showed consistent effects although they failed to reach statistical significance, whereas 19 did not show any convincing association.",
"   </p>",
"   <p>",
"    Using an analytical method that examined genetic regions, 27 genes with a strong enrichment of significant SNPs (p&lt;10",
"    <sup>",
"     -6",
"    </sup>",
"    ) were present; 20 of these were replicated with varying degrees of confidence. Among the replicated associations were SNPs in",
"    <em>",
"     KCNK6,",
"    </em>",
"    a potassium ion channel gene, along with a novel finding involving the telomere length regulator gene",
"    <em>",
"     TNKS.",
"    </em>",
"   </p>",
"   <p>",
"    These studies were the first to use GWAS to understand the genetic diversity that accounts for the phenotypic heterogeneity of sickle cell anemia as estimated by an integrated model of severity. They must be considered preliminary, as the findings have not yet been replicated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Stroke",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inheritance of certain genes, including HLA, has been shown to correlate with the risk of stroke in children with SCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/123\">",
"     123",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=see_link&amp;anchor=H3#H3\">",
"     \"Cerebrovascular complications of sickle cell disease\", section on 'Cerebral infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical samples from the Cooperative Study of Sickle Cell Disease (CSSCD) were surveyed for 104 polymorphic genetic markers among 65 candidate atherosclerotic, prothrombotic, and proinflammatory genes in a large population of children with SCA enrolled since birth in the CSSCD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/123,124\">",
"     123,124",
"    </a>",
"    ]. Using a logistic regression analysis, the following observations were made for risk of MRI-documented stroke before the age of 10 years:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following loci were associated with a significant",
"      <strong>",
"       increase",
"      </strong>",
"      in the risk of stroke: Interleukin-4 receptor (IL4R 503P), HLA-A, vascular cell adhesion molecule (VCAM1 -1594C), HLA-DPB1, and HLA homozygosity.",
"     </li>",
"     <li>",
"      The following genetic loci were associated with a significantly",
"      <strong>",
"       decreased",
"      </strong>",
"      risk of stroke: beta adrenergic receptor (ADRB2 27E), tumor necrosis factor (TNF -308A), and low density lipoprotein receptor (LDLR NcoI-).",
"     </li>",
"     <li>",
"      Children with SCA and a combination of the IL4R 503 SP or PP genotype and the TNF -308GG genotype had a particularly strong predisposition to large vessel stroke (relative risk 5.5, 95% CI: 2.3-13.1).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a Bayesian network analysis of 108 single nucleotide polymorphisms (SNPs) in 39 candidate genes in 1398 individuals with SCA, 31 SNPs in 12 genes interacting with fetal hemoglobin were found to modulate the risk of stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/125\">",
"     125",
"    </a>",
"    ]. This interacting network included three genes in the transforming growth factor-beta pathway and the selectin-P gene, which are associated with stroke in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/126,127\">",
"     126,127",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3786?source=see_link&amp;anchor=H2#H2\">",
"     \"Moyamoya disease: Etiology, clinical features, and diagnosis\", section on 'Etiology'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For 114 subjects not included in the original analysis, this model predicted the correct outcome for all 7 individuals with stroke and for 105 of 107 subjects without stroke, for an overall predictive accuracy of 98 percent. In a separate report of 130 pediatric SCA patients from the SWITCH Study&nbsp;StudyCCH with documented primary thrombotic stroke, when compared with 103 SCA patients without stroke from the HUSTLE Study, genotyping of 38 candidate SNPs in 22 genes found the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/128\">",
"     128",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      SNPs in the ANXA2, TGFBR3, and TEK genes were associated with increased stroke risk. These results confirm some of the observations from the Bayesian network study, but fail to confirm observations in other cited studies of SNPs and stroke.",
"     </li>",
"     <li>",
"      Alpha thalassemia and a SNP in the ADCY9 gene were associated with a decreased stroke risk.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Red cell membrane and cation transport",
"    </span>",
"    &nbsp;&mdash;&nbsp;Red cell heterogeneity is typical of SCA, with the simultaneous presence of normally shaped red cells, irreversibly sickled cells, and cells with markedly increased mean corpuscular hemoglobin concentration (MCHC) and density (",
"    <a class=\"graphic graphic_picture graphicRef64449 \" href=\"mobipreview.htm?1/42/1703\">",
"     picture 1",
"    </a>",
"    ). As an example, the MCHC ranges from 27 to 38",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in normal subjects, and may be as high as 50",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in some dense cells in SCA, with the attendant presence of polymerized HbS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Red cell density and shape depend upon the cell's capacity to maintain normal hydration and cation content. Such transport is modulated by at least three distinct channels: K(+)-Cl(-) cotransport, calcium-dependent movement of K(+), and a diffusional pathway. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37224?source=see_link\">",
"     \"Control of red blood cell hydration\"",
"    </a>",
"    .) Since increasing density adversely affects the red cell in SCA by increasing HbS polymerization, alterations in hydration and cation transport can adversely affect the red cell, its membrane, and cellular interactions with other cells and the vasculature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/129\">",
"     129",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    K(+)-Cl(-) cotransport is abnormally activated in sickle erythrocytes. When sickle cells are isosmotically swollen or are exposed to acid pH, this cotransport promotes K(+) and Cl(-) loss, resulting in cell dehydration. Each time sickle erythrocytes are exposed to a",
"    <span class=\"nowrap\">",
"     hypoxic/acidic",
"    </span>",
"    environment, activation of K(+)-Cl(-) cotransport is likely to follow, with attendant potassium loss, dehydration, increased MCHC, and increased density. These dense cells, especially those which do not contain HbF, are associated with in vivo sickling and vasoocclusion, and have a shorter in vivo survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/130\">",
"     130",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14583?source=see_link&amp;anchor=H9#H9\">",
"     \"Xerocytosis\", section on 'Sickle cell disease'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Calcium-dependent movement of potassium was first described by Gardos in 1958 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/131\">",
"     131",
"    </a>",
"    ]. When sickle erythrocytes are deoxygenated, free intracellular Ca++ is increased two- to threefold, resulting in Ca-dependent dehydration through activation of the Gardos channel. Deoxygenation is also associated with potassium loss and sodium gain, mediated by a diffusional pathway. The inward sodium flux and outward potassium fluxes are balanced, leading to no net changes in ion content or cell volume.",
"   </p>",
"   <p>",
"    Genetic variation in cation transporters that alter protein function and cell homeostasis are likely to exist and could affect the phenotype of SCA. While no clinical studies have been done, mutations altering the function of erythrocyte transport channels and cytoskeleton have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/129,132-134\">",
"     129,132-134",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14583?source=see_link\">",
"     \"Xerocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Vascular endothelium",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vascular endothelium helps control the balance between procoagulant and anticoagulant properties of the blood and vessel wall. By producing vasoconstrictors and vasodilators, the endothelium modulates vascular tone and contributes to the physiology of inflammation and hemostasis through its interactions with circulating proteins and blood cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/135\">",
"     135",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Biologic modifiers, including interleukins, tumor necrosis factor-alpha, thrombin, oxidation, hypoxia, and endotoxin, also affect the endothelium (see",
"    <a class=\"local\" href=\"#H13\">",
"     'Stroke'",
"    </a>",
"    above). Many of these endothelial cell activators are generated during sickle vasoocclusive episodes and infection, altering the surface features displayed by endothelium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/136-139\">",
"     136-139",
"    </a>",
"    ]. Although vascular endothelial cells are central to the pathobiology of SCA, and genetic disorders of the endothelium have been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/140\">",
"     140",
"    </a>",
"    ], the genetics of sickle cell-endothelial cell interactions have not been explored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Endothelial activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple etiologies could underlie the abnormal endothelial activation found in patients with SCA. Evidence at the clinical level includes the development of occlusion of large vessels in the lung and thrombotic stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/141\">",
"     141",
"    </a>",
"    ]. Histopathologic changes suggesting endothelial injury have also been observed in the splenic and cerebral vasculature [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/142\">",
"     142",
"    </a>",
"    ]. Circulating endothelial cells have been observed that are abnormally activated, as evidenced by expression of adhesion molecules VCAM-1 and ICAM-1 and tissue factor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/143,144\">",
"     143,144",
"    </a>",
"    ]. In addition, patients with SCA in the so-called \"steady-state\" can have elevated levels of IL2, TNF alpha, LPS, PAF, and thrombin generation, each a known stimulant for endothelial cell expression of tissue factor in vitro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/145\">",
"     145",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of 24 adults with sickle cell anemia, levels of TNF-R1 and VCAM-1 were significantly higher in the 12 subjects with severe SCA than in the 12 with mild disease. Data from a genome-wide association study also found evidence of genetic association between disease severity and several SNPs in ARFGEF2, a gene involved in TNF-R1 release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/146\">",
"     146",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endothelial inflammation, activation, and damage may be provoked by adherent sickle cells and shear stresses that cause prostacyclin release, oxidant free radical formation, inhibition of DNA synthesis, endothelin (ET-1) expression, and a disturbance of nitric oxide (NO) biology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/147-152\">",
"     147-152",
"    </a>",
"    ]. Finally, in other vascular disease models, reperfusion injury physiology can induce endothelial activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/153\">",
"     153",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pain and hypoxic injury following sickle cell vasoocclusive episodes bears some resemblance to ischemia-reperfusion injury. Nuclear factor (NF)-kB is a transcription factor that regulates endothelial cell genes associated with the activated phenotype, such as those for some cytokine, chemokine, and adherence molecules [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/154\">",
"     154",
"    </a>",
"    ]. Some of the pro-inflammatory molecules released by endothelial cells have been shown to activate the Gardos channel, causing red cell dehydration, which could further aggravate the underlying sickling process (see",
"    <a class=\"local\" href=\"#H14\">",
"     'Red cell membrane and cation transport'",
"    </a>",
"    above) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/155\">",
"     155",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activation of NF-kB-regulated genes may play a role in ischemia- reperfusion injury, and, by analogy, sickle cell vasoocclusive episodes. Heterogeneity of NF-kB genes may alter the transcription of genes activated by this transcription factor and modify interactions between endothelial cells and leukocytes (see",
"    <a class=\"local\" href=\"#H22\">",
"     'Inflammation'",
"    </a>",
"    below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/156\">",
"     156",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Genetic heterogeneity of adhesion molecules was suggested by the detection of SNPs in VCAM-1 in SCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/123,157,158\">",
"     123,157,158",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, a SNP of VCAM-1 in the G1238C nucleotide was associated with a significant reduction in the prevalence of stroke (odds ratio: 0.35, 95% CI: 0.15-0.83) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/158\">",
"       158",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a large study from the Cooperative Study of Sickle Cell Disease, the VCAM-1 -1594C polymorphism was associated with a significant increase in the risk of small vessel stroke (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Stroke'",
"      </a>",
"      above) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/123\">",
"       123",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Data from a genome-wide association study using sickle cell anemia severity as a disease phenotype found evidence of genetic association between disease severity and a SNP in VCAM1, which codes for VCAM-1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/146\">",
"       146",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Vasodilation and vasoconstriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the vascular endothelium plays a major role in vasodilation and vasoconstriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/159\">",
"     159",
"    </a>",
"    ]. When sickle cells perturb the endothelium, vasoconstriction may be favored [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/160,161\">",
"     160,161",
"    </a>",
"    ], due, in part, to increased endothelial production of the potent vasoconstrictor protein endothelin (ET)-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/161\">",
"     161",
"    </a>",
"    ]. Increased plasma levels in patients with SCA and acute chest syndrome may result from regulation of ET-1 gene expression by sickle erythrocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/149,162\">",
"     149,162",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Nitric oxide availability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nitric oxide (NO) is a major endothelium-derived vasodilator. Its production from L-arginine is mediated by endothelial nitric oxide synthase III (eNOS). In one study of patients with SCA, plasma NO metabolite concentrations were increased during acute painful episodes and during the \"steady state\" compared with normal controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/163\">",
"     163",
"    </a>",
"    ]. Inhibition of the NO pathway using the NO synthase inhibitor L-NAME increased the adhesion of sickle cells in the rat cerebral microcirculation and, in some experiments, resulted in reduced or occluded flow. These studies suggest that the NO pathway is critical in maintaining cerebral blood flow in the presence of sickle erythrocytes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/164\">",
"     164",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NO products released from cultured pulmonary artery and microvascular endothelial cells exposed to erythrocytes and plasma from patients with SCA taken during episodes of acute chest syndrome (ACS) or during painful episodes were increased 5- to 14-fold and were accompanied by increased eNOS protein and enzymatic activity, but not increased NOS III or NOS II gene transcripts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/165\">",
"     165",
"    </a>",
"    ]. This increase may reflect not only increased NO production but also an increase in oxidant stress along with oxidative inactivation of NO, with resultant production of damaging oxidative molecules.",
"   </p>",
"   <p>",
"    Hemolytic anemia may be the driving force behind some complications of SCA because of its effects on NO bioavailability. Under normal circumstances, NO binds soluble guanylate cyclase, which converts GTP to cGMP, relaxing vascular smooth muscle and causing vasodilatation. Plasma hemoglobin liberated from intravascularly destroyed sickle erythrocytes consumes NO, producing methemoglobin and bio-inactive nitrate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/166\">",
"     166",
"    </a>",
"    ]. This state of reduced endothelial NO bioavailability in sickle cell disease impairs downstream homeostatic vascular functions of NO, such as the inhibition of platelet activation and aggregation and transcriptional repression of some cell adhesion molecules. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'G6PD Deficiency'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Hemoglobin, heme, and heme iron catalyze the production of oxygen radicals and protein nitration, further limiting NO bioavailability and activating endothelium. Lysed erythrocytes also liberate arginase that destroys L-arginine, the substrate for NO production, providing another mechanism for endothelial NO deficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/167\">",
"     167",
"    </a>",
"    ]. Reactive oxygen species, generated at high rates in patients with sickle cell disease, also consume NO [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/168\">",
"     168",
"    </a>",
"    ]. The normal balance between vasoconstriction and vasodilation is therefore skewed toward vasoconstriction, endothelial activation, and proliferation. Clinically, these hemolysis-driven phenotypes include pulmonary hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/169\">",
"     169",
"    </a>",
"    ], priapism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/114\">",
"     114",
"    </a>",
"    ], leg ulcers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/170\">",
"     170",
"    </a>",
"    ], and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/171\">",
"     171",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These processes are all likely to be genetically modulated. As an example, in a retrospective study of 41 patients with SCA and ACS and 46 SCA controls without ACS, the relative risk of developing ACS in female carriers of the C-786 gene polymorphism of eNOS was 8.7 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/172\">",
"     172",
"    </a>",
"    ]. No such association was found for males or for the D298 allele.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Priapism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible association between SNPs in 44 candidate genes and priapism was studied in 148 men with SCA and incident or a confirmed history of priapism and 529 men with SCA who had not developed this complication. It was hypothesized that the likelihood of developing priapism and other vascular complications of SCA might be influenced by heterogeneity in genes modulating vasoregulation, cellular interactions, inflammation, oxidative radical formation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    NO biology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23017?source=see_link\">",
"     \"Diagnosis and management of priapism in sickle cell disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Polymorphisms in the KLOTHO gene (chromosomal location 13q12) showed an association with priapism by both genotypic (OR 1.7; 95% CI 1.2-2.6) and haplotype analyses (OR 2.3; 95% CI 1.5-3.4) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/173\">",
"     173",
"    </a>",
"    ]. These findings may have broader implications in sickle cell disease as the KLOTHO gene product is a beta-glucosidase-like membrane protein, which regulates both vascular endothelial growth factor (VEGF) expression and endothelial NO release.",
"   </p>",
"   <p>",
"    However, a second study of 199 (83 with a history of priapism) men with sickle cell disease was unable to confirm involvement of SNPs of the KLOTHO gene [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/174\">",
"     174",
"    </a>",
"    ]. There was evidence for SNPs involving genes in the transforming growth factor-beta, coagulation, cell adhesion, and cell hydration pathways.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Leg ulcers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leg ulcers are common in SCD. The risk is highest in tropical regions, and is increased in males and in those with a low hematocrit and increased evidence for hemolysis; HbF and alpha thalassemia appear to be protective. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=see_link&amp;anchor=H31#H31\">",
"     \"Overview of the clinical manifestations of sickle cell disease\", section on 'Leg ulcers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Polymorphisms in the KLOTHO gene, TEK gene, and several genes in the",
"    <span class=\"nowrap\">",
"     TGF-beta/BMP",
"    </span>",
"    signalling pathway have shown an association with leg ulcers by genotypic association analyses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/170\">",
"     170",
"    </a>",
"    ]. As noted above, the KLOTHO gene product regulates both VEGF expression and endothelial NO release, while the TEK receptor tyrosine kinase is involved in angiogenesis and the",
"    <span class=\"nowrap\">",
"     TGF-beta/BMP",
"    </span>",
"    signalling pathway modulates wound healing and angiogenesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Red cell adherence to endothelium",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endothelial cells express transmembrane alpha-beta heterodimers of the integrin superfamily, whose expression is modulated by many factors such as VEGF, basic fibroblast growth factor, and TGF-beta. Cellular damage enables adhesive interactions between sickle cells and endothelial cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/175\">",
"     175",
"    </a>",
"    ]. By assorted attachment mechanisms, perhaps differing by the type of endothelium encountered, the association of sickle and endothelial cells is postulated to sufficiently delay passage of the sickle cell such that polymerization, sickling, and vasoocclusion occur before microvasculature transit is complete (",
"    <a class=\"graphic graphic_figure graphicRef80615 \" href=\"mobipreview.htm?10/44/10945\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30104?source=see_link&amp;anchor=H16#H16\">",
"     \"Sickle hemoglobin polymer: Structure and functional properties\", section on 'Vascular occlusion by sickle cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sickle cells stick to the endothelial cell via surface antigens such as CD36 and CD44, and perhaps other unique features of the sickle erythrocyte membrane. Thrombospondin, a large glycoprotein produced by platelets, endothelial cells, and fibroblasts, bridges the CD36 molecule on sickle reticulocytes and the alpha(v)beta(3) integrin on large vessel endothelial cells. Circulating thrombospondin levels are increased in patients with sickle cell anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/176\">",
"     176",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Using at times plasma proteins such as von Willebrand factor, thrombospondin, fibrinogen, and fibronectin as intermediates, the sickle cell interacts with endothelial cell and extracellular matrix molecules including laminin, GPIb, integrins, VCAM-1, and the Fc receptor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/177\">",
"     177",
"    </a>",
"    ]. In addition, sickle reticulocytes bear alpha(4)beta(1) receptors for endothelial cell VCAM-1; these receptors are stimulated by cytokines or double-stranded RNA viruses.",
"   </p>",
"   <p>",
"    Because of genetic heterogeneity, endothelial cell genes may be differentially expressed or functionally different among patients with SCA and modulate the vasoocclusive severity of this disease. Preliminary evidence exists for genetic variation in molecules affecting the endothelium:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Relationships between SNPs in VCAM-1 and stroke risk have been reported [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/123,158\">",
"       123,158",
"      </a>",
"      ], but other SNPs in ICAM-1 and CD 36 were unrelated to stroke risk [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/178\">",
"       178",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      SNPs are present in the extracellular domain of VCAM-1 in patients with SCA; their functional significance is unknown.",
"     </li>",
"     <li>",
"      Genetic variations have been found in VEGF binding to its receptor, Flt-1 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/179\">",
"       179",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Polymorphisms in the genes for beta-2-adrenergic receptor and adenylate cyclase were associated with increased adhesion of sickle red cells to laminin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/180\">",
"     180",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Inflammation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophils are effectors and modulators of inflammation and tissue damage. When activated, neutrophils differentially express more than 250 different genes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/181\">",
"     181",
"    </a>",
"    ], suggesting that differences in neutrophil gene expression or polymorphisms in neutrophil-expressed genes may account for some phenotypic variation in sickle cell disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/54/36711?source=see_link\">",
"     \"Leukocyte-endothelial adhesion in the pathogenesis of inflammation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with sickle cell disease who are negative for the Duffy blood group antigens (ie, Fy(a-b-)) lack the integral red cell membrane glycoprotein DARC (Duffy antigen receptor for chemokines) and may less efficiently clear inflammatory cytokines, leading to increased end-organ damage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/182\">",
"     182",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/15/27898?source=see_link&amp;anchor=H45#H45\">",
"     \"A primer of red blood cell antigens and antibodies\", section on 'Duffy blood group system'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Leukocyte migration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemokines and their receptors are found in vascular endothelium. Chemokines are 8 to 10kDa cytokines that mediate leukocyte migration and activation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/183\">",
"     183",
"    </a>",
"    ]. Some chemokines attract neutrophils and some chemokines attract monocytes; both neutrophils and monocytes may play keys roles in the sickle vasoocclusion. Their expression can by modified by inflammatory cytokines, lipoproteins, and in some forms of vascular disease. Some chemokines are angiogenic and play a role in neovascularization, the process underlying proliferative sickle retinopathy. Along with other receptors for leukocytes, they could modulate the vasculopathy of SCA.",
"   </p>",
"   <p>",
"    In a mouse model of SCA, following hypoxia-reoxygenation there was a distinct inflammatory response characterized by an increased number of adherent and emigrated leukocytes with evidence of oxidant production in vascular endothelial cells. An anti-P-selectin antibody completely inhibited this inflammatory response, suggesting that leukocyte-endothelium interactions contribute to vasoocclusive events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/184\">",
"     184",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Platelet endothelial cell adhesion molecule (PECAM)-1, a member of the Ig gene superfamily homologous to VCAM-1 and ICAM-1, is expressed on endothelial surfaces. Located at the junction of adjoining endothelial cells, it mediates the transmigration of leukocytes via homophilic interactions with leukocyte PECAM-1 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/185\">",
"     185",
"    </a>",
"    ]. Heterophilic interactions between leukocyte PECAM-1 and subendothelial tissue ligands further regulate leukocyte migration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Leukocyte activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Granulocyte numbers are increased in the blood of patients with sickle cell anemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/186\">",
"     186",
"    </a>",
"    ]. In transgenic mice with SCA, baseline neutrophil counts may be normal or elevated up to nearly threefold, depending on the mouse strain employed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/187\">",
"     187",
"    </a>",
"    ]. Increased neutrophil counts have been associated with untoward events such as acute chest syndrome and stroke in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/14,171\">",
"     14,171",
"    </a>",
"    ], and have been shown to be an adverse risk factor for survival in SCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/12\">",
"     12",
"    </a>",
"    ]. Evidence for the importance of neutrophil activation in SCA includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neutrophil activation may accompany acute painful episodes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/188,189\">",
"       188,189",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neutrophil CD62L, CD11b, CD66b, CD63, and Fc gamma receptors and plasma levels of lactoferrin, elastase, soluble CD16, CD62L (L-selectin) and IL8 showed significant differences between control subjects and steady state sickle cell disease patients and more pronounced changes during painful episodes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/190,191\">",
"       190,191",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neutrophils from patients with SCA were more adherent to endothelial cells and fibronectin than control neutrophils [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/189\">",
"       189",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with SCA have increased numbers of neutrophils expressing CD64, suggesting that enhanced adhesion to endothelium could contribute to vaso-occlusive disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/192\">",
"       192",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Hemostasis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombosis and hemostasis may play roles in the pathophysiology of SCA; coincidental mutations that favor blood coagulation or thrombosis in general, or stroke in particular [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/193,194\">",
"     193,194",
"    </a>",
"    ], could influence the phenotype of disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=see_link&amp;anchor=H3#H3\">",
"     \"Cerebrovascular complications of sickle cell disease\", section on 'Cerebral infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Polymorphisms in a number of genes (eg, factor V, platelet glycoprotein IIIa, 5,10 methylenetetrahydrofolate reductase, angiotensin) have been associated with some vasoocclusive complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/195,196\">",
"     195,196",
"    </a>",
"    ]. Most studies involve few patients, and positive results are unconfirmed. Protein C, protein S,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    cofactor II, thrombin-antithrombin complexes, and resistance to activated protein C were measured in children who were being transfused for stroke, children at risk for stroke, and untransfused controls, but no important differences in levels among these groups have been found to date [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/197\">",
"     197",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Osteonecrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The possible association between SNPs in candidate genes and osteonecrosis was studied in 442 patients with SCA and osteonecrosis and 529 control subjects with SCA over the age of 20 who had not developed this complication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/198\">",
"     198",
"    </a>",
"    ]. It was hypothesized that the likelihood of developing osteonecrosis might be influenced by heterogeneity in genes modulating cytokines, inflammation, oxidant stress, and bone metabolism.",
"   </p>",
"   <p>",
"    As noted previously, individuals with osteonecrosis had a significantly higher incidence of alpha thalassemia, although there was no difference in total hemoglobin or fetal hemoglobin levels between the two groups. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18506?source=see_link&amp;anchor=H16#H16\">",
"     \"Bone and joint complications in sickle cell disease\", section on 'Osteonecrosis'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H11\">",
"     'Alpha thalassemia'",
"    </a>",
"    above.) SNPs in the genes for bone morphogenic protein 6, annexin A2, and KLOTHO, important in bone morphology, metabolism, and vascular disease, were found to be significantly associated with sickle cell osteonecrosis. The association of BMP6 SNP rs3812163 with sickle osteonecrosis was confirmed in a study of 39 cases compared with 205 controls; however, in this small study, association with annexin A2 and KLOTHO was not replicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/199\">",
"     199",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Renal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;In exploratory studies, the following SNP associations were found for renal function in patients with sickle cell disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Four SNPs in BMPR1B, a bone morphogenetic protein (BMP) receptor gene, yielded statistically significant associations with glomerular filtration rate [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/200\">",
"       200",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Seven SNPs in MYH9, the myosin heavy chain 9 non-muscle gene, and one in APOL1, the apolipoprotein L1 gene, were significantly associated with proteinuria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/201\">",
"       201",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;SNPs in 49 candidate genes involved in vaso-occlusion, nitric oxide biology, primary pulmonary hypertension, and the risk for pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia were evaluated in 111 patients with sickle cell disease who had been screened for pulmonary hypertension by echocardiography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/202\">",
"     202",
"    </a>",
"    ]. A multiple regression model identified SNPs in activin A receptor, type II-like 1 (ACVRL1), bone morphogenetic protein receptor 6 (BMPR6), and beta-1 adrenergic receptor (ADRB1) as independently contributing to the risk of pulmonary hypertension. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=see_link&amp;anchor=H18#H18\">",
"     \"Pulmonary complications of sickle cell disease\", section on 'Pulmonary hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     GALLSTONES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Promoter polymorphisms in the uridine diphosphate-glucuronosyltransferase 1A (UGT1A1) gene have been associated with unconjugated hyperbilirubinemia and Gilbert syndrome, and appear to be a risk factor for symptomatic gallstones in subjects with SCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/152,203,204\">",
"     152,203,204",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=see_link&amp;anchor=H3#H3\">",
"     \"Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction\", section on 'Gilbert's syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In three reports, children with SCA and the",
"    <span class=\"nowrap\">",
"     7/7",
"    </span>",
"    promoter UGT1A1 genotype had a significantly higher mean bilirubin level than those with the",
"    <span class=\"nowrap\">",
"     6/6",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     6/7",
"    </span>",
"    genotypes, and were more likely to have had a previous cholecystectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/152,205,206\">",
"     152,205,206",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Presence of the",
"    <span class=\"nowrap\">",
"     7/7",
"    </span>",
"    UGT1A1 genotype may also adversely affect the ability of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    to prevent gallstone formation in SCA. Carriers of the",
"    <span class=\"nowrap\">",
"     7/7",
"    </span>",
"    genotype had bilirubin levels greater than 3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    despite full-dose hydroxyurea therapy, while those with the",
"    <span class=\"nowrap\">",
"     6/6",
"    </span>",
"    genotype had normal bilirubin levels following treatment with this agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/207\">",
"     207",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     G6PD DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose-6-phosphate dehydrogenase (G6PD) deficiency is common in patients with SCA. When these two conditions coexist, the effects on phenotype have been disparate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/208-217\">",
"     208-217",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13289?source=see_link&amp;anchor=H12#H12\">",
"     \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\", section on 'Epidemiology of G6PD deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one large study of 800 males over age two years with SCA, the prevalence of G6PD deficiency did not change according to age and was not associated with differential survival or more pain crises [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/218\">",
"       218",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      It is not clear whether the presence of G6PD deficiency is [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/109\">",
"       109",
"      </a>",
"      ] or is not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/32/39434/abstract/110,219\">",
"       110,219",
"      </a>",
"      ] an independent risk factor for abnormally high cerebral velocities by transcranial doppler in children with SCA or stroke. However, results from two of these studies suggest that hemolysis, anemia, and lack of alpha thalassemia independently increase the risk of cerebrovascular vasculopathy in SCD. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=see_link&amp;anchor=H3#H3\">",
"       \"Cerebrovascular complications of sickle cell disease\", section on 'Cerebral infarction'",
"      </a>",
"      and",
"      <a class=\"local\" href=\"#H18\">",
"       'Nitric oxide availability'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18828143\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical features of sickle cell anemia (SCA) are exceptionally heterogeneous. As in most \"single-gene\" disorders, clinical heterogeneity is influenced by other genes that shape its intermediate phenotypes. The products of modifier genes, sometimes called epistatic genes, are also likely to interact, thus determining the specific phenotype within each affected family and patient (eg, stroke risk, other vasoocclusive events, HbF level, response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    ). Independent studies by four groups of investigators using different analytical methods have replicated the association of SNPs in the",
"    <span class=\"nowrap\">",
"     TGF-beta/BMP6",
"    </span>",
"    pathway with sickle cell pulmonary hypertension, stroke and osteonecrosis. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Overview'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18828243\">",
"    <span class=\"h2\">",
"     Major modifiers of SCA phenotype",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following are major genetic modifiers of the SCA phenotype:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Control of fetal hemoglobin expression is the best understood and most powerful genetic modifier of SCA. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Fetal hemoglobin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Presence of alpha thalassemia (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Alpha thalassemia'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18828401\">",
"    <span class=\"h2\">",
"     Other potential disease modulators",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other genetic modifiers are known or have been suggested for the following complications of SCA:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Overall disease severity (see",
"      <a class=\"local\" href=\"#H13644148\">",
"       'Overall disease severity'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Stroke (see",
"      <a class=\"local\" href=\"#H13\">",
"       'Stroke'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Vasoocclusive events, priapism, leg ulcers (see",
"      <a class=\"local\" href=\"#H15\">",
"       'Vascular endothelium'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Ability to respond to treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/16/16648?source=see_link\">",
"       hydroxyurea",
"      </a>",
"      (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Response to hydroxyurea'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Thrombotic events (see",
"      <a class=\"local\" href=\"#H25\">",
"       'Hemostasis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Osteonecrosis (see",
"      <a class=\"local\" href=\"#H26\">",
"       'Osteonecrosis'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Pulmonary hypertension (see",
"      <a class=\"local\" href=\"#H28\">",
"       'Pulmonary hypertension'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Gallstones (see",
"      <a class=\"local\" href=\"#H29\">",
"       'Gallstones'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/1\">",
"      Driscoll MC, Hurlet A, Styles L, et al. Stroke risk in siblings with sickle cell anemia. Blood 2003; 101:2401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/2\">",
"      Steinberg MH, Voskaridou E, Kutlar A, et al. Concordant fetal hemoglobin response to hydroxyurea in siblings with sickle cell disease. Am J Hematol 2003; 72:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/3\">",
"      Kwiatkowski JL, Hunter JV, Smith-Whitley K, et al. Transcranial Doppler ultrasonography in siblings with sickle cell disease. Br J Haematol 2003; 121:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/4\">",
"      Ma Q, Wyszynski DF, Farrell JJ, et al. Fetal hemoglobin in sickle cell anemia: genetic determinants of response to hydroxyurea. Pharmacogenomics J 2007; 7:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/5\">",
"      Steinberg MH, Rodgers GP. Pathophysiology of sickle cell disease: role of cellular and genetic modifiers. Semin Hematol 2001; 38:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/6\">",
"      Nagel RL. Pleiotropic and epistatic effects in sickle cell anemia. Curr Opin Hematol 2001; 8:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/7\">",
"      Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol 2005; 129:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/8\">",
"      Amer J, Ghoti H, Rachmilewitz E, et al. Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants. Br J Haematol 2006; 132:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/9\">",
"      Sangokoya C, Telen MJ, Chi JT. microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease. Blood 2010; 116:4338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/10\">",
"      Poillon WN, Kim BC, Rodgers GP, et al. Sparing effect of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S at physiologic ligand saturations. Proc Natl Acad Sci U S A 1993; 90:5039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/11\">",
"      Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Engl J Med 1991; 325:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/12\">",
"      Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994; 330:1639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/13\">",
"      Akinsheye I, Alsultan A, Solovieff N, et al. Fetal hemoglobin in sickle cell anemia. Blood 2011; 118:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/14\">",
"      Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease. Blood 1994; 84:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/15\">",
"      Walters MC, Nienhuis AW, Vichinsky E. Novel therapeutic approaches in sickle cell disease. Hematology Am Soc Hematol Educ Program 2002; :10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/16\">",
"      CONLEY CL, WEATHERALL DJ, RICHARDSON SN, et al. Hereditary persistence of fetal hemoglobin: a study of 79 affected persons in 15 Negro families in Baltimore. Blood 1963; 21:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/17\">",
"      Nagel RL, Bookchin RM, Johnson J, et al. Structural bases of the inhibitory effects of hemoglobin F and hemoglobin A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci U S A 1979; 76:670.",
"     </a>",
"    </li>",
"    <li>",
"     Nagel RL, Steinberg MH. Hemoglobins of the Embryo and Fetus and Minor Hemoglobins of Adults. In: Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, Steinberg MH, Forget BG, Higgs DR, Nagel RL (Eds), Cambridge University Press, Cambridge 2001. p.197.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/19\">",
"      Garner C, Tatu T, Reittie JE, et al. Genetic influences on F cells and other hematologic variables: a twin heritability study. Blood 2000; 95:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/20\">",
"      Dover GJ, Boyer SH, Charache S, Heintzelman K. Individual variation in the production and survival of F cells in sickle-cell disease. N Engl J Med 1978; 299:1428.",
"     </a>",
"    </li>",
"    <li>",
"     Genetic modulation of phenotype by epistatic genes. In: The management of sickle cell disease. NIH publication 02-2117, 4th ed, June, 2002. p.173.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/22\">",
"      Sebastiani P, Wang L, Nolan VG, et al. Fetal hemoglobin in sickle cell anemia: Bayesian modeling of genetic associations. Am J Hematol 2008; 83:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/23\">",
"      Creary LE, McKenzie CA, Menzel S, et al. Ethnic differences in F cell levels in Jamaica: a potential tool for identifying new genetic loci controlling fetal haemoglobin. Br J Haematol 2009; 144:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/24\">",
"      Wahlberg K, Jiang J, Rooks H, et al. The HBS1L-MYB intergenic interval associated with elevated HbF levels shows characteristics of a distal regulatory region in erythroid cells. Blood 2009; 114:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/25\">",
"      Wilber A, Tschulena U, Hargrove PW, et al. A zinc-finger transcriptional activator designed to interact with the gamma-globin gene promoters enhances fetal hemoglobin production in primary human adult erythroblasts. Blood 2010; 115:3033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/26\">",
"      Bank A. Regulation of human fetal hemoglobin: new players, new complexities. Blood 2006; 107:435.",
"     </a>",
"    </li>",
"    <li>",
"     Stamatoyannopoulos G. Molecular and cellular basis of hemoglobin switching. In: Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, Steinberg MH, Forget BG, Higgs DR, Nagel RL (Eds), Cambridge University Press, Cambridge 2001. p.131.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/28\">",
"      Grosveld F, Antoniou M, Berry M, et al. The regulation of human globin gene switching. Philos Trans R Soc Lond B Biol Sci 1993; 339:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/29\">",
"      Sankaran VG, Xu J, Orkin SH. Advances in the understanding of haemoglobin switching. Br J Haematol 2010; 149:181.",
"     </a>",
"    </li>",
"    <li>",
"     Blobel GA, Weiss MJ. Nuclear factors that regulate erythropoiesis. In: Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, Steinberg MH, Forget BG, Higgs DR, Nagel RL (Eds), Cambridge University Press, Cambridge 2001. p.72.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/31\">",
"      Ryan TM, Sun CW, Ren J, Townes TM. Human gamma-globin gene promoter element regulates human beta-globin gene developmental specificity. Nucleic Acids Res 2000; 28:2736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/32\">",
"      Sankaran VG, Menne TF, Xu J, et al. Human fetal hemoglobin expression is regulated by the developmental stage-specific repressor BCL11A. Science 2008; 322:1839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/33\">",
"      Thein SL, Menzel S. Discovering the genetics underlying foetal haemoglobin production in adults. Br J Haematol 2009; 145:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/34\">",
"      Wilber A, Nienhuis AW, Persons DA. Transcriptional regulation of fetal to adult hemoglobin switching: new therapeutic opportunities. Blood 2011; 117:3945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/35\">",
"      Steinberg MH, Lu ZH, Barton FB, et al. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Multicenter Study of Hydroxyurea. Blood 1997; 89:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/36\">",
"      Kumkhaek C, Taylor JG 6th, Zhu J, et al. Fetal haemoglobin response to hydroxycarbamide treatment and sar1a promoter polymorphisms in sickle cell anaemia. Br J Haematol 2008; 141:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/37\">",
"      Vasavda N, Badiger S, Rees D, et al. The presence of alpha-thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease. Br J Haematol 2008; 143:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/38\">",
"      Chang YC, Smith KD, Moore RD, et al. An analysis of fetal hemoglobin variation in sickle cell disease: the relative contributions of the X-linked factor, beta-globin haplotypes, alpha-globin gene number, gender, and age. Blood 1995; 85:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/39\">",
"      Brown AK, Sleeper LA, Miller ST, et al. Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative Study of Sickle Cell Disease. Arch Pediatr Adolesc Med 1994; 148:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/40\">",
"      Nagel RL, Labie D. DNA haplotypes and the beta s globin gene. Prog Clin Biol Res 1989; 316B:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/41\">",
"      Lapoum&eacute;roulie C, Dunda O, Ducrocq R, et al. A novel sickle cell mutation of yet another origin in Africa: the Cameroon type. Hum Genet 1992; 89:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/42\">",
"      el-Hazmi MA, Warsy AS, al-Swailem AR, et al. Sickle cell gene in the population of Saudi Arabia. Hemoglobin 1996; 20:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/43\">",
"      Ballas SK, Talacki CA, Adachi K, et al. The Xmn I site (-158, C----T) 5' to the G gamma gene: correlation with the Senegalese haplotype and G gamma globin expression. Hemoglobin 1991; 15:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/44\">",
"      Nagel RL, Fabry ME, Pagnier J, et al. Hematologically and genetically distinct forms of sickle cell anemia in Africa. The Senegal type and the Benin type. N Engl J Med 1985; 312:880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/45\">",
"      Nagel RL, Erlingsson S, Fabry ME, et al. The Senegal DNA haplotype is associated with the amelioration of anemia in African-American sickle cell anemia patients. Blood 1991; 77:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/46\">",
"      Steinberg MH, Hsu H, Nagel RL, et al. Gender and haplotype effects upon hematological manifestations of adult sickle cell anemia. Am J Hematol 1995; 48:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/47\">",
"      Chen Z, Luo HY, Basran RK, et al. A T-to-G transversion at nucleotide -567 upstream of HBG2 in a GATA-1 binding motif is associated with elevated hemoglobin F. Mol Cell Biol 2008; 28:4386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/48\">",
"      Harju-Baker S, Costa FC, Fedosyuk H, et al. Silencing of Agamma-globin gene expression during adult definitive erythropoiesis mediated by GATA-1-FOG-1-Mi2 complex binding at the -566 GATA site. Mol Cell Biol 2008; 28:3101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/49\">",
"      Tuan DY, Solomon WB, London IM, Lee DP. An erythroid-specific, developmental-stage-independent enhancer far upstream of the human \"beta-like globin\" genes. Proc Natl Acad Sci U S A 1989; 86:2554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/50\">",
"      Fraser P, Grosveld F. Locus control regions, chromatin activation and transcription. Curr Opin Cell Biol 1998; 10:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/51\">",
"      Townes TM, Behringer RR. Human globin locus activation region (LAR): role in temporal control. Trends Genet 1990; 6:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/52\">",
"      Caterina JJ, Ryan TM, Pawlik KM, et al. Human beta-globin locus control region: analysis of the 5' DNase I hypersensitive site HS 2 in transgenic mice. Proc Natl Acad Sci U S A 1991; 88:1626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/53\">",
"      Fraser P, Hurst J, Collis P, Grosveld F. DNaseI hypersensitive sites 1, 2 and 3 of the human beta-globin dominant control region direct position-independent expression. Nucleic Acids Res 1990; 18:3503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/54\">",
"      Pruzina S, Hanscombe O, Whyatt D, et al. Hypersensitive site 4 of the human beta globin locus control region. Nucleic Acids Res 1991; 19:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/55\">",
"      Talbot D, Grosveld F. The 5'HS2 of the globin locus control region enhances transcription through the interaction of a multimeric complex binding at two functionally distinct NF-E2 binding sites. EMBO J 1991; 10:1391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/56\">",
"      Fraser P, Pruzina S, Antoniou M, Grosveld F. Each hypersensitive site of the human beta-globin locus control region confers a different developmental pattern of expression on the globin genes. Genes Dev 1993; 7:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/57\">",
"      Navas PA, Peterson KR, Li Q, et al. Developmental specificity of the interaction between the locus control region and embryonic or fetal globin genes in transgenic mice with an HS3 core deletion. Mol Cell Biol 1998; 18:4188.",
"     </a>",
"    </li>",
"    <li>",
"     Nagel RL. Origins and dispersion of the sickle gene. In: Sickle Cell Diseae: Basic Principles and Clincal Practice, Embury SH, Hebbel RP, Mohandas N, Steinberg MH (Eds), Raven Press, New York 1994. p.353.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/59\">",
"      Adekile AD, Dimovski AJ, Oner C, et al. Haplotype-specific sequence variations in the locus control region (5' hypersensitive sites 2, 3, 4) of beta S chromosomes. Hemoglobin 1993; 17:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/60\">",
"      Morgan JC, Scott DF, Lanclos KD. Two mutations in the locus control region hypersensitivity site-2 (5' HS-2) of haplotype 19 beta s chromosomes alter binding of trans-acting factors. Am J Hematol 1996; 51:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/61\">",
"      Chung JH, Whiteley M, Felsenfeld G. A 5' element of the chicken beta-globin domain serves as an insulator in human erythroid cells and protects against position effect in Drosophila. Cell 1993; 74:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/62\">",
"      Li Q, Stamatoyannopoulos G. Hypersensitive site 5 of the human beta locus control region functions as a chromatin insulator. Blood 1994; 84:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/63\">",
"      Sorrentino B, Ney P, Bodine D, Nienhius AW. A 46 base pair enhancer sequence within the locus activating region is required for induced expression of the gamma-globin gene during erythroid differentiation. Nucleic Acids Res 1990; 18:2721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/64\">",
"      Reitman M, Lee E, Westphal H, Felsenfeld G. An enhancer/locus control region is not sufficient to open chromatin. Mol Cell Biol 1993; 13:3990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/65\">",
"      Caterina JJ, Ciavatta DJ, Donze D, et al. Multiple elements in human beta-globin locus control region 5' HS 2 are involved in enhancer activity and position-independent, transgene expression. Nucleic Acids Res 1994; 22:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/66\">",
"      Molete JM, Petrykowska H, Bouhassira EE, et al. Sequences flanking hypersensitive sites of the beta-globin locus control region are required for synergistic enhancement. Mol Cell Biol 2001; 21:2969.",
"     </a>",
"    </li>",
"    <li>",
"     Nagel RL, Steinberg MH. Genetics of the betaS gene: origins, epidemiology, and epistasis. In: Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, 1st ed, Steinberg MH, Forget BG, Higgs DR, Nagel RL (Eds), Cambridge University Press, Cambridge 2001. p.711.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/68\">",
"      Ofori-Acquah SF, Lalloz MR, Layton DM. Localisation of cis regulatory elements at the beta-globin locus: analysis of hybrid haplotype chromosomes. Biochem Biophys Res Commun 1999; 254:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/69\">",
"      Ofori-Acquah SF, Lalloz MR, Layton DM. Nucleotide variation regulates the level of enhancement by hypersensitive site 2 of the beta-globin locus control region. Blood Cells Mol Dis 2001; 27:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/70\">",
"      Ofori-Acquah SF, Lalloz MR, Serjeant G, Layton DM. Dominant influence of gamma-globin promoter polymorphisms on fetal haemoglobin expression in sickle cell disease. Cell Mol Biol (Noisy-le-grand) 2004; 50:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/71\">",
"      Lu ZH, Steinberg MH. Fetal hemoglobin in sickle cell anemia: relation to regulatory sequences cis to the beta-globin gene. Multicenter Study of Hydroxyurea. Blood 1996; 87:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/72\">",
"      Jackson JD, Petrykowska H, Philipsen S, et al. Role of DNA sequences outside the cores of DNase hypersensitive sites (HSs) in functions of the beta-globin locus control region. Domain opening and synergism between HS2 and HS3. J Biol Chem 1996; 271:11871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/73\">",
"      Hardison RC, Oeltjen J, Miller W. Long human-mouse sequence alignments reveal novel regulatory elements: a reason to sequence the mouse genome. Genome Res 1997; 7:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/74\">",
"      Solovieff N, Milton JN, Hartley SW, et al. Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster. Blood 2010; 115:1815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/75\">",
"      Menzel S, Garner C, Gut I, et al. A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15. Nat Genet 2007; 39:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/76\">",
"      Jiang J, Best S, Menzel S, et al. cMYB is involved in the regulation of fetal hemoglobin production in adults. Blood 2006; 108:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/77\">",
"      Wahlberg K, Jiang J, Rooks H, et al. Functional characterisation of a MYB-HBS1L intergenic region controlling fetal hemoglobin levels in adults (abstract). Blood 2008; 112:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/78\">",
"      Uda M, Galanello R, Sanna S, et al. Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of beta-thalassemia. Proc Natl Acad Sci U S A 2008; 105:1620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/79\">",
"      Sedgewick AE, Timofeev N, Sebastiani P, et al. BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobinopathies. Blood Cells Mol Dis 2008; 41:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/80\">",
"      Chen Z, Luo HY, Steinberg MH, Chui DH. BCL11A represses HBG transcription in K562 cells. Blood Cells Mol Dis 2009; 42:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/81\">",
"      Lettre G, Sankaran VG, Bezerra MA, et al. DNA polymorphisms at the BCL11A, HBS1L-MYB, and beta-globin loci associate with fetal hemoglobin levels and pain crises in sickle cell disease. Proc Natl Acad Sci U S A 2008; 105:11869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/82\">",
"      Galarneau G, Palmer CD, Sankaran VG, et al. Fine-mapping at three loci known to affect fetal hemoglobin levels explains additional genetic variation. Nat Genet 2010; 42:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/83\">",
"      Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood 2011; 118:4985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/84\">",
"      Makani J, Menzel S, Nkya S, et al. Genetics of fetal hemoglobin in Tanzanian and British patients with sickle cell anemia. Blood 2011; 117:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/85\">",
"      Creary LE, Ulug P, Menzel S, et al. Genetic variation on chromosome 6 influences F cell levels in healthy individuals of African descent and HbF levels in sickle cell patients. PLoS One 2009; 4:e4218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/86\">",
"      Farrell JJ, Sherva RM, Chen ZY, et al. A 3-bp deletion in the HBS1L-MYB intergenic region on chromosome 6q23 is associated with HbF expression. Blood 2011; 117:4935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/87\">",
"      Steinberg MH, Ma Q, Kutlar A, et al. Fetal Hemoglobin in Sickle Cell Anemia: Associations with Single Nucleotide Polymorphisms in Quantitative Trait Loci on Chromsomes 8q12 and Xp22 (abstract). Blood 2006; 108:360a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/88\">",
"      Perkins AC, Gaensler KM, Orkin SH. Silencing of human fetal globin expression is impaired in the absence of the adult beta-globin gene activator protein EKLF. Proc Natl Acad Sci U S A 1996; 93:12267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/89\">",
"      Tamaru H, Selker EU. A histone H3 methyltransferase controls DNA methylation in Neurospora crassa. Nature 2001; 414:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/90\">",
"      Bird A. The essentials of DNA methylation. Cell 1992; 70:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/91\">",
"      Bird A. Molecular biology. Methylation talk between histones and DNA. Science 2001; 294:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/92\">",
"      Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/93\">",
"      Dover GJ, Smith KD, Chang YC, et al. Fetal hemoglobin levels in sickle cell disease and normal individuals are partially controlled by an X-linked gene located at Xp22.2. Blood 1992; 80:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/94\">",
"      Chang YP, Maier-Redelsperger M, Smith KD, et al. The relative importance of the X-linked FCP locus and beta-globin haplotypes in determining haemoglobin F levels: a study of SS patients homozygous for beta S haplotypes. Br J Haematol 1997; 96:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/95\">",
"      Dozy AM, Kan YW, Embury SH, et al. alpha-Globin gene organisation in blacks precludes the severe form of alpha-thalassaemia. Nature 1979; 280:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/96\">",
"      Steinberg MH, Embury SH. Alpha-thalassemia in blacks: genetic and clinical aspects and interactions with the sickle hemoglobin gene. Blood 1986; 68:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/97\">",
"      Milner PF, Kraus AP, Sebes JI, et al. Sickle cell disease as a cause of osteonecrosis of the femoral head. N Engl J Med 1991; 325:1476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/98\">",
"      Milner PF, Kraus AP, Sebes JI, et al. Osteonecrosis of the humeral head in sickle cell disease. Clin Orthop Relat Res 1993; :136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/99\">",
"      Ballas SK, Talacki CA, Rao VM, Steiner RM. The prevalence of avascular necrosis in sickle cell anemia: correlation with alpha-thalassemia. Hemoglobin 1989; 13:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/100\">",
"      Embury SH, Dozy AM, Miller J, et al. Concurrent sickle-cell anemia and alpha-thalassemia: effect on severity of anemia. N Engl J Med 1982; 306:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/101\">",
"      Schroeder WA, Powars DR, Kay LM, et al. Beta-cluster haplotypes, alpha-gene status, and hematological data from SS, SC, and S-beta-thalassemia patients in southern California. Hemoglobin 1989; 13:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/102\">",
"      Adekile AD, Huisman TH. Level of fetal hemoglobin in children with sickle cell anemia: influence of gender, haplotype and alpha-thalassemia-2 trait. Acta Haematol 1993; 90:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/103\">",
"      Baysal E, Qin WB, Huisman TH. Alpha-Thalassemia and fetal hemoglobin. Blood 1994; 84:3241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/104\">",
"      K&eacute;clard L, Ollendorf V, Berchel C, et al. beta S haplotypes, alpha-globin gene status, and hematological data of sickle cell disease patients in Guadeloupe (F.W.I.). Hemoglobin 1996; 20:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/105\">",
"      Figueiredo MS, Kerbauy J, Gon&ccedil;alves MS, et al. Effect of alpha-thalassemia and beta-globin gene cluster haplotypes on the hematological and clinical features of sickle-cell anemia in Brazil. Am J Hematol 1996; 53:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/106\">",
"      Mears JG, Lachman HM, Labie D, Nagel RL. Alpha-thalassemia is related to prolonged survival in sickle cell anemia. Blood 1983; 62:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/107\">",
"      Fox PD, Higgs DR, Serjeant GR. Influence of alpha thalassaemia on the retinopathy of homozygous sickle cell disease. Br J Ophthalmol 1993; 77:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/108\">",
"      Adams RJ, Kutlar A, McKie V, et al. Alpha thalassemia and stroke risk in sickle cell anemia. Am J Hematol 1994; 45:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/109\">",
"      Bernaudin F, Verlhac S, Chevret S, et al. G6PD deficiency, absence of alpha-thalassemia, and hemolytic rate at baseline are significant independent risk factors for abnormally high cerebral velocities in patients with sickle cell anemia. Blood 2008; 112:4314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/110\">",
"      Rees DC, Lambert C, Cooper E, et al. Glucose 6 phosphate dehydrogenase deficiency is not associated with cerebrovascular disease in children with sickle cell anemia. Blood 2009; 114:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/111\">",
"      Koshy M, Entsuah R, Koranda A, et al. Leg ulcers in patients with sickle cell disease. Blood 1989; 74:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/112\">",
"      Adekile AD, Tuli M, Haider MZ, et al. Influence of alpha-thalassemia trait on spleen function in sickle cell anemia patients with high HbF. Am J Hematol 1996; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/113\">",
"      Guasch A, Zayas CF, Eckman JR, et al. Evidence that microdeletions in the alpha globin gene protect against the development of sickle cell glomerulopathy in humans. J Am Soc Nephrol 1999; 10:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/114\">",
"      Nolan VG, Wyszynski DF, Farrer LA, Steinberg MH. Hemolysis-associated priapism in sickle cell disease. Blood 2005; 106:3264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/115\">",
"      Haider MZ, Ashebu S, Aduh P, Adekile AD. Influence of alpha-thalassemia on cholelithiasis in SS patients with elevated Hb F. Acta Haematol 1998; 100:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/116\">",
"      Mukherjee MB, Lu CY, Ducrocq R, et al. Effect of alpha-thalassemia on sickle-cell anemia linked to the Arab-Indian haplotype in India. Am J Hematol 1997; 55:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/117\">",
"      Powars DR. Sickle cell anemia: beta s-gene-cluster haplotypes as prognostic indicators of vital organ failure. Semin Hematol 1991; 28:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/118\">",
"      Powars DR, Meiselman HJ, Fisher TC, et al. Beta-S gene cluster haplotypes modulate hematologic and hemorheologic expression in sickle cell anemia. Use in predicting clinical severity. Am J Pediatr Hematol Oncol 1994; 16:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/119\">",
"      Thomas PW, Higgs DR, Serjeant GR. Benign clinical course in homozygous sickle cell disease: a search for predictors. J Clin Epidemiol 1997; 50:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/120\">",
"      Alexander N, Higgs D, Dover G, Serjeant GR. Are there clinical phenotypes of homozygous sickle cell disease? Br J Haematol 2004; 126:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/121\">",
"      Taylor JG 6th, Nolan VG, Mendelsohn L, et al. Chronic hyper-hemolysis in sickle cell anemia: association of vascular complications and mortality with less frequent vasoocclusive pain. PLoS One 2008; 3:e2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/122\">",
"      Sebastiani P, Solovieff N, Hartley SW, et al. Genetic modifiers of the severity of sickle cell anemia identified through a genome-wide association study. Am J Hematol 2010; 85:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/123\">",
"      Hoppe C, Klitz W, Cheng S, et al. Gene interactions and stroke risk in children with sickle cell anemia. Blood 2004; 103:2391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/124\">",
"      Hoppe C, Klitz W, D'Harlingue K, et al. Confirmation of an association between the TNF(-308) promoter polymorphism and stroke risk in children with sickle cell anemia. Stroke 2007; 38:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/125\">",
"      Sebastiani P, Ramoni MF, Nolan V, et al. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Nat Genet 2005; 37:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/126\">",
"      Cook NR, Zee RY, Ridker PM. Tree and spline based association analysis of gene-gene interaction models for ischemic stroke. Stat Med 2004; 23:1439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/127\">",
"      Zee RY, Cook NR, Cheng S, et al. Polymorphism in the P-selectin and interleukin-4 genes as determinants of stroke: a population-based, prospective genetic analysis. Hum Mol Genet 2004; 13:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/128\">",
"      Flanagan JM, Frohlich DM, Howard TA, et al. Genetic predictors for stroke in children with sickle cell anemia. Blood 2011; 117:6681.",
"     </a>",
"    </li>",
"    <li>",
"     Brugnara C. Red cell membrane in sickle cell disease. In: Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management, Steinberg MH, Forget BG, Higgs DR, Nagel RL (Eds), Cambridge University Press, Cambridge 2001. p.550.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/130\">",
"      Franco RS, Yasin Z, Lohmann JM, et al. The survival characteristics of dense sickle cells. Blood 2000; 96:3610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/131\">",
"      GARDOS G. The function of calcium in the potassium permeability of human erythrocytes. Biochim Biophys Acta 1958; 30:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/132\">",
"      Liu SC, Jarolim P, Rubin HL, et al. The homozygous state for the band 3 protein mutation in Southeast Asian Ovalocytosis may be lethal. Blood 1994; 84:3590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/133\">",
"      Jarolim P, Rubin HL, Brabec V, Palek J. A nonsense mutation 1669Glu--&gt;Ter within the regulatory domain of human erythroid ankyrin leads to a selective deficiency of the major ankyrin isoform (band 2.1) and a phenotype of autosomal dominant hereditary spherocytosis. J Clin Invest 1995; 95:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/134\">",
"      Jarolim P, Murray JL, Rubin HL, et al. Characterization of 13 novel band 3 gene defects in hereditary spherocytosis with band 3 deficiency. Blood 1996; 88:4366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/135\">",
"      Wick TM, Eckman JR. Molecular basis of sickle cell-endothelial cell interactions. Curr Opin Hematol 1996; 3:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/136\">",
"      Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation 1990; 50:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/137\">",
"      Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev 1990; 70:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/138\">",
"      Rodgers GM. Hemostatic properties of normal and perturbed vascular cells. FASEB J 1988; 2:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/139\">",
"      Esmon CT. The regulation of natural anticoagulant pathways. Science 1987; 235:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/140\">",
"      Shovlin CL, Scott J. Inherited diseases of the vasculature. Annu Rev Physiol 1996; 58:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/141\">",
"      Chang Milbauer L, Wei P, Enenstein J, et al. Genetic endothelial systems biology of sickle stroke risk. Blood 2008; 111:3872.",
"     </a>",
"    </li>",
"    <li>",
"     Francis RB Jr, Hebbel RP. Hemostasis. In: Sickle Cell Disease: Basic Principles and Clinical Practice, Embury SH, Hebbel RP, Mohandas N, Steinberg MH (Eds), Lippincott-Raven, New York 1994. p.299.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/143\">",
"      Sowemimo-Coker SO, Meiselman HJ, Francis RB Jr. Increased circulating endothelial cells in sickle cell crisis. Am J Hematol 1989; 31:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/144\">",
"      Solovey A, Lin Y, Browne PV, et al. Phenotypic analysis of circulating endothelial cells reveals and activated endothelium in sickle cell anemia patients. Blood 1996; 88:648a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/145\">",
"      Kurantsin-Mills J, Ofosu FA, Safa TK, et al. Plasma factor VII and thrombin-antithrombin III levels indicate increased tissue factor activity in sickle cell patients. Br J Haematol 1992; 81:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/146\">",
"      Dworkis DA, Klings ES, Solovieff N, et al. Severe sickle cell anemia is associated with increased plasma levels of TNF-R1 and VCAM-1. Am J Hematol 2011; 86:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/147\">",
"      Sowemimo-Coker SO, Haywood LJ, Meiselman HJ, Francis RB Jr. Effects of normal and sickle erythrocytes on prostacyclin release by perfused human umbilical cord veins. Am J Hematol 1992; 40:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/148\">",
"      Weinstein R, Zhou MA, Bartlett-Pandite A, Wenc K. Sickle erythrocytes inhibit human endothelial cell DNA synthesis. Blood 1990; 76:2146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/149\">",
"      Phelan M, Perrine SP, Brauer M, Faller DV. Sickle erythrocytes, after sickling, regulate the expression of the endothelin-1 gene and protein in human endothelial cells in culture. J Clin Invest 1995; 96:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/150\">",
"      Mosseri M, Bartlett-Pandite AN, Wenc K, et al. Inhibition of endothelium-dependent vasorelaxation by sickle erythrocytes. Am Heart J 1993; 126:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/151\">",
"      Hebbel RP, Eaton JW, Balasingam M, Steinberg MH. Spontaneous oxygen radical generation by sickle erythrocytes. J Clin Invest 1982; 70:1253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/152\">",
"      Carpenter SL, Lieff S, Howard TA, et al. UGT1A1 promoter polymorphisms and the development of hyperbilirubinemia and gallbladder disease in children with sickle cell anemia. Am J Hematol 2008; 83:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/153\">",
"      Granger DN, Korthuis RJ. Physiologic mechanisms of postischemic tissue injury. Annu Rev Physiol 1995; 57:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/154\">",
"      Boyle EM Jr, Canty TG Jr, Morgan EN, et al. Treating myocardial ischemia-reperfusion injury by targeting endothelial cell transcription. Ann Thorac Surg 1999; 68:1949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/155\">",
"      Rivera A, Jarolim P, Brugnara C. Modulation of Gardos channel activity by cytokines in sickle erythrocytes. Blood 2002; 99:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/156\">",
"      Winn RK, Ramamoorthy C, Vedder NB, et al. Leukocyte-endothelial cell interactions in ischemia-reperfusion injury. Ann N Y Acad Sci 1997; 832:311.",
"     </a>",
"    </li>",
"    <li>",
"     Keller MA, Trottnow T, Ponte CM, et al. In vitro adhesion of sickle RBC to endothelial cells: Adhesion molecule genetic variation and choice of endothelial cells [abstract]. 24th Annual Meeting of the National Sickle Cell Disease Program 2000; 1a.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/158\">",
"      Taylor JG 6th, Tang DC, Savage SA, et al. Variants in the VCAM1 gene and risk for symptomatic stroke in sickle cell disease. Blood 2002; 100:4303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/159\">",
"      Vanhoutte PM. How to assess endothelial function in human blood vessels. J Hypertens 1999; 17:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/160\">",
"      Setty BN, Chen D, Stuart MJ. Sickle cell vaso-occlusive crisis is associated with abnormalities in the ratio of vasoconstrictor to vasodilator prostanoids. Pediatr Res 1995; 38:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/161\">",
"      Rybicki AC, Benjamin LJ. Increased levels of endothelin-1 in plasma of sickle cell anemia patients. Blood 1998; 92:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/162\">",
"      Hammerman SI, Kourembanas S, Conca TJ, et al. Endothelin-1 production during the acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med 1997; 156:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/163\">",
"      Rees DC, Cervi P, Grimwade D, et al. The metabolites of nitric oxide in sickle-cell disease. Br J Haematol 1995; 91:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/164\">",
"      French JA 2nd, Kenny D, Scott JP, et al. Mechanisms of stroke in sickle cell disease: sickle erythrocytes decrease cerebral blood flow in rats after nitric oxide synthase inhibition. Blood 1997; 89:4591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/165\">",
"      Hammerman SI, Klings ES, Hendra KP, et al. Endothelial cell nitric oxide production in acute chest syndrome. Am J Physiol 1999; 277:H1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/166\">",
"      Reiter CD, Wang X, Tanus-Santos JE, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nat Med 2002; 8:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/167\">",
"      Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA 2005; 294:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/168\">",
"      Aslan M, Freeman BA. Oxidant-mediated impairment of nitric oxide signaling in sickle cell disease--mechanisms and consequences. Cell Mol Biol (Noisy-le-grand) 2004; 50:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/169\">",
"      Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med 2004; 350:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/170\">",
"      Nolan VG, Adewoye A, Baldwin C, et al. Sickle cell leg ulcers: associations with haemolysis and SNPs in Klotho, TEK and genes of the TGF-beta/BMP pathway. Br J Haematol 2006; 133:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/171\">",
"      Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood 1998; 91:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/172\">",
"      Sharan K, Surrey S, Ballas S, et al. Association of T-786C eNOS gene polymorphism with increased susceptibility to acute chest syndrome in females with sickle cell disease. Br J Haematol 2004; 124:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/173\">",
"      Nolan VG, Baldwin C, Ma Q, et al. Association of single nucleotide polymorphisms in klotho with priapism in sickle cell anaemia. Br J Haematol 2005; 128:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/174\">",
"      Elliott L, Ashley-Koch AE, De Castro L, et al. Genetic polymorphisms associated with priapism in sickle cell disease. Br J Haematol 2007; 137:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/175\">",
"      Hebbel RP, Yamada O, Moldow CF, et al. Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest 1980; 65:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/176\">",
"      Browne PV, Mosher DF, Steinberg MH, Hebbel RP. Disturbance of plasma and platelet thrombospondin levels in sickle cell disease. Am J Hematol 1996; 51:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/177\">",
"      Hebbel RP. Perspectives series: cell adhesion in vascular biology. Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest 1997; 99:2561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/178\">",
"      Taylor JG, Tang D, Foster CB, et al. Patterns of low-affinity immunoglobulin receptor polymorphisms in stroke and homozygous sickle cell disease. Am J Hematol 2002; 69:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/179\">",
"      Li B, Fuh G, Meng G, et al. Receptor-selective variants of human vascular endothelial growth factor. Generation and characterization. J Biol Chem 2000; 275:29823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/180\">",
"      Eyler CE, Jackson T, Elliott LE, et al. beta(2)-Adrenergic receptor and adenylate cyclase gene polymorphisms affect sickle red cell adhesion. Br J Haematol 2008; 141:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/181\">",
"      Newburger PE, Subrahmanyam YV, Weissman SM. Global analysis of neutrophil gene expression. Curr Opin Hematol 2000; 7:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/182\">",
"      Afenyi-Annan A, Kail M, Combs MR, et al. Lack of Duffy antigen expression is associated with organ damage in patients with sickle cell disease. Transfusion 2008; 48:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/183\">",
"      Zimmerman SA, O'Branski EE, Rosse WF, Ware RE. Hemoglobin S/O(Arab): thirteen new cases and review of the literature. Am J Hematol 1999; 60:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/184\">",
"      Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest 2000; 106:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/185\">",
"      Svarch E, Nordet I, Gonz&aacute;lez A. Overwhelming septicaemia in a patient with sickle cell/beta(0) thalassaemia and partial splenectomy. Br J Haematol 1999; 104:930.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/186\">",
"      West MS, Wethers D, Smith J, Steinberg M. Laboratory profile of sickle cell disease: a cross-sectional analysis. The Cooperative Study of Sickle Cell Disease. J Clin Epidemiol 1992; 45:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/187\">",
"      Belcher JD, Bryant CJ, Nguyen J, et al. Transgenic sickle mice have vascular inflammation. Blood 2003; 101:3953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/188\">",
"      Mohamed AO, Hashim MS, Nilsson UR, Venge P. Increased in vivo activation of neutrophils and complement in sickle cell disease. Am J Trop Med Hyg 1993; 49:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/189\">",
"      Kasschau MR, Barabino GA, Bridges KR, Golan DE. Adhesion of sickle neutrophils and erythrocytes to fibronectin. Blood 1996; 87:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/190\">",
"      Lard LR, Mul FP, de Haas M, et al. Neutrophil activation in sickle cell disease. J Leukoc Biol 1999; 66:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/191\">",
"      Mollapour E, Porter JB, Kaczmarski R, et al. Raised neutrophil phospholipase A2 activity and defective priming of NADPH oxidase and phospholipase A2 in sickle cell disease. Blood 1998; 91:3423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/192\">",
"      Fadlon E, Vordermeier S, Pearson TC, et al. Blood polymorphonuclear leukocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood 1998; 91:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/193\">",
"      Styles LA, Hoppe C, Klitz W, et al. Evidence for HLA-related susceptibility for stroke in children with sickle cell disease. Blood 2000; 95:3562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/194\">",
"      Kinney TR, Sleeper LA, Wang WC, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease. Pediatrics 1999; 103:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/195\">",
"      Tankut G, Kutlar F, McKie V, et al. Frequency of the factor V R485K polymorphism in sickle cell disease: A potential genetic modifier [abstract]. Blood 2000; 96:13a.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/196\">",
"      Tang DC, Prauner R, Liu W, et al. Polymorphisms within the angiotensinogen gene (GT-repeat) and the risk of stroke in pediatric patients with sickle cell disease: a case-control study. Am J Hematol 2001; 68:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/197\">",
"      Liesner R, Mackie I, Cookson J, et al. Prothrombotic changes in children with sickle cell disease: relationships to cerebrovascular disease and transfusion. Br J Haematol 1998; 103:1037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/198\">",
"      Baldwin C, Nolan VG, Wyszynski DF, et al. Association of klotho, bone morphogenic protein 6, and annexin A2 polymorphisms with sickle cell osteonecrosis. Blood 2005; 106:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/199\">",
"      Ulug P, Vasavda N, Awogbade M, et al. Association of sickle avascular necrosis with bone morphogenic protein 6. Ann Hematol 2009; 88:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/200\">",
"      Nolan VG, Ma Q, Cohen HT, et al. Estimated glomerular filtration rate in sickle cell anemia is associated with polymorphisms of bone morphogenetic protein receptor 1B. Am J Hematol 2007; 82:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/201\">",
"      Ashley-Koch AE, Okocha EC, Garrett ME, et al. MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol 2011; 155:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/202\">",
"      Ashley-Koch AE, Elliott L, Kail ME, et al. Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease. Blood 2008; 111:5721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/203\">",
"      Haverfield EV, McKenzie CA, Forrester T, et al. UGT1A1 variation and gallstone formation in sickle cell disease. Blood 2005; 105:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/204\">",
"      Vasavda N, Menzel S, Kondaveeti S, et al. The linear effects of alpha-thalassaemia, the UGT1A1 and HMOX1 polymorphisms on cholelithiasis in sickle cell disease. Br J Haematol 2007; 138:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/205\">",
"      Passon RG, Howard TA, Zimmerman SA, et al. Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia. J Pediatr Hematol Oncol 2001; 23:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/206\">",
"      Fertrin KY, Melo MB, Assis AM, et al. UDP-glucuronosyltransferase 1 gene promoter polymorphism is associated with increased serum bilirubin levels and cholecystectomy in patients with sickle cell anemia. Clin Genet 2003; 64:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/207\">",
"      Heeney MM, Howard TA, Zimmerman SA, Ware RE. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia. J Lab Clin Med 2003; 141:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/208\">",
"      Piomelli S, Reindorf CA, Arzanian MT, Corash LM. Clinical and biochemical interactions of glucose-6-phosphate dehydrogenase deficiency and sickle-cell anemia. N Engl J Med 1972; 287:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/209\">",
"      Steinberg MH, Dreiling BJ. Glucose-6-phosphate dehydrogenase deficiency in Sickle-cell anemia. A study in adults. Ann Intern Med 1974; 80:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/210\">",
"      Saad ST, Costa FF, Salles TS, et al. Glucose-6-phosphate dehydrogenase deficiency in sickle cell disease by DNA analysis. Blood 1995; 85:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/211\">",
"      Mohammad AM, Ardatl KO, Bajakian KM. Sickle cell disease in Bahrain: coexistence and interaction with glucose-6-phosphate dehydrogenase (G6PD) deficiency. J Trop Pediatr 1998; 44:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/212\">",
"      Bouanga JC, Mou&eacute;l&eacute; R, Pr&eacute;hu C, et al. Glucose-6-phosphate dehydrogenase deficiency and homozygous sickle cell disease in Congo. Hum Hered 1998; 48:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/213\">",
"      Beutler E, Johnson C, Powars D, West C. Prevalence of glucose-6-phosphate dehydrogenase deficiency in sickle-cell disease. N Engl J Med 1974; 290:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/214\">",
"      Saad ST, Costa FF. Glucose-6-phosphate dehydrogenase deficiency and sickle cell disease in Brazil. Hum Hered 1992; 42:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/215\">",
"      Bienzle U, Sodeinde O, Effiong CE, Luzzatto L. Glucose 6-phosphate dehydrogenase deficiency and sickle cell anemia: frequency and features of the association in an African community. Blood 1975; 46:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/216\">",
"      el-Hazmi MA, Warsy AS. Aspects of sickle cell gene in Saudi Arabia--interaction with glucose-6-phosphate dehydrogenase deficiency. Hum Genet 1984; 68:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/217\">",
"      Nouraie M, Reading NS, Campbell A, et al. Association of G6PD with lower haemoglobin concentration but not increased haemolysis in patients with sickle cell anaemia. Br J Haematol 2010; 150:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/218\">",
"      Steinberg MH, West MS, Gallagher D, Mentzer W. Effects of glucose-6-phosphate dehydrogenase deficiency upon sickle cell anemia. Blood 1988; 71:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/32/39434/abstract/219\">",
"      Miller ST, Milton J, Steinberg MH. G6PD deficiency and stroke in the CSSCD. Am J Hematol 2011; 86:331.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7137 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-A6750C7309-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_32_39434=[""].join("\n");
var outline_f38_32_39434=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18828143\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      FETAL HEMOGLOBIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Control of HbF expression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Response to hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Effect of age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cis-acting elements",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Beta-globin gene cluster locus control region",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Trans-acting factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Sex-linked factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ALPHA THALASSEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      POTENTIAL DISEASE MODULATORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13644148\">",
"      Overall disease severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Stroke",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Red cell membrane and cation transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Vascular endothelium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Endothelial activation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Vasodilation and vasoconstriction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Nitric oxide availability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Priapism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Leg ulcers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Red cell adherence to endothelium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Inflammation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Leukocyte migration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Leukocyte activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Hemostasis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Osteonecrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Renal function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      GALLSTONES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      G6PD DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18828143\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18828243\">",
"      Major modifiers of SCA phenotype",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18828401\">",
"      Other potential disease modulators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7137\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7137|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/32/6656\" title=\"figure 1\">",
"      Alpha and beta globin gene clusters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?10/44/10945\" title=\"figure 2\">",
"      Vessel occlusion sickle cell",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7137|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?1/42/1703\" title=\"picture 1\">",
"      Sickle cell anemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/4/18506?source=related_link\">",
"      Bone and joint complications in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/11/31930?source=related_link\">",
"      Cerebrovascular complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37224?source=related_link\">",
"      Control of red blood cell hydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/30/23017?source=related_link\">",
"      Diagnosis and management of priapism in sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/38/3689?source=related_link\">",
"      Genetic association studies: Principles and applications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/62/13289?source=related_link\">",
"      Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/23/42359?source=related_link\">",
"      Gilbert's syndrome and unconjugated hyperbilirubinemia due to bilirubin overproduction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/54/36711?source=related_link\">",
"      Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/44/3786?source=related_link\">",
"      Moyamoya disease: Etiology, clinical features, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/11/42170?source=related_link\">",
"      Overview of the clinical manifestations of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/28/27082?source=related_link\">",
"      Pulmonary complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20650?source=related_link\">",
"      Regulation of erythropoiesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/25/30104?source=related_link\">",
"      Sickle hemoglobin polymer: Structure and functional properties",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23001?source=related_link\">",
"      Structure and function of normal human hemoglobins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/5/5209?source=related_link\">",
"      Variant sickle cell syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/15/14583?source=related_link\">",
"      Xerocytosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_32_39435="Nugent score for diagnosis of bacterial vaginosis";
var content_f38_32_39435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nugent's scoring system for diagnosis of bacterial vaginosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Lactobacillus morphotypes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Gardnerella and Bacteroides morphotypes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Curved gram-variable rods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        1+ or 2+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        2+",
"       </td>",
"       <td>",
"        3+ or 4+",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        1+",
"       </td>",
"       <td>",
"        3+",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        4+",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The score is determined by the average number of each morphotype seen per oil-immersion field, but varies with the type of bacteria. Excluding lactobacillus morphotypes, a score of 0 means no morphotypes are present; 1, 0 to 1 morphotype present per high power field; 2, 1 to 4 morphotypes present; 3, 5 to 30 morphotypes present; 4, 30 or more morphotypes present. A total score of 7 to 10 is indicative of bacterial vaginosis infection, 4 to 6 is indeterminate, and 0 to 3 is normal. (Total score = lactobacilli score and Gardnerella vaginalis score and Bacteroides species score and curved gram variable rod score).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from data in Nugent, RP. J Clin Microbiol 1991; 29:291.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_32_39435=[""].join("\n");
var outline_f38_32_39435=null;
var title_f38_32_39436="Hazards in hobbies";
var content_f38_32_39436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F62461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F62461&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Examples of hazards in hobbies",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Activity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Potential hazard",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left_left\">",
"        Painting",
"       </td>",
"       <td>",
"        Toxic pigments (eg, arsenic (emerald green), cadmium, chromium, lead, mercury), acrylic emulsions, solvents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Ceramics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Raw materials",
"       </td>",
"       <td class=\"sublist_other\">",
"        Colors and glazes containing barium carbonate, lead, chromium, uranium, cadmium, manganese",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Firing",
"       </td>",
"       <td class=\"sublist_other\">",
"        Vapors of fluoride, chlorine, sulfur dioxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Gas-fired kilns",
"       </td>",
"       <td class=\"sublist_other\">",
"        Carbon monoxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Sculpture and casting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Grinding silica-containing stone",
"       </td>",
"       <td class=\"sublist_other\">",
"        Silica (silicon dioxide)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Serpentine rock with asbestos",
"       </td>",
"       <td class=\"sublist_other\">",
"        Asbestos",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Woodworking",
"       </td>",
"       <td class=\"sublist_other\">",
"        Wood dust",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Metal casting",
"       </td>",
"       <td class=\"sublist_other\">",
"        Metal fume, sand (silica) from molding, binders of phenol formaldehyde or urea formaldehyde",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left_left\">",
"        Welding",
"       </td>",
"       <td>",
"        Metal",
"fume, ultraviolet light exposure, welding (metal-containing) fumes,",
"carbon dioxide, carbon monoxide, nitrogen dioxide, ozone, or phosgene",
"(if solvents nearby)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left_left\">",
"        Plastics",
"       </td>",
"       <td>",
"        Monomers",
"released during heating (polyvinyl chloride), methyl methacrylate,",
"acrylic glues, polyurethanes (toluene 2,4-diisocyanate), polystyrene",
"(methylchloride release), fiberglass, polyester or epoxy resins",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left_left\">",
"        Woodstripping",
"       </td>",
"       <td>",
"        Solvents, especially methylene chloride",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"2\" rowspan=\"1\">",
"        Photography",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Developer",
"       </td>",
"       <td class=\"sublist_other\">",
"        Hydroquinone, metal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Stop bath",
"       </td>",
"       <td class=\"sublist_other\">",
"        Weak acetic acid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Stop hardener",
"       </td>",
"       <td class=\"sublist_other\">",
"        Potassium chrome alum (chromium)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Fixer",
"       </td>",
"       <td class=\"sublist_other\">",
"        Sodium sulfite, acetic acid-sulfur dioxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Hardeners and stabilizers",
"       </td>",
"       <td class=\"sublist_other\">",
"        Formaldehyde",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Goldman RH, Peters JM. JAMA 1981; 246:2831.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_32_39436=[""].join("\n");
var outline_f38_32_39436=null;
var title_f38_32_39437="Differential diagnosis of chest pain";
var content_f38_32_39437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F87061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F87061&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of chest pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Cardiovascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Ischemic chest pain syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Coronary artery disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Obstructive atherosclerotic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Acute coronary syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent3\">",
"        Angina due to demand/supply mismatch",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist5_start\">",
"        Chronic stable angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist5_start\">",
"        Acutely increased myocardial oxygen demand",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Coronary vasospasm, \"variant angina\"",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Cardiac syndrome X",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Coronary artery dissection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Coronary anatomic anomalies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Valvular heart disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Non-ischemic chest pain syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Aortic dissection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myocarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stress-induced cardiomyopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute aortic syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Chest pain related to hyperadrenergic states",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cocaine intoxication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amphetamine intoxication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pheochromocytoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Chest wall",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Isolated musculoskeletal chest pain syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Costochondritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Tietze syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Costovertebral joint dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sternalis syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Xiphoidalgia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spontaneous sternoclavicular subluxation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rheumatic diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Nonrheumatic systemic diseases",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Stress fractures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Metastatic malignancy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute chest syndrome (sickle cell crisis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Skin and sensory syndromes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Herpes zoster (shingles)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Gastrointestinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Esophageal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Reflux",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Rupture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Spasm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Esophagitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pancreatobiliary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cholecystitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cholangitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Biliary colic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peptic ulcer disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pulmonary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Vasculature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Acute pulmonary embolism",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary hypertension",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Parenchyma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pneumonia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cancer",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sarcoidosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Airways: Bronchospasm*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Asthma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        COPD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Pleura",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pleuritis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pneumothorax (including tension)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mediastinal disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mediastinitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mediastinal tumors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pneumomediastinum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Psychiatric",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anxiety",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Depression",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Panic attacks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Munchausen",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     COPD: chronic obstructive pulmonary disease.",
"     <br/>",
"     * Usually described as chest tightness rather than pain per se.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_32_39437=[""].join("\n");
var outline_f38_32_39437=null;
var title_f38_32_39438="Pulsatile GnRH and LH release";
var content_f38_32_39438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F77183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F77183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Relationship between GnRH pulses and LH release",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 266px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Concentrations of gonadotropin-releasing hormone in hypophysial portal plasma and luteinizing hormone in jugular venous plasma in five ovariectomized ewes during estrogen-induced LH surges. Each pulse of LH measured in the peripheral blood corresponded to a hypothalamic pulse of GnRH into the portal system in a one-to-one relationship.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Clarke, IJ, Endocrinology 1993; 133:1624.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_32_39438=[""].join("\n");
var outline_f38_32_39438=null;
var title_f38_32_39439="Fibula fracture above lateral malleolus lateral view";
var content_f38_32_39439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82310&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Fibula fracture above lateral malleolus: Lateral view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This lateral plain radiograph shows an oblique fracture (black arrow)&nbsp;through the distal fibula.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott M Koehler, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_32_39439=[""].join("\n");
var outline_f38_32_39439=null;
